A.P. Pharma, Inc. (NASDAQ: APPA)
A.P. Pharma, Inc. (NASDAQ: APPA), a specialty pharmaceutical company, is committed to developing ethical (prescription) pharmaceuticals through the utilization of its proprietary polymer-based drug delivery systems. The Company's main focus is on developing and commercializing its bioerodible injectable and implantable systems under the trade name Biochronomer™. For further information, visit the Company's web site at www.appharma.com.
Aastrom Biosciences, Inc. (NASDAQ: ASTM)
Aastrom Biosciences, Inc. (NASDAQ: ASTM) is focused on the development of autologous cell products for the repair or regeneration of human tissue. The Company's proprietary Tissue Repair Cell (TRC) technology utilizes a patient's own cells to create products to treat an array of chronic diseases as well as serious injuries. Currently, Aastrom is conducting a Phase II clinical trial with dilated cardiomyopathy (DCM) patients (the IMPACT-DCM trial) and a Phase IIb clinical trial with critical limb ischemia patients (the RESTORE-CLI trial). For further information, visit the Company's web site at www.aastrom.com.
Abraxas Petroleum Corporation (NASDAQ: AXAS)
Abraxas Petroleum Corporation (NASDAQ: AXAS), an independent natural gas and crude oil exploitation and production company, is focused on increasing shareholder value while maintaining financial flexibility and liquidity. The company is currently committed to developing its existing asset base while acquiring leases that fit strategically within its current portfolio. Abraxas targets conventional reservoirs, as well as emerging resource plays. For further information, visit the Company's web site at www.abraxaspetroleum.com.
ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD)
ACADIA Pharmaceuticals, Inc. (NASDAQ: ACAD), a biopharmaceutical company, is focused on utilizing innovative technology to stimulate drug discovery and clinical development of novel treatments for central nervous system disorders. The company is currently developing a portfolio of its four most advanced product candidates, all of which originate from discoveries made using ACADIA’s proprietary drug discovery platform. For further information, visit the Company's web site at www.acadia-pharm.com.
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI)
Accentia Biopharmaceuticals, Inc. (NASDAQ: ABPI) is focused on commercializing patent-protected disruptive healthcare technologies specifically designed to take leading roles for the treatment of a broad array of chronic, debilitating and life-threatening diseases including respiratory, autoimmune and cancer indications. The company anticipates building significant value for its shareholders while meeting its objectives. For further information, visit the Company's web site at www.accentia.net.
Access Pharmaceuticals, Inc. (OTC BB: ACCP)
Access Pharmaceuticals, Inc. (OTC BB: ACCP), an emerging biopharmaceutical company, is committed to the development and commercialization of propriety products for the treatment and supportive care of cancer patients. Access' products currently include ProLindac(TM), the company’s lead oncology drug which is currently in Phase 2 clinical testing; and MuGard(TM), a viscous, mucoadhesive rinse for the management of patients with mucositis. For further information, visit the Company's web site at www.accesspharma.com.
Action Energy Inc. (TSX: AEC CN)
Action Energy Inc. (TSX: AEC CN), an Alberta-based emerging oil and natural gas exploration and production company, has an asset base that includes a mix of light oil, conventional heavy oil and natural gas-producing properties in west central Alberta, Peace River Arch, east central Alberta and southwest and southeast Saskatchewan. The properties offer extensive opportunities to add reserves and production at low cost and low risk. For further information, visit the Company's web site at www.action-energy.com.
Adanac Molybdenum Corporation (TSX: AUA CN)
Adanac Molybdenum Corporation (TSX: AUA CN) owns the Ruby Creek Molybdenum Project in Northern British Columbia. To date, the Company has advanced Ruby Creek through feasibility studies, a production decision and has ordered $137 million of long-lead equipment, completed permitting for construction, constructed a road to the site and secured US$80 million in bridge financing. This project has the potential of becoming the world’s first new large scale molybdenum open pit mine in more than 25 years. For further information, visit the Company's web site at www.adanacmoly.com.
Adherex Technologies, Inc. (AMEX: ADH)
Adherex Technologies, Inc. (AMEX: ADH), a biopharmaceutical company, is focused on discovering and developing novel cancer therapeutics. They currently have a number of products in the clinical stage of development, including eniluracil, ADH-1 and sodium thiosulfate (STS). Adherex’s mission is to become a leading developer of innovative treatments that address important unmet medical needs in cancer. For further information, visit the Company's web site at www.adherex.com.
Advanced Battery Technologies, Inc. (NASDAQ: ABAT)
Advanced Battery Technologies, Inc. (NASDAQ: ABAT), a developer, manufacturer and distributor of rechargeable Polymer Lithium-Ion (PLI) batteries, is focused on developing batteries that overcome many of the shortcomings of traditional rechargeable batteries by combining high-energy chemistry with state-of-the-art polymer technology. The company's products include rechargeable PLI batteries for electric automobiles, motorcycles, mine-use lamps, notebook computers, walkie-talkies and other electronic devices. For further information, visit the Company's web site at www.abat.com.cn.
Advanced Life Sciences Holdings, Inc. (NASDAQ: ADLS)
Advanced Life Sciences Holdings, Inc. (NASDAQ: ADLS), a biopharmaceutical company, is focused discovering, developing, and commercializing novel drugs in the therapeutic areas of respiratory diseases, infection, and cancer. Cethromycin, the Company's lead candidate, is a novel NDA-stage once-a-day oral antibiotic designed to treat respiratory tract infections, such as pneumonia. For further information, visit the Company's web site at www.advancedlifesciences.com.
Advanced Explorations Inc. (TSX: AXI CN)
Advanced Explorations Inc. (TSX: AXI CN) is focused on developing the Roche Bay magnetite project. Located in Nunavut, Canada, this project is believed to hold one of the world's largest undeveloped magnetite deposits. Roche Bay is strategically positioned nearby naturally deep tidewater with 20+ meter water depths and only nine days sailing to Europe, providing the perfect environment for development. For further information, visit the Company's web site at www.advanced-exploration.com.
ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX)
ADVENTRX Pharmaceuticals, Inc. (AMEX: ANX), a biopharmaceutical company, is dedicated to in-licensing, developing and commercializing proprietary product candidates. Their key focus is on the treatment of cancer. The Company intends to enhance the performance and commercial potential of existing treatments by addressing issues related with these treatment regimens. For further information, visit the Company's web site at www.adventrx.com.
AgFeed Industries, Inc. (NASDAQ: FEED)
AgFeed Industries, Inc. (NASDAQ: FEED), the largest commercial hog producer and the largest premix feed company in China, owns and operates 28 commercial hog farms with annual production of more than 650,000 hogs and five premix feed plants. The company’s hog farms and feed plants are strategically located in the most profitable feed and hog markets in south China. Currently, China represents more than 50 percent of the world's annual hog production and is the largest and most profitable pork consumer market, producing over 600 million hogs per year, compared to 100 million hogs per year in the United States. For further information, visit the Company's web site at www.agfeedinc.com.
Akesis Pharmaceuticals, Inc.’s (OTC BB: AKES)
Akesis Pharmaceuticals, Inc.’s (OTC BB: AKES) focus is on the treatment of diabetes and related metabolic disorders. They have a pipeline of innovative oral product candidates that are supported by issued and filed U.S. patents. Their product candidates are proven to lower and control blood glucose levels in patients with Type 2 diabetes. With approximately 20 million people suffering from diabetes in the U.S. alone, blood sugar control via oral drugs represents a multi-billion dollar market opportunity. For further information, visit the Company's web site at www.akesis.com.
Alberta Oilsands Inc. (TSX: (OTC BB: AOS CN)
Alberta Oilsands Inc. (TSX: AOS CN), a junior oil sands development company, is focusing their operations on the Athabasca oil sands region of northeast Alberta. The company intends to create long term, sustainable value through the rapid delineation of the oil sands resources. Alberta’s strategy is to leverage its proven oil sands experience to delineate and prove up bitumen reserves sufficient to support a minimum 10,000 barrel per day in-situ project within five years. For further information, visit the Company's web site at www.aboilsands.ca.
Alhambra Resources Ltd. (TSX: ALH CN)
Alhambra Resources Ltd. (TSX: ALH CN), a Canadian based exploration and gold production corporation, operates through its wholly owned subsidiary, Saga Creek Gold Corp LLP ("Saga Creek"). The company holds the rights to two Licenses that have an initial term of 25 years granted by the Republic of Kazakhstan in 1997. These two Licenses are the subject of an exploration and exploitation Contract between Saga Creek and the Republic of Kazakhstan, and will not expire until the year 2022. For further information, visit the Company's web site at www.alhambraresources.com.
Allos Therapeutics, Inc. (NASDAQ: ALTH)
Allos Therapeutics, Inc. (NASDAQ: ALTH), a biopharmaceutical company, is committed to developing and commercializing innovative small molecule drugs for the treatment of cancer. Pralatrexate (PDX), the Company's lead product candidate, is a novel antifolate currently in a pivotal Phase 2 (PROPEL) trial. RH1, a targeted chemotherapeutic agent, is Allos Therapeutics’ other product candidate and is currently being evaluated in a Phase 1 trial. For further information, visit the Company's web site at www.allos.com.
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY)
Alnylam Pharmaceuticals, Inc. (NASDAQ: ALNY), a biopharmaceutical company, is focused on developing novel therapeutics based on RNA interference, or RNAi. By applying its therapeutic expertise in RNAi, the company intends to address substantial medical needs, many of which cannot be effectively addressed with small molecules or antibodies, the current major classes of drugs. Alnylam has taken a leadership role in the translation of RNAi as a new class of innovative medicines with peer-reviewed research efforts published in the world’s top scientific journals including Nature, Nature Medicine, and Cell. For further information, visit the Company's web site at www.alnylam.com.
Alphatec Spine, Inc. (NASDAQ: ATEC)
Alphatec Spine, Inc. (NASDAQ: ATEC), a wholly owned subsidiary of Alphatec Holdings, Inc. (Nasdaq:ATEC), is focused on designing, developing, manufacturing and marketing products for the surgical treatment of spine disorders. The company aims to combine world-class customer service with innovative, surgeon-driven design to help improve the aging patient's quality of life. By using innovative solutions, Alphatec well positioned to accomplish its goal. For further information, visit the Company's web site at www.alphatecspine.com.
Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE
Alseres Pharmaceuticals, Inc. (NASDAQ: ALSE) is focused on developing therapeutic and diagnostic products designed mainly for disorders in the central nervous system. The company’s robust molecular imaging <http://www.bostonlifesciences.com/product-pipeline/product-candidates/molecular-imaging-program.asp> development program targets the diagnosis of Parkinson's disease <http://www.bostonlifesciences.com/product-pipeline/indications/parkinsons-disease.asp> and potentially dementia. Altropane, the company's lead molecular imaging product candidate, is currently in Phase III clinical trials for the diagnosis of Parkinsonian Syndromes, including Parkinson's Disease. For further information, visit the Company's web site at www.alseres.com.
Alyst Acquisition Corporation (AMEX: AYA
Alyst Acquisition Corporation (AMEX: AYA) was incorporated in August of 2006 for the purpose of raising capital from the public equity markets and using the capital to effectuate a merger, capital stock exchange, asset acquisition or other similar business combination. Since the young company’s IPO in June of 2007, Alyst has raised over $64 million and have recently announced a plan of merger with China Networks Media, Ltd. For further information, visit the company website at: www.alyst.net.
American Defense Systems, Inc. (AMEX: EAG)
American Defense Systems, Inc. (AMEX: EAG) is a leading provider of advanced solutions in the design, fabrication and installation of transparent and opaque armor, security doors, windows and curtain wall systems for use by military, law enforcement, homeland defense and corporate customers. The company’s business is focused on four primary areas, including Armor Solutions, Law Enforcement Protection, Architectural Hardening and Tactical Training Systems. For further information, visit the Company's web site at www.adsiarmor.com.
Amarin Corporation plc (NASDAQ: AMRN)
Amarin Corporation plc (NASDAQ: AMRN), a clinical-stage biopharmaceutical company, has a lead program entering Phase 3 for hypertriglyceridemia. The company’s cardiovascular programs take advantage of the staff’s expertise in the field of lipid science and the acknowledged therapeutic benefits of essential fatty acids in cardiovascular disease. In addition to Amarin’s lead program, their pipeline includes programs in myasthenia gravis, Huntington’s disease, Parkinson’s disease and epilepsy. For further information, visit the Company's web site at www.amarincorp.com.
American Lorain Corporation (OTC BB: ALRC)
American Lorain Corporation (OTC BB: ALRC) is a currently inactive shell company open to securing a business partnership with an enterprise that it may acquire, merge with or become engaged in. Considered a development stage company as defined in the Statement of Financial Accounting Standards No. 7, American Lorain Corporation currently has no on-going operations and has not secured any specific business partnership nor has the company entered into any agreements or arrangements at this time.
American Oil & Gas, Inc. (AMEX: AEZ)
American Oil & Gas, Inc. (AMEX: AEZ), a Denver Colorado based energy company, engages in oil and gas exploration, development and acquisition primarily in the Rocky Mountain region. This region is believed to hold one of the largest undeveloped natural gas resources remaining in the continental U.S. The company has acquired interests in more than 500,000 gross acres in three core project areas. All projects are positioned where there has been historical evidence of Hydrocarbon existence. For further information, visit the Company's web site at www.americanoilandgasinc.com.
American Tony Pharmaceutical, Inc. (OTC BB: AIMR)
American Tony Pharmaceutical, Inc. (OTC BB: AIMR), a manufacturer and distributor of pharmaceuticals and health care products in China, is focused on developing, manufacturing and marketing pharmaceutical and health care products through its wholly owned subsidiary, Harbin Tianmu Pharmaceutical Co., Ltd. ("Tianmu Pharmaceutical"). Founded in 1999 in Harbin, China, Tianmu Pharmaceutical operates all of its business activities in the People's Republic of China.
Amerigo Resources Ltd. (TSX: ARG CN)
Amerigo Resources Ltd. (TSX: ARG CN), through its wholly owned subsidiary, Minera Valle Central (MVC), focuses on producing copper and molybdenum concentrates. This subsidiary is treating all the fresh tailings from El Teniente's present production and has the right to treat the higher grade tailings from a 200 million tonne in situ tailings impoundment. Amerigo aims to increase production on an annualized basis to approximately 60 million pounds of copper and 1 million pounds of molybdenum. For further information, visit the Company's web site at www.amerigoresources.com.
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS)
Anadys Pharmaceuticals, Inc. (NASDAQ: ANDS), a clinical-stage biopharmaceutical company, is focused on improving patient care by developing novel medicines in the areas of hepatitis C and oncology. The Company is developing two potentially complementary agents for the treatment of chronic hepatitis C: ANA598, a non-nucleoside polymerase inhibitor; and ANA773, an oral TLR7 agonist prodrug. For further information, visit the Company's web site at www.anadyspharma.com.
Antigenics, Inc. (NASDAQ: AGEN)
Antigenics, Inc. (NASDAQ: AGEN) is focused on enhancing and extending the lives of patients by developing superior health care products for a broad array of cancers, infectious diseases and autoimmune disorders. Earlier this year, the company’s patient-specific cancer vaccine Oncophage <http://www.antigenics.com/products/cancer/oncophage/> ® (vitespen) was approved in Russia for the treatment of kidney cancer patients at intermediate risk for disease recurrence. Antigenics is now committed to exploring other major geographical territories for regulatory approval of Oncophage. For further information, visit the Company's web site at www.antigenics.com.
Aradigm Corporation (OTC BB: ARDM)
Aradigm Corporation (OTC BB: ARDM), an emerging specialty pharmaceutical company, is committed to developing and commercializing a portfolio of drugs designed to treat severe respiratory diseases. With its clinical expertise, targeted development efforts, and strength of a well accomplished leadership team, the company is poised to capitalize on niche opportunities for new and improved products used in the treatment of severe respiratory disease. For further information, visit the Company's web site at www.aradigm.com.
Arcade Acquisition Corporation (OTC BB: ACDQ)
Arcade Acquisition Corporation (OTC BB: ACDQ) is a private investment partnership that invests in middle-market leveraged buy-out and recapitalization transactions. Arcade gained national recognition for prior investments such as American Cellular Corporation and BoxUSA Inc. Led by their three principals John Chapman, Jonathan Furer and Muhit Rahman, Arcade Acquisition is well-placed for the future. For further information, visit the company website at: www.arcadepartners.com.
Arcan Resources Ltd. (TSX: ARN CN)
Arcan Resources Ltd. (TSX: ARN CN), a high-growth junior producer, has a balanced portfolio of assets positioned in the Deer Mountain, McLeod and Hamburg areas. The company is approximately 75 percent oil weighted and all oil production is greater than 40º API sweet crude. Arcan is a full cycle exploration company through the drill bit and anticipates adding acquisitions that consolidate holdings or accelerate growth. For further information, visit the Company's web site at www.arcanres.com.
Arena Resources, Inc. (NYSE: (TSX: ARD)
Arena Resources, Inc. (NYSE: ARD), an Oklahoma-based oil and gas exploration, development and production company, has its operations focused on Texas, Oklahoma, Kansas and New Mexico. Since the company’s beginning, experienced management executives have aggressively sought to acquire select properties that provide immediate positive cash flow and development opportunities for the future. So far, the company has made acquisitions representing an estimated 55.4 million BOE's (barrel of oil equivalents) and an estimated $1,982.0 billion* in PV-10 (future net revenues discounted 10%). For further information, visit the Company's web site at www.arenaresourcesinc.com.
Argentex Mining Corporation (TSX: ATX CN)
Argentex Mining Corporation (TSX: ATX CN), a junior mineral resource company, has extensive holdings in Argentina's Patagonia region, including its flagship Pinguino property, a new polymetallic discovery located in Santa Cruz province. This property covers an extensive silver-zinc-lead-indium mineralized system discovered by the company about two years ago. Pinguino holds more than eight mineralized zones, a combined strike length of over 60 kilometers (37 miles) and mineralization proven to depth. For further information, visit the Company's web site at www.argentexmining.com.
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA)
ARIAD Pharmaceuticals, Inc. (NASDAQ: ARIA) is focused on discovering and developing breakthrough medicines to treat cancer by regulating cell signaling with small molecules. The company has an exclusive license to pioneer technology and patents associated with certain NF-κB treatment methods, as well as the discovery and development of drugs to regulate NF-κB cell-signaling activity. These treatment methods and drugs could be useful in treating certain diseases. For further information, visit the Company's web site at www.ariad.com.
Arno Therapeutics, Inc. (OTC BB: ARNI)
Arno Therapeutics, Inc. (OTC BB: ARNI), a clinical-stage biopharmaceutical company, is focused on developing and commercializing innovative products designed to treat cancer patients. AR-67, a novel third-generation camptothecin analogue in Phase I studies, is the company’s lead compound. AR-67 has demonstrated high potency and significantly improved pharmacokinetic properties when compared with marketed second-generation products in its class. For further information, visit the Company's web site at www.arnothera.com.
Asia Time Corporation (AMEX: TYM)
Asia Time Corporation (AMEX: TYM) operates Financial Profiles, an independent investor relations and financial communications firm. Financial Profiles helps clients effectively communicate with investors and other stakeholders, prepare for earnings announcements and important corporate developments, enhance corporate visibility, conduct capital markets transactions and manage crisis situations. The company also provides customized communications counsel and services to public and pre-IPO companies.
Athabasca Potash Inc. (TSX: API CN)
Athabasca Potash Inc. (TSX: API CN) is focused on the exploration of potash projects in Saskatchewan, Canada. The company’s Burr Project is being explored aggressively. Athabasca aims to provide shareholders with an exceptional investment opportunity by establishing the company as a pre-eminent Canadian public resource company engaged solely on potash exploration and development. Currently, Athabasca holds 23 potash exploration permits averaging about 1,700,000 acres in Saskatchewan. For further information, visit the Company's web site at www.athabascapotash.ca.
Atna Resources Ltd. (TSX: ATN CN)
Atna Resources Ltd. (TSX: ATN CN) is focusing their efforts on building a successful gold mining company devoted to responsible gold production and the creation of sustainable value for shareholders, employees and communities. The company’s experienced management team is steadfast in integrity and is focused on creating a performance driven culture dedicated to safety and environmental responsibility. For further information, visit the Company's web site at www.atna.com.
ArQule, Inc. (NASDAQ: ARQL)
ArQule, Inc. (NASDAQ: ARQL), a biotechnology company, is committed to researching and developing next-generation, small-molecule cancer therapeutics. The company’s lead product, ARQ 197, is currently in clinical-stage development. ArQule’s discovery efforts are focused on identifying novel kinase inhibitors that are potent, selective and do not compete with ATP (adenosine triphosphate), an energy source for cells. For further information, visit the Company's web site at www.arqule.com.
AtriCure, Inc. (NASDAQ: ATRC)
AtriCure, Inc. (NASDAQ: ATRC), a medical device company, is focused on leading the development, manufacturing and selling of novel cardiac surgical ablation systems intended to create precise lesions, or scars, in cardiac tissue. The FDA has approved the AtriCure Isolator® system, including its Isolator SynergyTM ablation clamps, and AtriCure’s multifunctional pen and CoolrailTM linear ablation device, for the destruction of heart tissue during surgical procedures. For further information, visit the Company's web site at www.atricure.com.
ATS Medical, Inc. (NASDAQ: ATSI)
ATS Medical, Inc. (NASDAQ: ATSI) is focused on providing novel products and services designed specifically for cardiac surgery. Over 160,000 ATS Open Pivot(R) Heart Valves have been implanted in patients around the globe. ATS’ 3f(R) brand includes multiple tissue heart valve product offerings at varying steps from market introductions and clinical trials to development projects that utilize less invasive valve replacement technology. For further information, visit the Company's web site at www.atsmedical.com.
Ausam Energy Corporation (TSX: AZE CN)
Ausam Energy Corporation (TSX: AZE CN) is focused on oil & natural gas development and exploration in the Gulf Coast of the United States. The company currently has two producing wells in Texas and Louisiana. Ausam Energy’s 19 prospects and leads located onshore in the Gulf Coast region of the United States encompass more than 90,000 gross acres (50,000 net acres) and diversifies the company’s portfolio in areas of known commercial petroleum production with established infrastructure and gas markets. For further information, visit the Company's web site at www.ausamenergy.com.
Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX)
Avalon Pharmaceuticals, Inc. (NASDAQ: AVRX), a biopharmaceutical company, is committed to discovering, developing and commercializing superior cancer therapeutics. The company's proprietary platform, AvalonRx®, is designed to discover and develop therapeutics for pathways that have been characterized as "undruggable” in the past. For further information, visit the Company's web site at www.avalonrx.com.
Avanir Pharmaceuticals (NASDAQ: AVNR)
Avanir Pharmaceuticals (NASDAQ: AVNR) is dedicated to acquiring, developing, and commercializing innovative therapeutic products designed to treat chronic diseases. Zenvia™, the company’s lead product candidate, is currently being developed to treat pseudobulbar affect (PBA). GlaxoSmithKline Consumer Healthcare currently markets Avanir’s first commercialized product, Abreva®, in North America. Abreva is the leading over-the-counter product for the treatment of cold sores. For further information, visit the Company's web site at www.avanir.com.
AVI BioPharma, Inc. (NASDAQ: AVII)
AVI BioPharma, Inc. (NASDAQ: AVII) is committed to discovering and developing RNA-based drugs using its expanded portfolio of proprietary antisense compounds. Functional attributes of their unique approach may include correcting genetic defects, coding for novel soluble receptors, and the reduction in activity of immune modulators in disease states. Additionally, the company’s RNA-based drug programs include blocking mRNA translation. For further information, visit the Company's web site at www.avibio.com.
Avigen, Inc. (NASDAQ: AVGN)
Avigen, Inc. (NASDAQ: AVGN), a biopharmaceutical company, engages in the development and commercialization of small molecule therapeutics designed to treat serious neurological disorders, including neuropathic pain and opioid addiction and withdrawal. The company’s strategic aim is to complete the requirements of clinical development for each of the candidates in its product pipeline, while seeking opportunities to expand its pipeline through internal research, acquisitions, and in-licensing. For further information, visit the Company's web site at www.avigen.com.
Bayswater Uranium Corp. (TSX: ABAY CN)
Bayswater Uranium Corp. (TSX: BAY CN), a rapidly-growing international uranium exploration and development company, is the only uranium company to have major landholdings in each of Canada's most important producing and exploration regions -- the Athabasca Basin, the Central Mineral Belt, and the Thelon Basin. Additionally, the Company owns multiple advanced uranium properties in the United States that are being fast tracked to production. For further information, visit the Company's web site at www.bayswateruranium.com.
Bartronics India Limited (NSE: BARTRONICS)
Bartronics India Limited (NSE: BARTRONICS) is focused on providing businesses the ability to gain real-time visibility and information by utilizing the implementation, integration and support of Automatic Identification & Data Capture (AIDC) technologies, RFID, Smart Cards and Point of Sale (POS) solutions. Recognized as a dominant player in the domestic markets, the company has engaged in exclusive relationships with many of the leading vendors worldwide. For further information, visit the Company's web site at www.bartronicsindia.com.
BELLUS Health, Inc. (NASDAQ: BLUS)
BELLUS Health, Inc. (NASDAQ: BLUS), a global health company, is committed to developing and commercializing products that provide innovative health solutions to address substantial, but unmet needs. The company’s wholly owned subsidiary, OVOS Natural Health Inc., aims to develop a strong franchise with several products marketed to help brain function as well as expand to other conditions. For further information, visit the Company's web site at www.bellushealth.com.
Bio-Bridge Science, Inc. (OTC BB: BGES)
Bio-Bridge Science, Inc. (OTC BB: BGES) is a development stage biotechnology company committed to engaging in the commercial development of vaccines for the prevention and treatment of human infectious diseases. Currently, the company is focused on developing and commercializing HIV-PV Vaccine I to prevent and treat infection by the human immunodeficiency virus (HIV). The HIV vaccines developed by Bio-Bridge are designed for both preventive and therapeutic purposes. For further information, visit the Company's web site at www.bio-bridge-science.com.
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX)
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX), an integrated biopharmaceutical company, utilizes crystallography and structure-based drug design to develop a deep pipeline of innovative therapeutics. Currently, the company is progressing investigational new drugs discovered in-house in late-stage clinical trials for influenza and lymphoma. The U.S. Department of Health and Human Services, Shionogi & Co., Ltd., Green Cross Corporation and Mundipharma International Holdings Ltd. have all formed strategic alliances with the company and validate its scientific foundation and the utility of its product candidates. For further information, visit the Company's web site at www.biocryst.com .
BioDelivery Sciences International, Inc. (NASDAQ: BDSI)
BioDelivery Sciences International, Inc. (NASDAQ: BDSI), a specialty pharmaceutical company, is focused on utilizing its innovative and proprietary patented drug delivery technologies to develop and commercialize new applications of proven therapeutics. Currently, the company is developing formulations of pharmaceuticals primarily targeted at treatment opportunities in areas such as pain and infections. For further information, visit the Company's web site at www.biodeliverysciences.com.
Bioheart, Inc.’s (NASDAQ: BHRT)
Bioheart, Inc.’s (NASDAQ: BHRT) primary mission is to become a leading company focused on discovering, developing and commercializing innovative, autologous cell therapies and such devices. A number of cell therapies and related devices designed to treat chronic and acute heart damage consist of the company’s product line. They believe the market for treating patients in NYHA Class II or NYHA Class III heart failure is significant as there are approximately 5.2 million patients with heart failure in the United States alone. For further information, visit the Company's web site at www.bioheartinc.com.
Bionovo, Inc. (NASDAQ: BNVI)
Bionovo, Inc. (NASDAQ: BNVI), a drug discovery and development company, has their focus on developing safe and effective drugs to treat unmet medical needs in women’s health and cancer. Their aim is to improve the quality of women’s health and defeat life-threatening cancers. The company has a diverse pipeline of preclinical drug candidates to address both women’s health and cancer, and have identified or begun preclinical work on several multiple drug candidates for a variety of indications. For further information, visit the Company's web site at www.bionovo.com.
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX)
BioSante Pharmaceuticals, Inc. (NASDAQ: BPAX), a specialty pharmaceutical company, is committed to developing products for female sexual health, menopause, contraception and male hypogonadism. Lead products within their produce line include LibiGel® (transdermal testosterone gel), which is in Phase III clinical development under a U.S. Food and Drug Administration (FDA) SPA (Special Protocol Assessment); and Elestrin™ (estradiol gel) which has been developed through FDA approval. For further information, visit the Company's web site at www.biosantepharma.com.
BioSpecifics Technologies Corp. (OTC BB: BSTC)
BioSpecifics Technologies Corp. (OTC BB: BSTC), a biopharmaceutical company, has developed and licensed injectable collagenase for three clinical indications. Their development and licensing agreement with Auxilium Pharmaceuticals (Nasdaq GM: AUXL) is for clinical indications in Dupuytren’s disease, Peyronie’s disease and frozen shoulder (adhesive capsulitis). Currently, all of their efforts are focused on the future development and commercialization of injectable collagenase products. For further information, visit the Company's web site at www.biospecifics.com.
BioSphere Medical, Inc. (NASDAQ: BSMD)
BioSphere Medical, Inc. (NASDAQ: BSMD) is focused on applying their proprietary microsphere technology to medical applications through the use of embolotherapy techniques. The company’s core technologies consist of patented bio-engineered polymers and manufacturing methods, which are used to produce miniature spherical beads with uniquely beneficial properties for a variety of medical applications. For further information, visit the Company's web site at www.equityny.com.
Blue Note Mining (TSX: BN)
Blue Note Mining (TSX: BN CN) was founded with the purpose of taking advantage of Canadian metals mining opportunities. The company’s first asset acquisition was the Caribou and Restigouche lead-zinc mines located near Bathurst, New Brunswick. Blue Note intends to make other corporate and asset acquisitions in the near term future. Their exploration strategy is focused on providing a continuous source of sulphide ore feed for the concentrator at the Caribou mine/mill complex. For further information, visit the Company's web site at www.bluenotemining.ca.
BNK Petroleum Inc. (TSX: BKX CN)
BNK Petroleum Inc. (TSX: BKX CN), a California-based energy company, is focused on acquiring, exploring, and producing large oil and gas reserves. The company operates in the United States through its wholly-owned subsidiary BNK Petroleum (US) Inc., with properties located in Oklahoma, Texas, New York, Mississippi and Alabama. BNK Petroleum aggressively targets growth in production and reserves by tactically leveraging new and proven technologies. For further information, visit the Company's web site at www.bnkpetroleum.com.
Boots & Coots International Well Control, Inc. (AMEX: WEL)
Boots & Coots International Well Control, Inc. (AMEX: WEL) is focused on offering its suite of integrated pressure control and related services to onshore and offshore oil and gas exploration and development companies around the world. The company manufactures much of its own equipment, resulting in a faster, fit-for-purpose product. For faster, more economical workovers under live well conditions, Boots & Coots’ truck-mounted hydraulic rig-assist units provide for quick and easy rig-ups. For further information, visit the Company's web site at www.bootsandcoots.com.
BPZ Resources, Inc. (AMEX: BPZ)
BPZ Resources, Inc. (AMEX: BPZ), an oil and gas exploration and production company, has exclusive license contracts for oil and gas exploration and production covering about 2.4 million acres in four properties in northwest Peru. The company also owns a minority working interest in a producing property in southwest Ecuador. Currently, BPZ Resources is focusing its efforts on the execution of an integrated gas-to-power strategy, which includes generation and sale of electric power in Peru and sales of gas into Ecuador. For further information, visit the Company's web site at www.bpzenergy.com.
Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI)
Brainstorm Cell Therapeutics, Inc. (OTC BB: BCLI), a leading developer of stem cell technologies, is committed to providing treatments for neurodegenerative diseases that are currently incurable. The company’s focus is on developing NTF cells from the patient's own bone marrow to treat, Parkinson, ALS, and Spinal Cord Injury. The Brainstorm management and scientific teams are devoted to the company’s mission to regenerate the mind in their lifetime. For further information, visit the Company's web site at www.brainstorm-cell.com.
Bravo Venture Group Inc. (TSX: BVG CN)
Bravo Venture Group Inc. (TSX: BVG CN) is devoted to their shareholders and focused on increasing the value of the company by leveraging their experienced management team that has a successful track record of identifying, exploring and developing gold/silver properties within North America that exhibit potential for discovery. The company’s current focus is on N.W. British Columbia, Nevada, and S.E. Alaska. For further information, visit the Company's web site at www.bravoventuregroup.com.
Bucking Horse Energy, Inc. (TSX: BUC CN)
Bucking Horse Energy, Inc. (TSX: BUC CN), an independent oil and gas exploration and production company, has its operations focused on the prolific Pinedale field, in the Green River Basin of southwestern Wyoming. As of the end of 2007, the Company had proved reserves of approximately 101 Bcfe, comprised of 95% gas. Bucking Horse Energy is positioned to recognize double-digit reserve and production growth as its high-impact legacy asset in the Pinedale Anticline Field continues to be advanced. For further information, visit the Company's web site at www.buckinghorseenergy.com.
Buffalo Gold Ltd. (TSX: BUF CN)
Buffalo Gold Ltd. (TSX: BUF CN) owns a portfolio of projects ranging from grassroots exploration in known gold regions of Australia, to a +1 million ounce advanced gold project in Papua New Guinea. Additionally, the company has a producing gold deposit in Sardinia, Italy that has substantial upside potential for expansion. Buffalo's management is comprised of industry leaders that have experience in exploration, socially responsible development & mining, and a successful history of fund-raising. For further information, visit the Company's web site at www.buffalogold.net.
Canadian Arrow Mines Ltd. (TSX: CRO CN)
Canadian Arrow Mines Ltd. (TSX: CRO CN), an experienced exploration and mine company, is dedicated to acquiring and developing economically viable nickel sulphide deposits located near existing infrastructure. Arrow is rapidly advancing to develop its Kenbridge Nickel Copper deposit located within 40 km of established communities and infrastructure in northwestern Ontario, Canada. By building the next Canadian junior nickel mining company, Arrow aims to establish wealth for shareholders. For further information, visit the Company's web site at www.canadianarrowmines.ca.
Canadian Phoenix Resources Corp. (TSX: CPH CN)
Canadian Phoenix Resources Corp. (TSX: CPH CN), a publicly-traded junior oil and gas exploration, development and production company, has its operations in Western Canada. The company aims to strategically consolidate undervalued oil and gas assets located in the Western Canadian Sedimentary Basin. Canadian Phoenix controls about 276,000 net acres of land through its two subsidiary partners: Serrano Energy & Marble Point Energy. For further information, visit the Company's web site at www.canadian-phoenix.com.
CanAlaska Uranium Ltd. (TSX: CVV CN)
CanAlaska Uranium Ltd. (TSX: CVV CN) is focused on exploring for uranium in the Athabasca Basin of Saskatchewan, Canada. This region contains the world's richest and most profitable uranium deposits, and has accounted for one-third of the world’s global uranium supply and contributed 25% of global production in 2007. The company’s team is led by Dr. Karl Schimann, a veteran Athabasca uranium geologist who was a senior member of the team that discovered the prolific Cigar Lake Mine (grading 20% U3O8) in 1981. For further information, visit the Company's web site at www.canalaska.com.
Candax Energy Inc. (TSX: CAX CN)
Candax Energy Inc. (TSX: CAX CN), a Toronto-based oil and natural gas company, is focused on exploring, acquiring, developing and producing natural gas and crude oil, with emphasis on the Middle East and Africa. The company has concentrated their efforts on Tunisia and holds an interest in an exploration permit in Madagascar. Candax was founded by highly skilled executives and successful Canadian founders and financiers to develop an international upstream oil and gas asset portfolio. For further information, visit the Company's web site at www.candax.com.
Capitol Acquisition Corporation (AMEX: CLA)
Capitol Acquisition Corporation (AMEX: CLA) is a blank check company formed for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, one or more operating businesses or assets. Located in Washington, DC, Capitol is led by their CEO Mark D. Ein. For further information, visit the company website at: www.venturehousegroup.com.
Capstone Therapeutics (NASDAQ: CAPS)
Capstone Therapeutics (NASDAQ: CAPS), a biotechnology company, is focused on developing a pipeline of innovative therapeutic peptides designed to help patients with under-served medical conditions. The Company is currently committed to developing and commercializing two product platforms: AZX100 and Chrysalin® (rusalatide acetate or TP508). AZX100 is currently under evaluation for commercially significant medical applications such as treating pulmonary disease, and Chrysalin is currently under evaluation for treating disorders that involve vascular endothelial dysfunction. For further information, visit the Company's web site at www.capstonethx.com.
Carrizo Oil & Gas, Inc. (NASDAQ: CRZO)
Carrizo Oil & Gas, Inc. (NASDAQ: CRZO), a Houston based independent energy company, focuses on the exploration, development and production of natural gas and oil. The company’s current operations are concentrated in the Barnett Shale area of North Texas and the U.K. North Sea where two significant discoveries were made last year. Through the leveraging of a 3-D seismic database, Carrizo’s staff is continually adding to and refining the company’s substantial inventory of drilling locations. For further information, visit the Company's web site at www.carrizo.cc.
CAS Medical Systems, Inc. (NASDAQ: CASM)
CAS Medical Systems, Inc. (NASDAQ: CASM) is focused on designing and manufacturing novel, non-invasive technologies and products essential to patient care in the most challenging clinical environments. The company’s products are used by clinicians worldwide and are recognized for their highest quality. Each and every individual at CAS Medical is dedicated to demonstrating the highest standards of innovation, quality, service and performance. For further information, visit the Company's web site at www.casmed.com.
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX)
Catalyst Pharmaceutical Partners, Inc. (NASDAQ: CPRX), a specialty pharmaceutical company, is focused on developing and commercializing prescription drugs designed to treat drug addiction. Currently, CPP-109 is being developed to treat addiction to cocaine, methamphetamine and other addictive substances. The company’s mission is much larger than only serving their patients, as they also seek to benefit investors and the society at large. For further information, visit the Company's web site at www.catalystpharma.com.
Cavico Corp. (OTC BB: CVIC)
Cavico Corp. (OTC BB: CVIC), a major infrastructure construction, infrastructure investment and natural resources conglomerate headquartered in Hanoi, Vietnam, is focused on large infrastructure projects, which include the construction of hydropower facilities, dams, bridges, tunnels, roads, mines and urban buildings. Cavico’s project partners include top multi-national corporations and government organizations. For further information, visit the Company's web site at www.cavicocorp.com.
Celgene Corporation (NASDAQ: CELG)
Celgene Corporation (NASDAQ: CELG), a multinational biopharmaceutical company, is dedicated improving the lives of patients worldwide by delivering novel and life-changing drugs. Their aim is to build a major global biopharmaceutical corporation while discovering, developing, and commercializing products for the treatment of cancer and other severe, immune, inflammatory conditions. For further information, visit the Company's web site at www.celgene.com.
Cell Genesys, Inc. (NASDAQ: CEGE)
Cell Genesys, Inc. (NASDAQ: CEGE) has their focus on developing and commercializing novel biological therapies for cancer patients. GVAX® cancer imunotherapy, the company's lead product platform, holds the potential to treat several types of cancer. Cell Genesys also holds an equity interest in its former subsidiary, Ceregene, Inc., which is developing gene therapies for neurodegenerative disorders. For further information, visit the Company's web site at www.cellgenesys.com.
Cell Therapeutics, Inc. (NASDAQ: CTIC)
Cell Therapeutics, Inc. (NASDAQ: CTIC) is focused on leading the biopharmaceutical industry with their diversified portfolio of proprietary oncology drugs. They manage each and every aspect of the manufacturing process, but outsource their clinical and commercial active pharmaceutical ingredient (API) and finished product (FP) production activities to superior contract manufacturing organizations, both in the US and in Europe. For further information, visit the Company's web site at www.ctiseattle.com.
Celsion Corporation (NASDAQ: CLN)
Celsion Corporation (NASDAQ: CLN) is committed to developing and commercializing oncology drugs including tumor-targeting treatments. The company has research, license or commercialization agreements with leading institutions such as the National Institutes of Health, Duke University Medical Center, University of Hong Kong, North Shore Hospital-Albert Einstein Medical School. By using technology that delivers high concentrations of anti-cancer agents directly the tumor site, they are able to maximize efficacy while minimizing side-effects common to cancer treatment. For further information, visit the Company's web site at www.celsion.com.
Chariot Resources Limited (TSX: CHD CN)
Chariot Resources Limited (TSX: CHD CN) is focused on developing one of the world’s premier advanced stage copper projects. The Company’s 70% owned Marcona Copper Property in Peru is quickly progressing toward feasibility completion and production. The Mina Justa start-up project is poised for near-term production with an offtake agreement already in place, financial contributions from two Korean joint venture partners, and project financing of up to $325 million committed. For further information, visit the Company's web site at www.chariotresources.com www.chariotresources.com.
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP)
Chelsea Therapeutics International, Ltd. (NASDAQ: CHTP), a biopharmaceutical development company, is focused on acquiring and developing innovative products designed to treat a variety of human diseases. Currently, the company is developing a portfolio of metabolically inert antifolate compounds engineered to have potent anti-inflammatory and anti-tumor activity to treat a range of immunological disorders. Chelsea Therapeutics purposes to create value by building a world-class team, accelerating the development of its product candidates and expanding its therapeutic pipeline. For further information, visit the Company's web site at www.chelseatherapeutics.com.
China Agritech, Inc. (OTC BB: CAGC)
China Agritech, Inc. (OTC BB: CAGC) is a leading developer, manufacturer and distributor of environmentally friendly liquid compound organic fertilizers. As a profitable and rapidly growing U.S. public company operating in the People’s Republic of China, the company provides unique, proprietary fertilizers that are the result of over 12 years of intense research and development in cooperation with leading agricultural experts. For further information, visit the Company's web site at www.chinaagritechinc.com.
China Aoxing Pharmaceutical Company (OTC BB: CAXG)
China Aoxing Pharmaceutical Company (OTC BB: CAXG), a pharmaceutical company located in China, specializes in researching, developing, manufacturing and distributing a variety of narcotics and pain-management products. The company has China's largest product pipeline and largest manufacturing facility (1.2 million sq. ft.) for highly regulated narcotic medicines. This facility is one of the few GMP facilities licensed for narcotics medicines.
China Armco Metals, Inc. (OTC BB: CNAM)
China Armco Metals, Inc. (OTC BB: CNAM) is a U.S. based company engaged in the distribution of metal ores, steel scrap, and non-ferrous metals within China. The company’s products include iron ore, nickel ore, chrome ore, copper ore and zinc ore. Leveraging management's proven experience in the industry and the company’s extended sales network that covers all major provinces of China, China Armco Metals has successfully established stable partnerships with many metal manufacturing enterprises through long-term collaboration.
China Automotive Systems, Inc. (NASDAQ: CAAS)
China Automotive Systems, Inc. (NASDAQ: CAAS), a leading supplier of power steering systems and components to China’s automotive industry, is aggressively pursuing strategies in technology to maintain a competitive edge within the automobile industry. Operating through nine subsidiaries, the company has more than ten years experience in power steering manufacturing with a current annual capability of 1 million units. For further information, visit the Company's web site at www.caasauto.com.
China Cablecom Holdings, Ltd. (NASDAQ: CABL)
China Cablecom Holdings, Ltd. (NASDAQ: CABL) is an emerging consolidated cable network operator and service provider. The company is currently establishing a dominant market share in Shandong, one of China’s most affluent and addressable cable markets, and where 17 municipal cable operators and 57 county-level cable operators jointly provide cable television services to more than 10 million cable TV households. For further information, visit the Company's web site at www.chinacablecom.net.
China Clean Energy Inc., (OTCBB: CCGY)
China Clean Energy Inc., (OTCBB: CCGY) is a developer, manufacturer and distributor of biodiesel fuel and high-quality specialty chemical products from renewable resources, including waste grease and vegetable oils. With a number of proprietary and patented innovations and processes, China Clean Energy is well positioned to continue its expansion, and demand for the company's products is rapidly accelerating due to China's rapidly growing fuel needs, escalating energy prices and increasing environmental concerns. For further information, visit the Company's web site at www.chinacleanenergyinc.com.
China Direct Inc. (NASDAQ: CDS)
China Direct Inc. (NASDAQ: CDS), a diversified management and advisory services organization headquartered in the United States, owns and consults business entities operating in the People’s Republic of China. The company’s Management Services division acquires controlling interest in Chinese businesses, creating a platform to expand business opportunities globally while accessing the U.S. capital markets. China Direct’s Advisory Services division provides comprehensive advisory and consulting services to Chinese business entities seeking to access the U.S. capital markets. For further information, visit the Company's web site at www.chinadirectinc.com.
China Donghang Printing Technology Inc.
China Donghang Printing Technology Inc., a sheet-fed offset printing company, is soon to be a U.S. publicly listed entity with primary operations conducted through the its wholly owned PRC subsidiary, Weifang Donghang Precision Technology Co. Ltd. China Donghang Printing Technology has created 17 different sheet-fed offset printing presses, which can be divided into two types: Flexographic printing presses and sheet-fed offset printing presses. For further information, visit the Company's web site at www.china-donghang.com.
China Education Alliance, Inc. (OTC BB: CEUA)
China Education Alliance, Inc. (OTC BB: CEUA), an educational service company offering high-quality online education materials and on-site training and tutoring to families, education officials, schools and teachers in China, disseminates online test preparation materials, researchers' materials, study guides, audio recordings, and provides vocational skills and certification training. The company’s training programs include: the “Famed Instructors Test Paper Store,” which is marketed to its database of more than 300,000 exams and test papers and courseware. For further information, visit the Company's web site at www.chinaeducationalliance.com.
China Education Resources Inc. (TSX: CHN CN)
China Education Resources Inc. (TSX: CHN CN), a leading provider of products and services to China's kindergarten to grade 12 market, is focused on building the most robust and flexible educational portal in the world, capable of handling the online teaching, learning, and administrative requirements of 600,000 schools, 12 million teachers and 230 million students in China. For further information, visit the Company's web site at www.chinaeducationresources.com.
China Energy Recovery (OTC BB: CGYV)
China Energy Recovery (OTC BB: CGYV), an international leader in designing, fabricating, implementing and servicing energy recovery systems, utilizes industrial waste energy to create low-cost electrical power. The company's industrial waste recycling systems are effective at reducing sulfur dioxide emissions, and allow industrial manufacturers to reduce their energy costs, decrease their emissions footprint, and generate sellable emissions credits. For further information, visit the Company's web site at www.chinaenergyrecovery.com.
China Green Agriculture (OTC BB: CGAG)
China Green Agriculture (OTC BB: CGAG) is a leading green fertilizer manufacturer that produces and distributes humic acid liquid compound fertilizer throughout 27 provinces in China. The green fertilizer industry is experiencing significant growth due to the deteriorating quality of land from the use of harsh chemicals and limited per capita arable land. China Green Agriculture operates a 137,000-square-meter state-of-the-art research and development facility and a fully automated 47,000-square-meter production facility that has an annual capacity of 10,000 metric tons of green fertilizer. For further information, visit the Company's web site at www.cgagri.com.
China Health Care Acquisition Corporation (AMEX: CHM)
China Health Care Acquisition Corporation (AMEX: CHM) was formed on June 7, 2006 for the purpose of acquiring one or more businesses with operations primarily in China and currently does not have significant operations. The company is identifying prospective targets, not be limited to a particular industry; however, China Healthcare Acquisition Corp. intends to focus its efforts on acquiring one or more operating businesses in the healthcare sector.
China Marine Food Group Ltd. (OTC BB: CMFO)
China Marine Food Group Ltd. (OTC BB: CMFO), a distributor of processed seafood products, was founded in 1994. With operations in the Fujian Province, one of the largest coastal provinces in China and an ideal hub between the East China Sea and the South China Sea, China Marine Food Group has grown steadily and positioned its "Mingxiang" brand as a category leader in 1,400 retail sales points in the PRC. Additionally, the company is ISO9001, ISO14001, HACCP certified, solidifying its commitment to overall quality.
China Natural Gas, Inc. (OTC BB: CHNG)
China Natural Gas, Inc. (OTC BB: CHNG) is a U.S. publicly traded company that owns and operates its natural gas related businesses in China. As a leading provider of pipeline natural gas for industrial, commercial and residential use and compressed natural gas (CNG) for vehicular fuel, the company operates a 120 kilometer long compressed natural gas pipeline in Xi'an, China, a rapidly growing Chinese city with a population of approximately 8 million people. For further information, visit the Company's web site at www.naturalgaschina.com.
China North East Petroleum Holdings Limited (OTC BB: CNEH)
China North East Petroleum Holdings Limited (OTC BB: CNEH), established in 2003 under the name of Hong Xiang Petroleum, is a pioneer in China’s private oilfield services industry. Through its three Chinese subsidiaries, the company has entered into 20-year lease agreements with PetroChina Jilin Branch for the extraction of crude oil in Jilin Qian’an Oilfield. China North and its 312 results-driven employees are dedicated to accelerating production, generating strong cash flow and creating shareholder value. For further information, visit the Company's web site at www.cnepetroleum.com.
China Precision Steel, Inc. (NASDAQ: CPSL)
China Precision Steel, Inc. (NASDAQ: CPSL), a niche and high value-added steel processing company, focuses on taking commodity steel and using it to create a specialty premium steel that yields above industry gross margins. The company produces and sells high precision ultra-thin and high strength (7.5 mm to 0.03 mm) cold-rolled steel products and offers heat treatment and cutting for steel strips. For further information, visit the Company's web site at www.chinaprecisionsteelinc.com.
China Recycling Energy Corp. (OTCBB: CREG)
China Recycling Energy Corp. (OTCBB: CREG) is a provider of environmentally friendly waste-to-energy technologies. By recycling industrial byproducts from steel mills, cement factories and coke plants in China, the company uses the byproducts, including heat, steam, pressure and exhaust, to generate cost-effective electricity solutions, while reducing the need for outside electrical sources. For further information, visit the Company's web site at www.creg-cn.com/en.
China Ritar Power Corp. (OTC BB: CRTP)
China Ritar Power Corp. (OTC BB: CRTP), a leading valve-control lead-acid battery manufacturer with its headquarters in Shenzhen High-tech Industrial Park in the People’s Republic of China, operates two production bases; one 19,326-square-meter workshop in Shenzhen and another 13,000-square-meter workshop in Shanghai. Valve-control lead-acid batteries are used in: light-type electric vehicles (e.g. electric bikes and scooters), standby energy of communication systems, and solar and wind energy storage systems. For further information, visit the Company's web site at www.ritarpower.com.
China Sky One Medical, Inc., (NASDAQ: CSKI)
China Sky One Medical, Inc., (NASDAQ: CSKI), a manufacturer, marketer and distributor of pharmaceutical, medicinal and diagnostic products, operates through its wholly owned subsidiaries, Harbin Tian Di Ren Medical Science and Technology Company, Harbin First Bio- Engineering Company Limited and Heilongjiang Tianlong Pharmaceutical, Inc. Founded in 1994, the company manufactures and sells external TCMs and over-the-counter non-prescription healthcare products. For further information, visit the Company's web site at www.skyonemedical.com.
China Solar & Clean Energy Solutions, Inc. (OTC BB: CSOL)
China Solar & Clean Energy Solutions, Inc. (OTC BB: CSOL), a leading provider of solar and renewable energy products in the PRC through its subsidiaries, is focused on designing, manufacturing, marketing and servicing the most efficient and reliable solar hot water heaters and space heating devices. Currently, the company has about 364 employees and operates three factory facilities in Bazhou with a total of over 72,590 square meters of production, warehouse, and office space and space for use as a distribution center.
China Wind Systems, Inc. (OTC BB: CWSI)
China Wind Systems, Inc. (OTC BB: CWSI) is focused on supplying forged components for use in the wind energy industry. Through its affiliates, the Company manufactures and sells high-precision components to the wind power industry and industrial equipment to the textile and energy industries in China. The Company is currently completing its phase I expansion to manufacture forged products including rolled rings up to 6.3 meters, with a cross section up to 700 millimeters used in 5 megawatts(MW) wind turbine units; gear rims and flanges; and shafts used in 1-3 MW wind turbine units. For further information, visit the Company's web site at www.chinawindsystems.cn.
China Yingxia International Inc. (OTC BB: CYXI)
China Yingxia International Inc. (OTC BB: CYXI), a leading health and nutritional foods company based in the Peoples Republic of China, has a product portfolio that includes hundreds of different products categorized into five product lines: nutritional foods, dietary supplements, raw cactus products, cosmetic products, and personal care & other products. The company’s products are sold throughout China as well as around the globe. For further information, visit the Company's web site at www.chinayingxia.com.
ChinaCast Education Corporation (NASDAQ: CAST)
ChinaCast Education Corporation (NASDAQ: CAST), a leading for-profit, post-secondary education and e-learning services provider in China, provides its education services through a 80% ownership in the holding company of the Foreign Trade and Business College (FTBC) of Chongqing Normal University. FTBC offers fully-accredited, career-oriented bachelor's degree and diploma programs in business, economics, trade, tourism management, advertising, language, IT and music. For further information, visit the Company's web site at www.ir.chinacast.com.cn.
Clarient, Inc. (NASDAQ: CLRT)
Clarient, Inc. (NASDAQ: CLRT) is focused on providing services, resources and critical information that improve the quality of life of patients, while reducing the cost of patient care. Pathologists, oncologists, hospitals and biopharmaceutical companies are the company’s primary customers. Clarient’s state-of-the-art commercial cancer laboratory provides the most sophisticated oncology testing and drug development services available both onsite and over the web. For further information, visit the Company's web site at www.clarientinc.com.
Cleveland BioLabs, Inc. (NASDAQ: CBLI)
Cleveland BioLabs, Inc. (NASDAQ: CBLI), a drug discovery and development company, is focused on using its proprietary discoveries to develop treatments for cancer and protection of normal tissues from exposure to radiation and other stresses. The company’s pipeline includes products from two primary families of compounds: Protectans and Curaxins. Protectans are being developed as drug candidates that protect normal tissues from acute stresses such as radiation, chemotherapy and ischemias, while Curaxins are being developed as anticancer agents that may function as mono-therapy drugs. For further information, visit the Company's web site at www.cbiolabs.com.
Coda Octopus Group, Inc. (OTC BB: CDOC)
Coda Octopus Group, Inc. (OTC BB: CDOC), an internationally recognized specialist in underwater technologies for imaging, mapping, defense and survey, has dramatically expanded from its single-product beginnings and now has a global customer base and a growing range of products used in increasingly diverse applications. The company intends to become the world's leading sonar technology company and be ranked amongst the top companies in the broader $1 billion international marine products market. For further information, visit the Company's web site at www.codaoctopus.com.
CombiMatrix Corporation (NASDAQ: CBMX)
CombiMatrix Corporation (NASDAQ: CBMX) is a diversified biotechnology company focused on developing proprietary technologies, products and services in the areas of drug development, genetic analysis, molecular diagnostics, nanotechnology research, defense and homeland security markets, as well as other potential markets. Their unique technology has a wide range of potential applications in the areas of genomics, proteomics, biosensors, drug discovery, drug development, diagnostics, combinatorial chemistry, material sciences and nanotechnology. For further information, visit the Company's web site at www.combimatrix.com.
CombinatoRx, Incorporated (NASDAQ:CRXX)
CombinatoRx, Incorporated (NASDAQ: CRXX) is a biopharmaceutical company focused on developing synergistic combinations of approved drugs using its proprietary combination high throughput screening (cHTS) technology. The company’s lead product candidate is CRx-102, a novel dissociated immuno-inflammatory glucocorticoid product candidate under Phase IIb clinical development for osteoarthritis and rheumatoid arthritis. Other products include CRx-139, a dissociated glucocorticoid product candidate; CRx-191, a topical synergistic combination drug candidate; and CRx-197, a novel topical anti-inflammatory product candidate. For further information, visit the Company's web site at www.combinatorx.com.
Compugen, Ltd. (NASDAQ: CGEN)
Compugen, Ltd. (NASDAQ: CGEN) is a genomics-based drug and diagnostic discovery company focused on becoming a world leader in the discovery and licensing of product candidates to the drug and diagnostic industries under milestone and revenue sharing agreements. The Company’s powerful, proprietary discovery platforms enable the predictive discovery of numerous therapeutic and diagnostic product candidates. Their collboarations include Biosite, Medarex, Inc., Merck & Co., Inc., Ortho-Clinical Diagnostics, Roche, Siemens Healthcare Diagnostics, Inc., and Teva Pharmaceutical Industries. For further information, visit the Company's web site at www.cgen.com.
Copper Mountain Mining Corporation (TSX: CUM CN)
Copper Mountain Mining Corporation (TSX: CUM CN), a British Columbia resource company, owns 100% of the Copper Mountain Project located just south of the town of Princeton. Recently, the Company completed an independent feasibility study that verified the economic viability of bringing a conventional open pit mine back into production. The mine is a former producer, with a Measured and Indicated Mineral Resource of 260.2 million tons averaging 0.357% Cu containing 1.8 billion lb copper. For further information, visit the Company's web site at www.cumtn.com.
Converted Organics, Inc. (NASDAQ: COIN)
Converted Organics, Inc. (NASDAQ: COIN)is focused on producing a valuable organic biostimulant (a natural fertilizing product) through food waste recycling. The company leverages proven, state-of-the-art technologies and creates a product that helps farmers and gardeners grow healthier food crops. Their recycling facilities have no negative environmental impacts on hosting communities, and are dedicated to bringing real benefits to the communities in which they conduct their work. For further information, visit the Company's web site at www.convertedorganics.com.
Corcept Therapeutics Incorporated (NASDAQ: CORT)
Corcept Therapeutics Incorporated (NASDAQ: CORT), a pharmaceutical company, is focused on engaging in the development of GR-II antagonist drugs for the treatment of severe psychiatric and metabolic diseases. CORLUX, the company’s lead product, is currently in Phase 3 clinical trials for the treatment of the psychotic features of psychotic depression and Cushing's Syndrome. Additionally, Corcept is preparing for clinical trials to evaluate CORLUX for the mitigation of weight gain induced by antipsychotic medications as well as continuing the development of its proprietary, selective GR-II antagonists. For further information, visit the Company's web site at www.corcept.com.
Cortex Pharmaceuticals, Inc. (AMEX: COR)
Cortex Pharmaceuticals, Inc. (AMEX: COR), a biopharmaceutical company, is focused on the discovery, development and commercialization of AMPAKINE molecules designed to treat human central nervous system diseases. These novel small molecule drugs represent usher a new approach to treating psychiatric disorders, neurological diseases and brain mediated breathing disorders. For further information, visit the Company's web site at www.cortexpharm.com.
Cougar Biotechnology, Inc. (NASDAQ: CGRB)
Cougar Biotechnology, Inc. (NASDAQ: CGRB), a Los Angeles-based biotechnology company, was established to in-license and develop clinical stage drugs. Their specific focus is on the field of oncology. The company’s portfolio includes CB7630, which is being tested in a Phase III clinical trial in prostate cancer; CB3304, which is in a Phase I trial in multiple myeloma; and CB1089, which has been clinically tested in a number of solid tumor types. For further information, visit the Company's web site at www.cougarbiotechnology.com.
CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX)
CPEX Pharmaceuticals, Inc. (NASDAQ: CPEX), a specialty pharmaceutical company, is focused on the development, licensing and commercialization of pharmaceutical products through the leveraging of their validated drug delivery technology. The company has U.S. and international patents as well as other proprietary rights to technologies that encourage the absorption of drugs. For further information, visit the Company's web site at www.cpexpharm.com.
Crimson Exploration, Inc. (OTC BB: CXPO)
Crimson Exploration, Inc. (OTC BB: CXPO), an independent oil and gas company based in Houston, Texas, has focused its efforts on the U.S. Gulf Coast Region. The company owns and operates over 280 wells located in Texas, Colorado, Louisiana and Mississippi, and had estimated proved reserves of 130 Bcfe of natural gas equivalents. The Company's major properties are located in Liberty County, Texas (the Felicia Fields), the SW Speaks Field in Lavaca County, Texas, the Cage Ranch Field in Brooks County, Texas and the Iowa Field area in southwest Louisiana. For further information, visit the Company's web site at www.crimsonexploration.com.
Crosshair Exploration & Mining Corp. (AMEX: CXZ)
Crosshair Exploration & Mining Corp. (AMEX: CXZ), a leading junior exploration company, has focused their efforts on exploring and developing uranium in the Central Mineral Belt of Labrador. The company has planned an intensive 8,000 m drill program for the remainder of 2008, which will be directed at expanding known mineralization along the C Zone - Armstrong Corridor. As exploration advances, the Central Mineral Belt may take its place as the next big uranium district in Canada. For further information, visit the Company's web site at www.crosshairexploration.com.
CuraGen Corporation (NASDAQ: CRGN)
CuraGen Corporation (NASDAQ: CRGN), a biopharmaceutical company, is devoted to improving the lives of patients by developing pharmaceutical products that address medical needs that are currently unmet. The company’s therapeutics are based on the research of novel drug targets and mechanisms that are believed to play a role in underlying diseases. Through its efforts, CuraGen has utilized this research and understanding to develop a pipeline of protein, antibody, and antibody-drug conjugate drugs. For further information, visit the Company's web site at www.curagen.com.
Curis, Inc. (NASDAQ: CRIS)
Curis, Inc. (NASDAQ: CRIS), a drug development company, is focused on utilizing its innovative signaling pathway drug technologies to discover new targeting small molecule drug candidates for cancer. Through the expansion of its drug development efforts in the field of cancer, the company is building upon its previous experiences in targeting signaling pathways to develop next generation targeted cancer therapies. For further information, visit the Company's web site at www.curis.com.
CV Therapeutics, Inc.’s (NASDAQ: CVTX)
CV Therapeutics, Inc.’s (NASDAQ: CVTX) primary focused is on applying molecular cardiology to the discovery, development and commercialization of novel, small molecule drugs for the treatment of cardiovascular diseases. The company is devoted to discovering new solutions for the unmet medical needs of patients. By emphasizing on discovery science and small molecule therapeutics, the company’s drug candidates are usually able to be produced by conventional pharmaceutical manufacturing methods. For further information, visit the Company's web site at www.cvt.com.
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC)
Cyclacel Pharmaceuticals, Inc. (NASDAQ: CYCC), a diversified biopharmaceutical company, is focused on discovering, developing, and commercializing innovative mechanism-targeted drugs to treat human cancers and other serious disorders. The company’s strategic goal is to discover and develop oral anticancer agents that target the cell cycle with the intent to slow the growth of tumors or even shrink their size while enhancing the patient’s quality of life. For further information, visit the Company's web site at www.cyclacel.com.
Cytokinetics, Incorporated (NASDAQ: CYTK)
Cytokinetics, Incorporated (NASDAQ: CYTK), a biopharmaceutical company, is devoted to the discovery, development and commercialization of innovative small molecule drugs. The company’s cardiovascular disease program is focused on cardiac myosin, which is a motor protein vital to cardiac muscle contraction. CK-1827452, Cytokinetics' lead compound from this program, is a small molecule cardiac myosin activator that has entered Phase II clinical trials for the treatment of heart failure. For further information, visit the Company's web site at www.cytokinetics.com.
Cytomedix, Inc. (AMEX: GTF)
Cytomedix, Inc. (AMEX: GTF), a biotechnology company, is focused on developing, selling and licensing regenerative biological therapies. Their AutoloGel(tm) System, a device used to produce platelet rich plasma gel derived from the patient's own blood, has been cleared by the Food and Drug Administration (``FDA'') for use on a variety of exuding wounds. Currently, the Company is executing a multi-faceted strategy to infiltrate the chronic wound market with its AutoloGel(tm) System. For further information, visit the Company's web site at www.cytomedix.com
Cytori Therapeutics, Inc. (NASDAQ: CYTX)
Cytori Therapeutics, Inc. (NASDAQ: CYTX) is committed to becoming the global leader in regenerative medicine. The company focuses on providing patients with new options for reconstructive and aesthetic surgery, developing treatments for cardiovascular disease, and banking adipose-derived, adult stem and regenerative cells (ADRCs). To meet its objective, Cytori developed Celution® Technology to separate and concentrate a patient’s own ADRCs for delivery back to the same patient in a single surgical procedure. For further information, visit the Company's web site at www.cytoritx.com.
CytRx Corporation (NASDAQ: CYTR)
CytRx Corporation (NASDAQ: CYTR), a biopharmaceutical research and development company, is focused on developing high-value human therapeutics. Their drug development pipeline includes six programs in clinical development. The Company owns and operates a research and development facility in San Diego, California, and holds a 45% equity interest in RXi Pharmaceuticals (NasdaqCM: RXII <http://finance.yahoo.com/q?s=rxii> ). For further information, visit the Company's web site at www.cytrx.com.
Delcath Systems, Inc. (NASDAQ: DCTH)
Delcath Systems, Inc. (NASDAQ: DCTH), a medical technology company specializing in cancer treatment, is currently testing a proprietary, patented drug delivery system designed to treat liver cancers. The company is enrolling patients in Phase III and Phase II clinical studies for the treatment of liver cancers using high doses of melphalan. Twenty-eight international patents consist of the Company's intellectual property portfolio. For further information, visit the Company's web site at www.delcath.com.
Dejour Enterprises, Ltd. (AMEX: DEJ)
Dejour Enterprises, Ltd. (AMEX: DEJ) is an active micro cap oil and natural gas explorer and producer focused on strategically assembling and developing North American energy properties. The company has 149,852 net acres of premium energy assets in two of North America’s most prolific areas. Dejour’s flagship properties cover 128,000 net acres in the U.S. Rocky Mountains and 21,852 net acres in Canada’s Peace River Arch. For further information, visit the Company's web site at www.dejour.com.
Delphi Energy Corp. (TSX: DEE CN)
Delphi Energy Corp. (TSX: DEE CN), a Calgary-based public junior oil and natural gas company, has concentrated its efforts on northwestern Alberta and northeast British Columbia. The company is poised for organic growth with a large inventory of development opportunities complemented by a high-impact exploration program. Delphi is led by a team of experienced executives and board of directors, all of which are shareholders focused on efficient share-value growth. For further information, visit the Company's web site at www.delphienergy.ca.
DelSite Biotechnologies, Inc. (OTC BB: DSII)
DelSite Biotechnologies, Inc. (OTC BB: DSII), an ISO 9001-certified, research-based, biopharmaceutical and consumer products company, has a core technology based on naturally-occurring complex carbohydrates. The company is focused on manufacturing and marketing consumer products as well as manufacturing quality products for other companies. Its proprietary GelSite(r) technology is protected by more than 130 patents in 26 countries. For further information, visit the Company's web site at www.delsite.com.
Delta Petroleum Corporation (NASDAQ: DPTR)
Delta Petroleum Corporation (NASDAQ: DPTR), a Denver, Colorado based independent energy company, is focused on exploring for, acquiring, developing, and producing natural gas and crude oil. The company has significant leaseholds in the Columbia River Basin in eastern Washington, a prospective frontier resource province. Delta’s strategy is to grow proven reserves and production through development drilling and acquisitions. For further information, visit the Company's web site at www.deltapetro.com.
Dendreon Corporation (NASDAQ: DNDN)
Dendreon Corporation (NASDAQ: DNDN), a biotechnology company, is focused on targeting cancer and transforming lives through the discovery, development and commercialization of therapeutics. The Company leverages its staff’s expertise in antigen identification, engineering and cell processing to produce active cellular immunotherapy product candidates that stimulate an immune response. Additionally, Dendreon is developing an orally-available small molecule that targets Trp-p8, which could applicable to multiple types of cancer as well as benign prostatic hyperplasia. For further information, visit the Company's web site at www.dendreon.com.
Depomed, Inc. (NASDAQ: DEPO)
Depomed, Inc. (NASDAQ: DEPO), a specialty pharmaceutical company, is devoted to enhancing existing pharmaceutical products. To date, the company has brought two products to market and has developed a pipeline with late-stage product opportunities designed to address common medical conditions. Depomed’s core delivery technology, AcuForm, is a patented, polymer-based technology that improves delivery through gastric retention. For further information, visit the Company's web site at www.depomedinc.com.
Derma Sciences, Inc. (OTC BB: DSCI)
Derma Sciences, Inc. (OTC BB: DSCI), a global manufacturer and marketer of advanced wound-care products, sells its primary product, MEDIHONEY(TM), around the globe through Derma Sciences and Comvita New Zealand, and is known as the leading brand of honey-based dressings for wounds and burns. MEDIHONEY has been proven to effectively treat a variety of wounds and burns, and was recently the focus of a large-scale randomized controlled trial on leg ulcers. For further information, visit the Company's web site at www.dermasciences.com.
Diamond Discoveries International Corp. (OTC BB: DMDD)
Diamond Discoveries International Corp. (OTC BB: DMDD), a wholly owned subsidiary of Diamond Discoveries International Corp., is a U.S. exploration company with executive offices in New York, NY and Toronto Ontario. The company has obtained 100% interest in 91 mining claims (covering 3855 hectares) in the Thetford Mines area of Southern Quebec. The rocks of the Thetford Mines Ophiolite Complex represent a historic chrome resource. For further information, visit the Company's web site at www.platinumdiscoveriescorp.com.
DOR BioPharma, Inc. (OTC BB: DORB)
DOR BioPharma, Inc. (OTC BB: DORB), a late-stage biopharmaceutical company, is committed to developing products that treat the life-threatening side effects of cancer treatments and serious gastrointestinal diseases; in addition to vaccines for certain bioterrorism agents. orBec®, DOR's lead product, is a potent, locally acting corticosteroid being developed to treat gastrointestinal Graft-versus-Host disease (GI GVHD), a common and potentially life-threatening complication of bone marrow transplantation. For further information, visit the Company's web site at www.dorbiopharma.com.
ouble Eagle Petroleum Co. (NASDAQ: DBLE)
Double Eagle Petroleum Co. (NASDAQ: DBLE) is focused on exploring, developing and transporting oil and gas in the Rocky Mountains. The company's operations are currently focused on the prolific Rocky Mountain Basins, the Green River Basins and Washakie Basins. The company’s aim is to increase stockholder value by providing a positive and rewarding work environment for employees while operating profitably and expanding assets. For further information, visit the Company's web site at www.dble.us.
Duckwall-ALCO Stores, Inc. (NASDAQ: DUCK)
Duckwall-ALCO Stores, Inc. (NASDAQ: DUCK) has grown from a company with a single retail store to a 264 store retail chain that operates in 22 states. Although Duckwall has dramatically increased in size, it still maintains a personal mission of providing convenient, friendly small-town service. The company believes its disciplined product presentation, attractive displays, and efficient checkout procedures have made its stores the choice of millions of consumers every month. For further information, visit the Company's web site at http://www.duckwall.com.
Duluth Metals Limited (TSX: DM CN)
Duluth Metals Limited (TSX: DM CN), a Canadian Corporation, is dedicated to exploring and developing copper, nickel and platinum group metal (PGM) deposits within the emerging Duluth Complex mining camp in northeastern Minnesota, USA. The company’s asset, Nokomis Deposit, is estimated to contain 449 million tonnes of the higher classification resource category of Indicated Resources grading 0.624% copper, 0.199% nickel, 0.600 grams per tonne of total precious metals (TPM = Platinum+Palladium+Gold), and an additional 284 million tonnes of Inferred Resources grading 0.627% copper, 0.194% nickel, 0.718 grams per tonne of TPM. For further information, visit the Company's web site at www.duluthmetals.com.
Dune Energy, Inc. (AMEX: DNE)
Dune Energy, Inc. (AMEX: DNE), an independent exploration and development company, has its operations focused along the Louisiana/Texas Gulf Coast. The company currently operates more than 90% of its production and typically maintains a 100% WI. As of January 1, 2008, the company’s proved reserves totaled 175 Bcfe. Dune intends to continue exploiting its existing asset base, while seeking accretive acquisitions and entering into additional joint venture drilling programs. For further information, visit the Company's web site at www.duneenergy.com.
Alpharma, Inc. (NYSE: ALO)
Alpharma, Inc. (NYSE: ALO), a global specialty pharmaceutical company, has an expanding branded franchise within the U.S. pain market with its KADIAN Capsules and the FLECTOR Patch 1.3%. The company is active in over 80 countries and is known throughout the world as a leading provider of pharmaceutical products for poultry and livestock. For further information, visit the Company's web site at www.alpharma.com.
DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA)
DUSA Pharmaceuticals, Inc. (NASDAQ: DUSA), an integrated dermatology pharmaceutical company, has its primary focus on developing and marketing its Levulan® Photodynamic Therapy (PDT) technology platform, and complementary dermatology products. Levulan PDT is approved to treat of Grade 1 or 2 actinic keratoses of the face or scalp. ClindaReach is the company’s other dermatology product. Additionally DUSA is researching other indications for Levulan PDT including oral Leukoplakia and the prevention of AKs and SCCs. For further information, visit the Company's web site at www.dusapharma.com.
Dyax Corp. (NASDAQ: DYAX)
Dyax Corp. (NASDAQ: DYAX) is focused on discovering, developing, and commercializing novel biopharmaceuticals for medical needs that are currently unmet. The company hopes to meet its objectives while delivering outstanding value to patients and stockholders. Their produce candidates include fully human monoclonal antibodies in addition to small proteins and peptides. For further information, visit the Company's web site at www.dyax.com.
East Asia Minerals Corporation (TSX: EAS CN)
East Asia Minerals Corporation (TSX: EAS CN), a well-financed, Asian-based, Canadian mineral exploration company, is focused on executing its aggressive exploration, acquisition and growth strategy. The company explores advanced gold and gold-copper properties in Indonesia and advanced uranium properties in Mongolia. East Asia currently owns ten uranium properties, including the advanced Ingiin-Nars, Ulaan Nuur and Enger uranium projects, and a 75% interest in the Khok Adar copper oxide discovery in Mongolia. For further information, visit the Company's web site at www.eaminerals.com.
Echo Therapeutics, Inc. (OTC BB: ECTE)
Echo Therapeutics, Inc. (OTC BB: ECTE) has their focus on thelate-stage development of transdermal diagnostic devices as well as specialty pharmaceuticals. The company is currently developing a needle-free, transdermal continuous glucose monitoring system in conjunction with novel transdermal reformulations of existing FDA-approved products. Echo Therapeutics hopes to change the paradigm of invasive, episodic glucose testing in diabetes home use and hospital critical care markets. For further information, visit the Company's web site at www.echotx.com.
ECU Silver Mining, Inc. (TSX: (OTC BB: ECU CN)
ECU Silver Mining, Inc. (TSX: ECU CN), a Canadian-based, mid-tier, producing mining company, has been focused on the engagement of gold, silver, lead and zinc exploration and exploitation since 1997. The Company has a cluster of seven mines in the historically prolific Velardeña mining district, Central Mexico, where it has had a number of major discoveries. ECU processes ore at its wholly owned milling facilities. For further information, visit the Company's web site at www.ecu.ca.
eFuture Information Technology, Inc. (NASDAQ:EFUT)
eFuture Information Technology, Inc. (NASDAQ: EFUT) is focused on applying advanced technology, valuable professional service and best practices to help clients purge inefficiencies and ineffectiveness in business. The company’s clients are centered in the retail, automotive, general household appliance and consumer goods industries. e-Future currently provides software products and services to more than 800 clients. For further information, visit the Company's web site at www.e-future.com.cn.
Emergent BioSolutions, Inc. (NYSE: EBS)
Emergent BioSolutions, Inc. (NYSE: EBS), a leading biopharmaceutical company, is focused on its mission to protect life. To achieve this goal, the company develops, manufactures, and commercializes immune related biologics, vaccines and biotherapeutics designed to support the body’s immune system to prevent or treat infectious and other life threatening diseases. Their broad product pipeline also includes: two “next generation” anthrax vaccines, two anthrax therapeutics (immunoglobulin and monoclonal), two botulinum vaccines and a botulinum therapeutic, an oral typhoid vaccine, a next generation tuberculosis vaccine, a hepatitis B immunotherapy, and a chlamydia vaccine. For further information, visit the Company's web site at www.ebsi.com.
Emisphere Technologies, Inc. (NASDAQ: EMIS)
Emisphere Technologies, Inc. (NASDAQ: EMIS), a biopharmaceutical company, is focused on utilizing its Eligen(r) Technology to uniquely deliver therapeutic molecules. Traditionally, these molecules are delivered by injection, and in many cases, are limited because of poor bioavailability, slow on-set of action or variable absorption. With Eligen(r) Technology, oral administration is possible as well other delivery pathways. For further information, visit the Company's web site at www.emisphere.com.
Enable Holdings, Inc. (OTC BB: ENAB)
Enable Holdings, Inc. (OTC BB: ENAB), the world's leading excess inventory solutions company, is focused on linking brand name sellers with customers around the globe. The company does this through its multi-channel asset-recovery solution that includes an online auction platform located at www.ubid.com, upcoming fixed-price commerce solution RedTag.com, offline excess inventory solution RedTag Live!, business-to-business solution Dibu Trading Company, and upcoming private auction software company Commerce Innovations. For further information, visit the Company's web site at www.enableholdings.com.
Endeavour Silver Corp. (AMEX: EXK)
Endeavour Silver Corp. (AMEX: EXK), a Canadian based silver mining company, is focusing their efforts on growing silver production, reserves and resources in Mexico. Currently, the company is executing expansion programs at the high grade Guanacevi Mines Project in the state of Durango and the Guanajuato Project in the state of Guanajuato. Endeavour is also actively exploring projects in Chihuahua and Michoacan states. For further information, visit the Company's web site at www.edrsilver.com.
Energy Fuels Inc. (TSX: EFR CN)
Energy Fuels Inc. (TSX: EFR CN) is focused on developing and mining uranium & vanadium property interests located in the States of Colorado, Utah, and Arizona, as well as conducting exploration activities to define and acquire additional recoverable resources. The Company has already acquired property interests that encompass six former operating uranium mines. Energy Fuels currently controls over 40,000 acres of BLM mineral claims and fee leases in highly prospective uranium provinces. For further information, visit the Company's web site at www.energyfuels.com.
EnerJex Resources, Inc. (OTC BB: ENRJ)
EnerJex Resources, Inc. (OTC BB: ENRJ), an oil and natural gas acquisition, exploration and development company, is focused on acquiring oil and natural gas mineral leases that have existing production and cash flow. After acquiring a prospect, the company implements an accelerated development program that leverages capital resources, a regional operating focus, an experienced management and technical team, and enhanced recovery technologies to attempt to increase production as well as returns for stockholders. For further information, visit the Company's web site at www.enerjexresources.com.
Enterprise Acquisition Corporation (AMEX: EST)
Enterprise Acquisition Corporation (AMEX: EST) is a Delaware blank check company incorporated on July 9, 2007 for the purpose of serving as a vehicle to acquire one or more operating businesses. The company recently signed a merger agreement with Workflow Management, Inc. Led by their President and CEO Daniel E. Straton, Enterprise Acquisition is making great strides in their field. For further information, visit the company website at: www.enterpriseacq.com.
Entree Gold, Inc. (AMEX: EGI)
Entree Gold, Inc. (AMEX: EGI) is a junior resource company focused on meeting global demand for products such as gold, copper, molybdenum and coal through concerted exploration efforts. The company has developed a portfolio of gold and copper exploration projects balanced between grass roots and advanced exploration with operations in emerging markets such as Mongolia and China as well as proven jurisdictions such as Arizona and New Mexico in the United States. For further information, visit the Company's web site at www.entreegold.com.
EntreMed, Inc. (NASDAQ: ENMD)
EntreMed, Inc. (NASDAQ: ENMD), a clinical-stage pharmaceutical company, develops therapeutic candidates mainly for the treatment of cancer and inflammation. The company has focused their efforts on developing drugs that are safe and convenient, and provide the potential for improved patient outcomes. EntreMed’s expertise lies in angiogenesis, cell cycle regulation, cell signaling and inflammation. For further information, visit the Company's web site at www.entremed.com.
Epic Energy Resources, Inc. (OTC BB: EPCC)
Epic Energy Resources, Inc. (OTC BB: EPCC), a Houston based integrated energy services company, is focused on providing consulting, engineering, construction management, operations, maintenance, specialized training and data management services. The company provides these services through its business units: Pearl, The Carnrite Group, and Epic Integrated Solutions. Epic is led by CEO Rex Doyle who has more than 25 years of diversified experience in oil and gas, industrial distribution and energy services. For further information, visit the Company's web site at www.1epic.com.
EpiCept Corporation (NASDAQ: EPCT)
EpiCept Corporation (NASDAQ: EPCT), a specialty pharmaceutical company, is focused on meeting unmet medical needs in cancer treatment and pain management. The company has approval from the European Commission to use Ceplene for the remission maintenance and prevention of relapse in adult patients with Acute Myeloid Leukemia in first remission. Additionally, EpiCept is utilizing its biopharmaceutical discovery capabilities for the discovery and advancement of apoptosis inducers. For further information, visit the Company's web site at www.epicept.com.
Erdene Resources Development Corp. (TSX: ERD CN)
Erdene Resources Development Corp. (TSX: ERD CN) is focused on providing investors with a solid platform to invest in the mineral exploration sector. Their aim is to combine near-term cash flow projects with diversified, high growth exploration opportunities. By establishing tactical relationships with industry leaders, the company intends to minimize risk and maximize opportunities for success. For further information, visit the Company's web site at www.erdene.com.
Evolution Petroleum Corporation (AMEX: EPM)
Evolution Petroleum Corporation (AMEX: EPM) is focused on acquiring controlling working interests in oil and gas resources within established fields. The company then plans to redevelop those fields through the application of capital and technology to convert the oil and gas resources into profitable producing reserves. Evolution intends to generate scalable development opportunities at normally pressured depths, exhibiting relatively low completion risk. For further information, visit the Company's web site at www.evolutionpetroleum.com.
Evolving Gold Corp. (TSX: EVG CN)
Evolving Gold Corp. (TSX: EVG CN) is focused on discovering multi-million ounce gold deposits in proven gold producing areas. The company’s geoscience team has more than 200 years of collective experience. Currently, the company is focused on its discovery property in Wyoming where it has just completed a 15 hole, 7,000 meter drilling program. Additionally, Evolving has 8 other gold properties primarily in Nevada including a lease agreement with Newmont Mining Corporation on four prospective gold properties. For further information, visit the Company's web site at www.evolvinggold.com.
EXACT Sciences Corporation (NASDAQ: EXAS)
EXACT Sciences Corporation (NASDAQ: EXAS) is focused on developing technologies that help to eliminate mortality from common cancers through the leveraging of advances in the field of genomics to facilitate the early detection of disease. The company’s first target is colorectal cancer, which is the second leading cause of cancer deaths as well as the most deadly cancer among non-smoking men and women in the U.S., providing the company with a large opportunity. For further information, visit the Company's web site at www.exactsciences.com.
Far East Energy Corporation (OTC BB: FEEC)
Far East Energy Corporation (OTC BB: FEEC) has dedicated its efforts to becoming a recognized leader in coalbed methane gas technologies, property acquisition, exploration, development, production, and innovative products applications. The Company focused on promoting economic growth, while building an energy-related business with a high return on stockholders’ equity. The Chinese government hopes that by 2010, methane gas production from CBM and CMM will reach 10 billion cubic meters. For further information, visit the Company's web site at www.fareastenergy.com.
First Majestic Silver Corp. (TSX: FR CN)
First Majestic Silver Corp. (TSX: FR CN) is focused on building a senior Silver producing mining company by executing an aggressive development and acquisition plan within the borders of Mexico. Currently, the company owns and operates three producing silver mines in Mexico: the La Parrilla Silver Mine, the San Martin Silver Mine and the La Encantada Silver Mine. It is anticipated that production from these three mines will reach 4.5 million ounces of silver in 2008 with further increases in 2009 and beyond. For further information, visit the Company's web site at www.firstmajestic.com.
First Nickel Inc. (TSX: FNI CN)
First Nickel Inc. (TSX: FNI CN), a Canadian mining and exploration company, has its focus primarily on the Sudbury Basin in northern Ontario, the location of four of its exploration properties and the Lockerby Mine. Indicated resources at its Lockerby Mine increased ten-fold since it was acquired by First Nickel in 2005. In addition to the properties above, the company also has two exploration properties in the Timmins region of northern Ontario. For further information, visit the Company's web site at www.firstnickel.com.
Fronteer Development Group, Inc. (AMEX: FRG)
Fronteer Development Group, Inc. (AMEX: FRG), a gold-focused exploration and development company, has dedicated its efforts to discovering and advancing large deposits with substantial production potential. The company currently has a portfolio of advanced-stage gold projects in Nevada, a 40% interest in three gold and copper-gold projects in Turkey, and a 42.2% interest in Aurora Energy Resources (AXU-TSX), a leading Canadian uranium company. For further information, visit the Company's web site at www.fronteergroup.com.
Fuqi International, Inc. (NASDAQ: FUQI)
Fuqi International, Inc. (NASDAQ: FUQI) designs precious metal jewelry in China and develops, promotes and sells an array of products in the Chinese luxury goods market. The company’s products consist of a range of styles and designs made from precious metals, such as platinum, gold and Karat gold (K-gold), as well as diamonds and other precious stones. By leveraging its distribution network, Fuqi can test-market, promote and sell its products in almost every province in China. For further information, visit the Company's web site at www.fuqi.com.cn.
FX Energy, Inc. (NASDAQ: FXEN)
FX Energy, Inc. (NASDAQ: FXEN), an independent oil and gas company, has its efforts focused on Plan, where they believe hydrocarbon producing areas are underexplored. The company has accumulated a large land position in known productive areas, assembled a sophisticated technical team, and generated a number of attractive gas prospects. FX Energy aims to increase production and reserves in its core area while utilizing revenues to support high potential exploration on substantial non-core acreage. For further information, visit the Company's web site at www.fxenergy.com.
Gastar Exploration, Ltd. (AMEX: GST)
Gastar Exploration, Ltd. (AMEX: GST), a Houston-based independent E&P company, is focused on the exploration, development and production of natural gas and oil in the United States and Australia. The company’s drilling operations are concentrated on exploiting locations in the Deep Bossier Sands and Knowles Limestone plays in the Hilltop area of East Texas and the emerging Marcellus Shale play in Appalachia, along with coalbed methane, or "CBM" development in southeast Australia and the Rocky Mountains. For further information, visit the Company's web site at www.gastar.com.
Genaera Corporation (NASDAQ: GENR)
Genaera Corporation (NASDAQ: GENR) has their efforts focused on advancing the science and treatment of metabolic diseases. They have identified significant market opportunities with a first-in-class molecule that may revolutionize the treatment paradigm for obesity and type 2 diabetes. They currently have two products in their pipeline: MSI-1436 , the core internal asset of Genaera designed to treat obesity and has applicability in type 2 diabetes; and MEDI-528, which is under evaluation in Phase 2 clinical studies for the treatment of asthma. For further information, visit the Company's web site at www.genaera.com Generex is focused on researching, developing, and commercializing drug delivery systems and technologies. Their proprietary platform technology delivers drugs into the human body orally (with no deposit in the lungs). Through the utilization of the company’s liquid formulations, drugs that are typically administered by injection can be absorbed into the body through the lining of the inner mouth using the Company's proprietary RapidMist(tm) device. For further information, visit the Company's web site at www.generex.com.
Genco Resources Ltd. (TSX: GGC CN)
Genco Resources Ltd. (TSX: GGC CN), a junior silver mining company, has its core assets in a number of mining sites including the La Guitarra Mine. This mine is located within the Sierra Madre silver and gold Metallogenic Province that has historically produced some of the world's most extraordinary mines. The La Guitarra Mine produces precious metals from a classic epithermal vein system, part of a mineralized corridor that measures 15 kilometers in length and averages 4 kilometers in width. For further information, visit the Company's web site at www.gencoresources.com.
Generex Biotechnology Corporation (NASDAQ: GNBT)
Generex Biotechnology Corporation (NASDAQ: GNBT), a biopharmaceutical company, has a diversified product portfolio designed to deliver innovative products to treat patients with cancer. DNA/RNA-based Medicines and Small Molecules are the two major programs that anchor the Company's research platform. Ganite® (gallium nitrate injection) is the company’s leading drug in the Small Molecule program. Ganite is exclusively marketed in the U.S. to treat symptomatic patients with cancer-related hypercalcemia that is resistant to hydration. For further information, visit the Company's web site at www.genta.com.
Genesis Pharmaceuticals Enterprises, Inc. (OTC BB: GTEC)
Genesis Pharmaceuticals Enterprises, Inc. (OTC BB: GTEC) is a U.S. public company engaged in the research, development, production, marketing and sales of pharmaceutical products in the People's Republic of China. Genesis is a major pharmaceutical company in China producing tablets, capsules, and granules for both western and Chinese herbal- based medical drugs. The company has recently appointed Michael Marks to its Board of Directors and is looking to capitalize on the international pharmaceutical market.
Gentium S.p.A. (NASDAQ: GENT)
Gentium S.p.A. (NASDAQ: GENT), a biopharmaceutical company, specializes in discovering, researching, developing and manufacturing active ingredients derived from natural sources as potential therapeutic agents. The company focuses on developing relationships with industrial and academic institutions and intends to discover further beneficial effects of its products as well as develop pharmaceuticals with a broader range of treatment indications. For further information, visit the Company's web site at http://www.gentium.com.
Geologix Explorations Inc. (TSX: GIX CN)
Geologix Explorations Inc. (TSX: GIX CN), a mineral exploration company, is committed to acquiring, exploring and developing gold properties in North and South America, as well as Mexico. Their projects include: San Agustin, La Casita, Consejo, Silver Cloud, QC Property, RO Property, OZ Property, Geologix-Newmont Alliance, Liscay Property, Cayhua, San Felipe, Sura, Patcorral, and Toro Blanco. The Company’s management has extensive expertise in the mining industry and have track record of brning early stage exploration prospects to final feasibility and ultimately to production. For further information, visit the Company's web site at http://www.geologix.ca.
GeoResources, Inc. (NASDAQ: GEOI)
GeoResources, Inc. (NASDAQ: GEOI) owns and operates producing oil and gas properties in the Gulf Coast, Permian Basin, Rocky Mountains and Williston Basin through its three subsidiaries G3 Operating, LLC and Southern Bay Operating, LLC. The company leverages its management’s expertise in mergers and acquisitions, which is further enhanced by relationships with investment and commercial bankers, institutional investors, brokers and principals. For further information, visit the Company's web site at www.georesourcesinc.com.
Geron Corporation (NASDAQ: GERN)
Geron Corporation (NASDAQ: GERN) is a biopharmaceutical company focused on developing biopharmaceuticals for the treatment of cancer and chronic degenerative diseases, including heart failure, spinal cord injury and diabetes. The company’s mission is to develop an array of anti-cancer therapies based on telomerase inhibitors, telomerase therapeutic vaccines, and telomerase-based oncolytic viruses, and diagnostics based on telomerase detection. For further information, visit the Company's web site at www.geron.com.
Gilead Sciences, Inc. (NASDAQ: GILD)
Gilead Sciences, Inc. (NASDAQ: GILD), a research-based biopharmaceutical company, is focused on discovering, developing, and commercializing novel medicines to address unmet medical needs. The company’s aim is to improve the care of patients suffering from life-threatening diseases with every new discovery and experimental drug candidate. Primary areas of focus include: antivirals, cardiovascular conditions and respiratory diseases. For further information, visit the Company's web site at www.gilead.com.
Glass Earth Gold Ltd. (TSX: GEL CN)
Glass Earth Gold Ltd. (TSX: GEL CN) is focused on discovering and developing gold and geothermal opportunities in New Zealand. Currently, the company is known to hold the largest on-shore gold exploration and prospecting permit portfolio in all of New Zealand. The company takes a scientific approach to gold exploration, leveraging its highly skilled international exploration team and the sophisticated use of new technology. For further information, visit the Company's web site at www.glassearthlimited.com.
Global Brands Acquisition Corporation (AMEX: GQN)
Global Brands Acquisition Corporation (AMEX: GQN) is a company organized for the purpose of acquiring, through a merger, capital stock exchange, asset acquisition, stock acquisition, stock purchase, reorganization or similar business combination, one or more operating business. The Company's efforts in identifying a prospective target business will not be limited to a particular industry although the Company will focus its efforts on acquiring an operating business in the branded consumer industry. Units of the young company were first listed on the AMEX on December 7, 2007. For further information, visit the company website at: www.enterpriseacq.com.
Global Med Technologies, Inc. (OTC BB: GLOB)
Global Med Technologies, Inc. (OTC BB: GLOB), an international medical software company, is focused on developing regulated and non-regulated software products and services for application in the medical field. The company’s products are currently deployed in 20 countries and serve more than 1,600 transfusion centers, blood banks and laboratories. Global Med’s U.S. division provides Vein-to- Vein® tracking through its Donor Doc(TM), SafeTrace®, SafeTrace Tx® and ElDorado Donor(TM) software products. For further information, visit the Company's web site at www.wyndgate.com.
Globex Mining Enterprises Inc. (TSX: GMX CN)
Globex Mining Enterprises Inc. (TSX: GMX CN) has a very large portfolio of advanced properties that contain gold, copper, zinc, silver, uranium, platinum, palladium, magnesium, and talc potential. Currently, all of their properties are located within North America. The company aims to create value for stockholders by acquiring mineral properties, enhancing them, then developing them to production or in some cases sell the projects. For further information, visit the Company's web site at www.globexmining.com.
Goodrich Petroleum Corporation (NYSE: GDP)
Goodrich Petroleum Corporation (NYSE: GDP), an independent oil and gas company engaged in the exploration, exploitation, development and production of oil and natural gas properties, focuses its efforts on the Cotton Valley Trend of East Texas and Northwest Louisiana. As of December 31, 2007, the Company owned working interests in 301 active oil and gas wells located in 26 fields. Goodrich aims to provide long term growth through the growth and expansion of their oil and gas reserves and production. For further information, visit the Company's web site at www.goodrichpetroleum.com.
GPC Biotech AG (NASDAQ: GPCB)
GPC Biotech AG (NASDAQ: GPCB), a biopharmaceutical company, is focused on discovering, developing, and commercializing anticancer drugs. Its pipeline of products include satraplatin, an oral platinum-based anticancer agent that is in phase 1 and 2 trials; RGB-286638, a broad-spectrum kinase inhibitor that has completed pre-clinical testing; and RGB-344064, a selective inhibitor of cyclin-dependent kinases that is in pre-clinical testing. For further information, visit the Company's web site at www.gpc-biotech.com.
Golden Pond Healthcare, Inc. (AMEX: GPH)
Golden Pond Healthcare, Inc. (AMEX: GPH) is a company focused on making investments in the Healthcare industry. The principals of Golden Pond have extensive experience in various sectors of healthcare, including managed care and disease management; healthcare services; pharmaceuticals and specialty pharmaceuticals; and medical devices. Golden Pond was organized as special purpose acquisition corporation (SPAC) which gives it great leverage. For further information, visit the company website at: www.goldenpondhealthcare.com.
Gran Tierra Energy Inc. (TSX: GTE CN)
Gran Tierra Energy Inc. (TSX: GTE CN), an international oil and gas exploration and production company, holds interests in producing and prospective properties in Colombia, Argentina and Peru. The Company aims to establish a portfolio of drilling opportunities to exploit undeveloped reserves to grow production, as well as undertake exploration drilling to grow future reserves. Grey Wolf has a working interest in nineteen different blocks that cover approximately 6.5 million acres. For further information, visit the Company's web site at www.grantierra.com.
Great Panther Resources Limited (TSX: GPR CN)
Great Panther Resources Limited (TSX: GPR CN), one of the fastest growing primary silver producers in Mexico, owns 100% interest in two operating mines and two high quality exploration projects and employs almost 600 people. The company is devoted to conducting all operations with fairness and integrity while maintaining cost-effective efforts. With strong, experienced local management and infrastructure, Great Panther’s primary aim is to generate positive cash flow through the advancing of production rates. For further information, visit the Company's web site at www.greatpanther.com.
Grey Wolf Exploration Inc. (TSX: GWE CN)
Grey Wolf Exploration Inc. (TSX: GWE CN), an independent, Alberta-based, junior energy company, is focused on the development and production of natural gas and crude oil in the Western Canadian Sedimentary Basin. The company aims to redevelop under-exploited properties through the use of inhouse expertise, current technologies such as 3D seismic, and prudent business practices. Grey Wolf’s internally-generated portfolio of drilling opportunities also includes complementary exploration projects. For further information, visit the Company's web site at www.greywolf.ca.
GTC Biotherapeutics, Inc. (NASDAQ: GTCB)
GTC Biotherapeutics, Inc. (NASDAQ: GTCB) is focused on developing, supplying, and commercializing therapeutic proteins created through transgenic animal technology. ATryn, the company’s recombinant human antithrombin, has received approval for use in Europe and is in the review process in the United States under a rolling Biologics License Application. The company’s intellectual property includes a patent in the United States for the production of therapeutic proteins in the milk of transgenic mammals. For further information, visit the Company's web site at www.gtc-bio.com.
GTx, Inc. (NASDAQ: GTXI)
GTx, Inc. (NASDAQ: GTXI) is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecules to treat cancer, osteoporosis and bone loss, muscle wasting, and other serious medical conditions. The company’s product candidate in clinical development, ACAPODENE, is a selective estrogen receptor modulator that is in pivotal Phase III clinical trials for the treatment of multiple serious side effects of androgen deprivation therapy for advanced prostate cancer. For further information, visit the Company's web site at www.gtxinc.com.
Gulf Resources (OTC BB: GFRE)
Gulf Resources (OTC BB: GFRE) is a leading provider of bromine, crude salt and a portfolio of various specialty chemicals throughout China. Gulf is one of only six companies with a highly coveted Chinese license for bromine exploration, production and distribution. Gulf also develops for Chinese paper making and oil and gas industries. The company is looking to expand by pursuing complimentary acquisitions. This, coupled with organic growth, makes Gulf Resources a company to keep an eye on. For further information, visit the company website at: www.gulfresources.com.
Hana Biosciences, Inc. (NASDAQ: HNAB)
Hana Biosciences, Inc. (NASDAQ: HNAB), a South San Francisco, CA-based biopharmaceutical company, is focused on the acquisition, development and commercialization of novel products to strengthen the foundation of cancer care. The company is dedicated to creating value by accelerating the development of lead product candidates, building a best-in-class team, expanding its pipeline, and nurturing a unique company culture. For further information, visit the Company's web site at www.hanabiosciences.com.
HemoBioTech, Inc. (OTC BB: HMBT)
HemoBioTech, Inc. (OTC BB: HMBT), a biopharmaceutical company, is focused on developing HemoTech™, which may be the first viable substitute for human blood. HemoTech™, the company’s core product, is a bovine-hemoglobin (Hb) based human blood substitute that has the capability of replacing red blood cells in the human body. The company has an exclusive worldwide license for HemoTech, and intends to use its technology to meet the increasing demand for safe and inexpensive human blood substitute product around the world. For further information, visit the Company's web site at www.hemobiotech.com.
Highlands Acquisition Corporation (AMEX: HIA)
Highlands Acquisition Corporation (AMEX: HIA), a special purpose acquisition company, is organized to acquire one or more operating businesses. Highlands seek all attractive business opportunities with the potential for significant returns. The New Jersey Company is led by their CEO Bob Pangia who has a wealth of experience in the healthcare industry. For further information, visit the company website at: www.highlandscorp.com.
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH)
Hollis-Eden Pharmaceuticals, Inc. (NASDAQ: HEPH) is focused on developing a proprietary class of adrenal steroid hormones as innovative pharmaceuticals for human health. Through its Hormonal Signaling Technology Platform, the company is developing a new series of small molecule compounds that are metabolites or synthetic analogs of endogenous hormones derived by the adrenal glands from the body’s most abundant circulating adrenal steroid. For further information, visit the Company's web site at www.holliseden.com.
Homeland Energy Group Ltd. (TSX: HEG CN)
Homeland Energy Group Ltd. (TSX: HEG CN) has its efforts focused on producing coal from existing South African mines, resource development in South Africa, energy exploration in southern Africa and strategic acquisitions of properties and projects that support continued growth of Homelands energy resources and reserves. The company’s Eloff Mining Project, currently in the development stage, has an estimated 452 million tonnes (Measured and Indicated) of coal. For further information, visit the Company's web site at www.homelandcorp.com.
Hong Kong Highpower Technology, Inc. (AMEX: HPJ)
Hong Kong Highpower Technology, Inc. (AMEX: HPJ) is a holding company that specializes in the development and manufacturing of nickel metal hydride (Ni-MH) rechargeable battery cells through its manufacturing facilities in China. The company’s rechargeable batteries allow it to capitalize in electronic and industrial applications. Hong Kong Highpower Technology is led by Dang Yu Pan who serves as both CEO and Chairman of the company. For further information, visit the company website at: www.haopengbattery.com.
Hudson Technologies, Inc. (NASDAQ: HDSN)
Hudson Technologies, Inc. (NASDAQ: HDSN), a leading provider of traditional reclamation services and refrigerant sales to the commercial and industrial air conditioning and refrigeration markets, provides innovative solutions to recurring problems within the refrigeration industry. The company’s RefrigerantSide® Services increase operating efficiency and energy savings, and remove moisture, oils and other contaminants. For further information, visit the Company's web site at www.hudsontech.com.
Hythiam, Inc. (NASDAQ: HYTM)
Hythiam, Inc. (NASDAQ: HYTM) is focused on providing comprehensive behavioral health management services to health plans, employers, criminal justice, and government agencies. Additionally, the company researches, develops, licenses and commercializes innovative and proprietary physiological, nutritional, and behavioral treatment programs. Currently, Hythiam provides initial disease management offerings that incorporate medical and behavioral treatments for substance dependence. For further information, visit the Company's web site at www.hythiam.com.
iCAD, Inc. (NASDAQ: ICAD)
iCAD, Inc. (NASDAQ: ICAD), an industry-leading provider of Computer-Aided Detection (CAD) solutions, enables healthcare professionals to identify pathologies and pinpointing cancer earlier. The company provides a broad range of high-performance, upgradeable CAD systems and workflow solutions for mammography, Magnetic Resonance Imaging (MRI), and Computed Tomography (CT). iCAD's solutions are available in more than 2,200 healthcare centers worldwide. For further information, visit the Company's web site at
www.icadmed.com.
ICP Solar Technologies, Inc. (OTC BB: ICPR)
ICP Solar Technologies, Inc. (OTC BB: ICPR), a developer, manufacturer and marketer of solar panels and solar cell based products as well as building materials, seeks to build name recognition in three high growth solar categories: recreational, industrial, and residential. By leveraging next-generation technologies and using proprietary intellectual design, the Company aims to be the industry's innovation leader. The company's headquarters are located in Montreal, Canada. For further information, visit the Company's web site at www.icpsolar.com.
Icagen, Inc. (NASDAQ: ICGN)
Icagen, Inc. (NASDAQ: ICGN) is a biopharmaceutical company based in Research Triangle Park, North Carolina, focused on the discovery, development and commercialization of novel orally-administered small molecule drugs that modulate ion channel targets. Utilizing its proprietary know-how and integrated scientific and drug development capabilities, Icagen has identified multiple drug candidates that modulate ion channels. The Company is conducting research and development activities, in some cases in collaboration with leading pharmaceutical companies, in a number of disease areas, including epilepsy, pain and inflammation. The Company has clinical stage programs in epilepsy and asthma. For further information, visit the Company's web site at
www.icagen.com.
ICU Medical, Inc. (NASDAQ: ICUI)
ICU Medical, Inc. (NASDAQ: ICUI), founded in 1984 by Dr. George Lopez, a practicing internist who believed there was a better way of securing I.V. lines, is focused on developing and manufacturing products that both protect the Health Care worker from accidental needle sticks as well as protect the reliability of IV systems. With an approximate market cap of nearly 500 million, ICU’s products include the CLAVE NeedleFree Connector and the CLC2000 Catheter Patency Device. For further information, visit the Company's web site at
www.icumed.com.
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA)
Idera Pharmaceuticals, Inc. (NASDAQ: IDRA) is focused on developing drug candidates that treat infectious diseases, autoimmune diseases, cancer, and respiratory diseases, and can be used as vaccine adjuvants. The company’s pioneering DNA and RNA chemistry expertise enables them to develop drug candidates for internal development while creating opportunities for multiple collaborative alliances. For further information, visit the Company's web site at
www.iderapharma.com.
IR Biosciences Holdings Inc.’s (IRBS.OB)
IR Biosciences Holdings Inc.’s (IRBS.OB) subsidiary is a development-stage biotechnology company devoted to researching, developing and licensing Homspera® and its derivatives. Homspera is an adult stem cell active compound that has been demonstrated the ability to regenerate and strengthen the immune system as well as enhance wound healing. To further its mission, IR BioSciences has forged a number of study partnerships with industry and academic leaders. For more information, please visit www.immuneregen.com.
ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC)
ImmunoCellular Therapeutics, Ltd. (OTC BB: IMUC), a clinical-stage company, is focused on developing new therapeutics to fight cancer using the human body’s immune system. Their product pipeline consists of cellular immunotherapies that target brain cancer, and monoclonal antibodies designed to diagnose and treat various cancers. The company’s lead product candidate is currently in a Phase I clinical trial to treat glioblastoma multiforme, the most common type of brain tumor. For further information, visit the Company's web site at
www.imuc.com.
Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV)
Indevus Pharmaceuticals, Inc. (NASDAQ: IDEV), a specialty pharmaceutical company, is focused on the acquisition, development, and commercialization of products designed to treat conditions in urology and endocrinology. The company's approved products include SANCTURA® and SANCTURA XR(TM) for overactive bladder, SUPPRELIN® LA for central precocious puberty, VANTAS® for advanced prostate cancer, and DELATESTRYL® to treat male hypogonadism. For further information, visit the Company's web site at
www.indevus.com.
India Globalization Capital, Inc. (AMEX: IGC)
India Globalization Capital, Inc. (AMEX: IGC) is a company that was formed to acquire operating businesses located in India through merger, capital stock exchange, asset acquisition or other similar business combination. India Globalization Capital (IGC) has three main competencies which are: Highway and Heavy Construction, Mining and Quarrying, and Civil Construction and Engineering of high-temperature plants. IGC is a step ahead of their competition because they are the only Indian infrastructure company listed and trading in the United States. For further information, visit the company website at: www.indiaglobalcap.com.
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI)
Infinity Pharmaceuticals, Inc. (NASDAQ: INFI), an innovative cancer drug discovery and development company, is focused on discovering, developing, and delivering best-in-class medicines designed to treat cancer and related conditions. The company leverages its proven scientific expertise and passion for developing novel small molecule drugs designed to target emerging cancer pathways. Infinity's two most advanced programs are examples of its innovative approach to oncology drug discovery and development. For further information, visit the Company's web site at
www.infi.com.
Inhibitex, Inc. (NASDAQ: INHX)
Inhibitex, Inc. (NASDAQ: INHX) is a biopharmaceutical company engaging in the development of differentiated anti-infective products designed to prevent and treat serious infections. The company’s products include FV-100, a nucleoside analogue prodrug; HIV Integrase Inhibitors class of anti-retroviral agents; and a series of nucleoside and non-nucleoside HCV polymerase inhibitors designed to treat the hepatitis C virus. For further information, visit the Company's web site at www.inhibitex.com.
Inovio Biomedical Corporation (AMEX: INO)
Inovio Biomedical Corporation (AMEX: INO) has their focus on developing multiple DNA-based immunotherapies. The company is known as a leading developer of human applications of electroporation using brief, controlled electrical pulses to increase cellular uptake of a useful biopharmaceutical. Inovio's DNA delivery technology has demonstrated the ability to substantially increase gene expression and immune responses from DNA vaccines. For further information, visit the Company's web site at www.inovio.com.
|
InSite Vision Incorporated (AMEX: ISV)
InSite Vision Incorporated (AMEX: ISV) is focused on developing novel ophthalmic products for the treatment of a growing range of common eye problems, including ocular infection, glaucoma, and retinal disease. Their goal as a company is to provide patients and physicians with better treatment options that help preserve and improve vision worldwide. By leveraging their proprietary DuraSite® drug delivery technology, the company is creating alternative ocular anti-infective therapies that may provide substantial advantages over existing treatment options. For further information, visit the Company's web site at www.insite.com.
Insmed Incorporated (NASDAQ: INSM)
Insmed Incorporated (NASDAQ: INSM), a development stage company, has comprehensive expertise in protein drug development. The company has a state-of-the art FDA-approved biologic commercial manufacturing facility in Boulder, Colorado and a corporate office in Richmond Virginia. By pursuing a dual path strategy, Insmed aims to advance its proprietary protein platform into niche markets with unmet needs while entering into the follow on biologics arena. For further information, visit the Company's web site at www.insmed.com.
InterAmerican Acquisition Group Inc. (OTC BB: IAQG)
InterAmerican Acquisition Group Inc. (OTC BB: IAQG) is a blank check company recently formed for the purpose of acquiring, through a merger, stock exchange, asset acquisition or other similar business combination, an unidentified operating business. The company specializes in Project Management, Project Financing and Investment Banking. Recently, the company made news by raising $46 million. For further information, visit the company website at: www.interamerican-group.com.
Inter-Atlantic Financial, Inc. (AMEX: IAN)
Inter-Atlantic Financial, Inc. (AMEX: IAN) is a newly organized blank check company formed for the purpose of acquiring, through a merger, a capital stock exchange, asset acquisition, stock purchase or other similar business combination, an unidentified domestic and/or foreign operating business in the financial services industry or businesses deriving a majority of their revenues from providing services to financial services companies, including for example, payment processing companies and technology providers. For further information, visit the company website at: www.interatlantic.com.
International Montoro Resources Inc. (TSX: IMT CN)
International Montoro Resources Inc. (TSX: IMT CN), an emerging resource company, is focused on the acquisition, exploration and development of Uranium mineral properties in Saskatchewan, Ontario, British Columbia and Labrador as well as other resource properties in New Brunswick and Ontario. The company has been listed on the TSX Venture Exchange (formerly Vancouver Stock Exchange) for 18 years and has submitted its application to list on the Frankfurt Stock Exchange. For further information, visit the Company's web site at www.montororesources.com.
International Royalty Corporation (AMEX: ROY)
International Royalty Corporation (AMEX: ROY), a global mineral royalty company, has more than 85 royalties including an effective 2.7% NSR on the Voisey's Bay mine, a sliding scale NSR on the Chilean portion of the Pascua-Lama project, and a 1.5% NSR on approximately 3.0 million acres of gold lands in Western Australia. The company is led by CEO Douglas Silver who has 25 years of experience as an active professional in the minerals industries. For further information, visit the Company's web site at www.internationalroyalty.com.
INX Inc. (NASDAQ: INXI)
INX Inc. (NASDAQ: INXI) is a publicly traded network infrastructure professional services firm delivering best-of-class “Business Ready Solutions” to enterprise organizations. The company designs, implements, and supports the IP network infrastructure with a special emphasis on the Call Flow, Messaging, and Enablement layers. Inx Inc. is led by James H. Long who serves as the company’s CEO and Chairman of the Board. Long has a strong reputation in his field and an aggressive style that allows Inx to stay a step ahead of the competition. For further information, visit the company website at: www.inxi.com.
Iteris, Inc. (AMEX: ITI)
Iteris, Inc. (AMEX: ITI), a leader in the traffic management market, is focused on the development and application of advanced technologies that reduce traffic congestion, minimize the environmental impact of traffic congestion and improve the safety of surface transportation systems. By integrating outdoor image processing, traffic engineering and information technology, the company provides a wide array of Intelligent Transportation Systems and driver safety solutions to customers worldwide. For further information, visit the Company's web site at www.iteris.com.
Ivernia Inc. (TSX: IVW CN)
Ivernia Inc. (TSX: IVW CN), an international base metals, exploration, development and operating company, is the sole owner and operator of the Magellan lead mine in Western Australia. Once the mine reaches full production, it is anticipated to be one of the top five lead-producing mines in the world. Currently, the mine is under temporary care and maintenance pending final requisite shipping approvals from the Western Australian Government to employ a newly-developed sealed shipping process to transfer its lead concentrate to port for export. For further information, visit the Company's web site at www.ivernia.com.
Jaguar Mining Inc. (TSX: JAG CN)
Jaguar Mining Inc. (TSX: JAG CN), one of the fastest growing gold producers in the world, intends to substantially expand gold production from 70,000 ounces produced in 2007 to approximately 700,000 ounces by 2014 through its wholly-owned operations in the state of Minas Gerais, Brazil. The company is currently in active exploration and development of additional mineral resources at its 72,000 acre land base in Minas Gerais and on an additional concession base totaling 159,000 acres in the state of Ceará. For further information, visit the Company's web site at www.jaguarmining.com.
Javelin Pharmaceuticals, Inc. (AMEX: JAV)
Javelin Pharmaceuticals, Inc. (AMEX: JAV), a specialty pharmaceutical company, is focused on applying its novel proprietary technologies to develop new drugs and improve existing drugs that target unmet as well as underserved medical needs in the pain management market. Compared to existing treatments, Javelin’s product candidates, which include Dyloject™, Rylomine™ and PMI-150, provide better pain relief with fewer adverse side effects. For further information, visit the Company's web site at www.javelinpharma.com.
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ)
Jazz Pharmaceuticals, Inc. (NASDAQ: JAZZ), a specialty pharmaceutical company, focuses their efforts on identifying, developing and commercializing innovative products designed to address unmet medical needs in neurology and psychiatry. Their goal as a company is to develop a broad portfolio of products through internal development and acquisition/in-licensing while utilizing a specialty sales force to promote products in target markets. For further information, visit the Company's web site at www.jazzpharmaceuticals.com.
Jingwei International Ltd. (OTC BB: JNGW)
Jingwei International Ltd. (OTC BB: JNGW) is an integrated marketing service provider that has quickly become one of the leaders in providing direct marketing services to global companies doing business in China. The company has a geographic presence in 20 cities and a customer database that contains detailed biographical, demographic and purchasing data of over 300 million Chinese consumers. Jingwei enables companies to reach their targeted advertising audience. For further information, visit the company website at: www.jingweicom.com.
KBL Healthcare Acquisition Corporation III (AMEX: KHA)
KBL Healthcare Acquisition Corporation III (AMEX: KHA) is a special purpose acquisition company (SPAC) established for the purpose of effecting a merger, capital stock exchange, stock purchase, asset acquisition or other similar business combination with an operating business in the healthcare or healthcare-related industries. In an IPO dated July 31, 2007, KBL raised over $138 million. With headquarters located in New York, the young company is quickly becoming a force in the healthcare field. For further information, visit the company website at: www.kblhealthcare.com.
Kinbauri Gold Corp. (TSX: KNB CN)
Kinbauri Gold Corp. (TSX: KNB CN) is a junior mining company based in Ottawa, Ontario, Canada with an immediate focus to upgrade resources to reserves and complete a mine development plan at El Valle. Through their efforts, they anticipate the production of gold and copper at the mine and mill complex by 2010. This site has the potential to become the largest gold producer in Western Europe. Other mining properties include: Corcoesto, and five North American precious metals properties. For further information, visit the Company's web site at www.kinbauri-gold.com.
Kit digital (OTC BB:KITD)
Kit digital (OTC BB: KITD) is a pioneer provider in video distributions in online, mobile and set-top box environments. With video as the company’s passion, Kit digital recently announced it was selected by TV2Moro, a new firm backed by several top-tier ethnic television aggregators and producers, to deploy a new IPTV set-top box (STB) service to deliver programming to ethnic consumers in North America. With this new deal in place and the growth of the young company, Kit digital may optimize the future of the marketplace. For further information, visit the company website at: www.kit-digital.com.
Kodiak Energy, Inc. (TSX: KDK CN)
Kodiak Energy, Inc. (TSX: KDK CN), a publicly traded junior oil and gas exploration and development company, is a multi-project company with a significant land position of more than 340,000 gross acres leased for exploration and development in multiple jurisdictions and work environments. The company’s focus is on the development of onshore oil, gas and CO2 properties within North America. In an effort to minimize shareholder dilution, financing activities are project based, within stages of each project. For further information, visit the Company's web site at www.kodiakpetroleum.com.
Kodiak Exploration Limited (TSX: KXL CN)
Kodiak Exploration Limited (TSX: KXL CN) is a Canadian mineral exploration company. The Vent Gold Zone is known as one of the company’s most important targets because of the large extent of sulphide mineralization and intense alteration that measures approximately 3.0 kilometres long and between 400 and 700 metres wide. The Hercules Gold Property, another significant target, has great access and infrastructure, and gold-bearing veins are concentrated along at least two large gold-bearing structures. For further information, visit the Company's web site at www.kodiakexp.com.
Kodiak Oil & Gas Corp. (AMEX: KOG)
Kodiak Oil & Gas Corp. (AMEX: KOG), an independent energy exploration and development company, is focused on exploring, developing and producing oil and natural gas in the U.S. Rocky Mountains. The company’s primary operating areas are the Green River Basin in Wyoming and the Williston Basin in North Dakota and Montana. Kodiak’s geologists, petroleum engineers and geophysicists have years of relevant industry experience in these basins. For further information, visit the Company's web site at www.kodiakog.com.
L & L International Holdings, Inc. (OTC BB: LLFH)
L & L International Holdings, Inc. (OTC BB: LLFH) is a US public traded company that serves as a bridge connecting coal (energy) business between the US and China. While capitalizing on this market, L & L is continuing to make profit in the marketplace and friends in the environment. L & L is acquiring additional coal mines, and in the process, doing their part to improve the quality of air. For further information, visit the company website at: www.lnlinternational.com.
La Jolla Pharmaceutical Company (NASDAQ: LJPC)
La Jolla Pharmaceutical Company (NASDAQ: LJPC) is focused on improving and preserving human life through the development of novel pharmaceutical products. Riquent®, the company's leading product in development, treats lupus renal disease, a leading cause of sickness and death in patients with lupus, by preventing or delaying renal flares. Additionally, La Jolla has developed small molecules designed to treat other autoimmune and inflammatory conditions. For further information, visit the Company's web site at www.ljpc.com.
Labrador Iron Mines Holdings Limited (TSX: LIR CN)
Labrador Iron Mines Holdings Limited (TSX: LIR CN) has acquired interests in mineral claims and mineral licenses, through its wholly owned subsidiary, that contain an estimated 100 million tons of high grade iron ore. The company’s management team is comprised of experienced mining professionals, each of which has at least 30 years experience in the resource industry covering exploration, development, operations, company and project financing. For further information, visit the Company's web site at www.labradorironmines.ca.
Lake Shore Gold Corp. (TSX: LSG CN)
Lake Shore Gold Corp. (TSX: LSG CN), a mineral exploration company, is focused on rapidly moving towards production through a portfolio which includes an existing processing facility and a number of quality mineral properties located in the Timmins gold mining district of northern Ontario and Québec. In just the past year, Lake Shore Gold has completed a pre-feasibility study, identified a 1.2 million ounce ore reserve (uncut) and commenced an advanced exploration program at its 100%-owned Timmins West project. For further information, visit the Company's web site at www.lsgold.com.
LAURION Mineral Exploration Inc. (TSX: LME CN)
LAURION Mineral Exploration Inc. (TSX: LME CN), an exploration company, has its focus on discovering multiple, high-impact project, from gold projects to base metals and PGE’s. The company has key interests in highly prospective properties and aims to achieve long-term growth by making sound business decisions, creating strategic alliances with companies that have high technical expertise, and strategically target well positioned projects in geological systems where discoveries have been repetitive. For further information, visit the Company's web site at www.laurion.ca.
LCA-Vision, Inc. (NASDAQ: LCAV)
LCA-Vision, Inc. (NASDAQ: LCAV) provides laser vision correction services under its well known Lasik Plus brand. The company currently owns and operates over 70 LasikPlus fixed-site laser vision correction centers in the United States and a joint venture in Canada. These laser correction centers are staffed with experienced ophthalmologists, optometrists and other healthcare professionals. To date, the company has performed more than a million vision correction procedures. For further information, visit the Company's web site at www.lcavision.com.
LightPath Technologies, Inc. (NASDAQ: LPTH)
LightPath Technologies, Inc. (NASDAQ: LPTH) is a recognized leader in optical solutions for industrial, defense, communications, test and measurement, and medical applications. With unique products such as Black Diamond Infrared Lenses and Gradium Lenses, LightPath Technologies is shedding light in the field of optical solutions. For further information, visit the company website at: www.lightpath.com.
Lorus Therapeutics, Inc. (AMEX: LRP)
Lorus Therapeutics, Inc. (AMEX: LRP), a biopharmaceutical company, is focused on discovering, researching and developing effective anticancer therapies with high safety profiles. By utilizing its own discovery efforts, in addition to acquisition and in-licensing programs, the company is building a portfolio of anticancer drugs ranging from discovery and preclinical to an advanced Phase II clinical trial. Each of the drug candidates in their current pipeline are backed by a strong intellectual property portfolio. For further information, visit the Company's web site at www.lorusthera.com.
Lotus Pharmaceuticals Inc. (OTC BB: LTUS)
Lotus Pharmaceuticals Inc. (OTC BB: LTUS) is becoming one of China’s leaders in the marketing of prescription and over the counter medications. Lotus develops high quality, low cost generic medication and other over the counter brands. Led by their CEO Dr. Liu Zhongyi, the company expects to have continued growth of 20% per year and yearly revenues of over $140 million. For further information, visit the company website at: www.lotuseast.com.
Lucas Energy, Inc. (AMEX: LEI)
Lucas Energy, Inc. (AMEX: LEI), an independent oil and gas company, has focused its efforts on building a diversified portfolio of valuable oil and gas assets in the United States. The company is focused on identifying underperforming oil and gas assets, which are then brought online through a careful process of evaluation, application of modern well technology, and stringent management controls. Lucas Energy's financial structure allows it to minimize the high overhead of traditional E&P companies. For further information, visit the Company's web site at www.lucasenergy.com.
MannKind Corporation (NASDAQ: MNKD)
MannKind Corporation (NASDAQ: MNKD), a biopharmaceutical company, has focused their efforts on the discovery, development and commercialization of therapeutic products for diseases such as diabetes and cancer. Technosphere® Insulin System, the company’s lead investigational product candidate, is currently in Phase 3 clinical trials in the U.S., Europe and Latin America. MannKind believes the Technosphere® Insulin System has the potential to revolutionize the way diabetes is treated. For further information, visit the Company's web site at www.mannkindcorp.com.
Marifil Mines Ltd. (TSX: MNKD)
Marifil Mines Ltd. (TSX: MFM CN), a Canadian resource exploration company is focused on aggressively exploring for precious and base metals in Argentina, home of some of the world's most prolific recent discoveries. The Company has built a remarkable portfolio of approximately 20 properties, including several showing bonanza grade gold and silver values. Marifil strategically enhances its properties through focused exploration and drilling, and then utilizes joint ventures with other mining companies to build greater shareholder value. For further information, visit the Company's web site at www.marifilmines.com.
Maxygen, Inc. (NASDAQ: MAXY)
Maxygen, Inc. (NASDAQ: MAXY) was founded with the purpose of developing important commercial products by leveraging biotechnology. Since then, the company has established a pipeline of product candidates that address unmet medical needs. Maxygen’s key protein pharmaceutical programs include: MAXY-G34 , an improved G-CSF protein to treat neutropenia; MAXY-VII , an improved factor VIIa protein to treat hemophilia; and MAXY-4 , an improved CTLA4-Ig protein to treat rheumatoid arthritis. For further information, visit the Company's web site at www.maxygen.com.
MediciNova, Inc. (NASDAQ: MNOV)
MediciNova, Inc. (NASDAQ: MNOV), a biopharmaceutical company, is dedicated to acquiring and developing innovative, small-molecule therapeutics designed to treat diseases with medical needs that are currently unmet. By strategically forming alliances with other pharmaceutical companies, the company holds rights to a diversified portfolio of clinical and preclinical product candidates. MediciNova believes each of these candidates has a well-characterized and unique therapeutic profile, attractive commercial potential and patent assets having claims of commercially adequate scope. For further information, visit the Company's web site at www.medicinova.com.
Memory Pharmaceuticals Corp. (NASDAQ: MEMY)
Memory Pharmaceuticals Corp. (NASDAQ: MEMY) is a biopharmaceutical company focused on developing novel drugs designed to treat debilitating central nervous system (CNS) disorders, many of which significantly impair memory and other cognitive function. The company utilizes their staff’s expertise of the neuronal pathways involved in memory formation and cognition to identify highly relevant targets. By using in-house expertise in drug discovery and development, Memory Pharmaceuticals has generated a diverse pipeline of promising drug development programs. For further information, visit the Company's web site at www.memorypharma.com.
Metabasis Therapeutics, Inc. (NASDAQ: MBRX)
Metabasis Therapeutics, Inc. (NASDAQ: MBRX), a biopharmaceutical company, focuses their efforts on discovering, developing and commercializing innovative drugs by applying its scientific expertise, proprietary technologies and unique capabilities for targeting the liver and liver pathways. The company has established advanced research programs and a broad pipeline of product candidates, all of which were developed through the leveraging of their proprietary technologies. For further information, visit the Company's web site at www.mbasis.com.
MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK)
MiddleBrook Pharmaceuticals, Inc. (NASDAQ: MBRK), a pharmaceutical company, is focused on developing and commercializing anti-infective drug products that address unmet medical needs in anti-infective therapy. The company’s aim is to develop a portfolio of drugs based on their biological finding that bacteria are killed more efficiently and effectively when exposed to antibiotics in front-loaded, sequential bursts, or pulses, than those exposed to standard antibiotic treatment regimens. For further information, visit the Company's web site at www.middlebrookpharma.com.
Midnight Oil Exploration Ltd. (TSX: MOX CN)
Midnight Oil Exploration Ltd. (TSX: MOX CN), a top quality junior exploration and production company, focuses on selected multi-zone, high-potential areas of the Western Canadian Sedimentary Basin. The company has a high-end technical team with experience, expertise, and innovative business execution skills that provide a competitive edge. Midnight's investment strategy is driven by a risk-balanced portfolio of high-potential exploration and development prospects and strategic acquisitions. For further information, visit the Company's web site at www.midnightoil.ca.
Millennium India Acquisition Company, Inc. (NASDAQ: SMCG)
Millennium India Acquisition Company, Inc. (NASDAQ: SMCG) is a closed-end, non-diversified management investment company that is focused on emerging market leaders in the Indian economy. Recently, the young company made news when it announced an online trading alliance with Punjab National Bank, which is India’s second largest public-sector commercial bank. With new alliances and an aggressive style, Millennium has a strong grasp on the future.
MiMedx Group, Inc. (OTC BB: MDXG)
MiMedx Group, Inc. (OTC BB: MDXG)is focused on developing biomaterial-based products for application in the musculoskeletal specialties. The company intends to leverage their experienced management team to commercializes medical technologies by facilitating their progression through the proper regulatory approval processes, arranging for reliable and cost-effective manufacturing, and delivering these products to markets throughout the world. For further information, visit the Company's web site at www.mimedx.com.
Misonix, Inc. (NASDAQ: MSON)
Misonix, Inc. (NASDAQ: MSON) has their efforts focused on designing, developing, and manufacturing one of the broadest ranges of Therapeutic Ultrasonic Medical Devices. The company’s aim is to develop products that will improve patients’ quality of life by incorporating the highest level of quality and innovation into each and every product. Current application of their technology ranges from kidney stone pulverization and the aspiration of brain tumors to the latest technological breakthrough HIFU (High Intensity Focused Ultrasound) for various cancer treatments. For further information, visit the Company's web site at www.misonix.com.
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI)
Molecular Insight Pharmaceuticals, Inc. (NASDAQ: MIPI), a biopharmaceutical company, specializes in the emerging field of molecular medicine. The company is committed to applying innovations in the identification and targeting of disease to enhance patient healthcare by treating significant, but unmet medical needs. Their focus is on discovering, developing and commercializing novel radiotherapeutics and molecular imaging pharmaceuticals for initial application in the areas of oncology and cardiology. For further information, visit the Company's web site at www.molecularinsight.com.
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA)
Momenta Pharmaceuticals, Inc. (NASDAQ: MNTA) focuses its efforts on leveraging its proprietary technology to discover the structural secrets of complex sugars and other complex mixtures. The company’s novel approach to drug development and innovative tools have yielded a diversified product pipeline containing technology-enabled generic drugs, re-engineered drugs and novel drug candidates. Momenta’s strategic objective is to create near-term revenue opportunities that will fund longer-term discovery and development. For further information, visit the Company's web site at www.momentapharma.com.
Nanogen, Inc. (NASDAQ: NGEN)
Nanogen, Inc. (NASDAQ: NGEN) is focused on developing diagnostic products that provide enhanced patient care. The company’s products are designed to offer faster and easier diagnosis, treatment and monitoring of cardiovascular disease and infectious diseases. These superior products include molecular diagnostic kits and reagents, as well as rapid test kits that can be utilized in urgent care settings or at the point-of-care. Nanogen is committed to bringing better results to diagnostics and healthcare. For further information, visit the Company's web site at www.nanogen.com.
NAPCO Security Systems, Inc. (NASDAQ:NSSC)
NAPCO Security Systems, Inc. (NASDAQ:NSSC) is a leading manufacturer of a wide array of security products, developing advanced technologies for intrusion, fire, video, wireless, access control and door locking systems. With headquarters in New York, the company has branched into the international market by opening offices in the United Kingdom, the Caribbean, and Dubai. While many of NAPCO’s products have gained national attention, their Alarm Lock Division is the company’s fastest growing product and has been a leader in the marketplace since 1987. For further info, visit the company website at: www.napcosecurity.com.
NeoGenomics, Inc. (OTC BB: NGNM)
NeoGenomics, Inc. (OTC BB: NGNM) is known as the only publicly-traded pure-play laboratory testing service provider that has a specific focus on high revenue cancer genetics testing. The combination of advances in technology and genetic research, with the complete sequencing of the human genome, sophisticated new scientific testing tools to diagnose and treat diseases have been made possible. The company’s two facilities in Ft. Myers, Fla., and other facilities in Nashville, Tenn. and Irvine, Calif provide state of the art genetic testing. For further information, visit the Company's web site at www.neogenomics.org.
Neoprobe Corporation (OTC BB: NGNM)
Neoprobe Corporation (OTC BB: NEOP) has focused their efforts on developing and commercializing novel biomedical products that address the critical intraoperative, diagnostic and therapeutic treatment needs of patients and physicians. The company’s main area of dedication is on improving cancer surgery outcomes by utilizing their market-leading gamma detection devices in conjunction with radiopharmaceutical agents.
NetSol Technologies, Inc. (NASDAQ: NGNM)
NetSol Technologies, Inc. (NASDAQ: NTWK) is a leading global IT solutions and services provider catering to clients all over the world. While catering to the private and public sector, NetSol made national news when it was announced that Najeeb Ghauri, , chairman and chief executive officer, and Mitch Van Wye, chief operating officer, will present at the Rodman & Renshaw Annual Global Investment Conference in New York City on Monday, November 10, 2008 at the New York Palace Hotel. For further information, visit the company website at: www.netsoltek.com.
Neuralstem, Inc. (AMEX: CUR)
Neuralstem, Inc. (AMEX: CUR), a publicly traded biotherapeutics company, is focused on applying stem cell research and its patented human neural stem cell technology to treat diseases of the central nervous system. The company’s patent-protected technology allows them to produce mature, commercial quantities of neural stem cells that have the capability to control the differentiation of the cells into physiologically relevant human neurons and glia. For further information, visit the Company's web site at www.neuralstem.com.
Neurobiological Technologies, Inc. (NASDAQ: NTII)
Neurobiological Technologies, Inc. (NASDAQ: NTII), a biotechnology company, has their focus on acquiring and developing central nervous system (CNS) related drug candidates. The company strategically in-licenses late-stage CNS agents and then pursues regulatory approval and commercialization. Neurobiological’s goal as a company is to develop and market drug candidates in the United States, Europe and Asia while possibly seeking partnerships with pharmaceutical and biotechnology companies. For further information, visit the Company's web site at www.ntii.com.
NeurogesX, Inc. (NASDAQ: NTII)
NeurogesX, Inc. (NASDAQ: NGSX), a biopharmaceutical company based in the San Francisco Bay Area, is focused on developing effective treatments that relieve chronic pain and improve quality of life. NGX-4010, the company’s leading product candidate, could possibly revolutionize the treatment of neuropathic pain as a single application may provide months of relief. The product candidate is currently in Phase 3 clinical trials. For further information, visit the Company's web site at www.neurogesx.com.
Nevsun Resources, Ltd. (AMEX: NSU)
Nevsun Resources, Ltd. (AMEX: NSU), a gold and base metal explorer/developer, is focused on developing mining projects in Africa. Currently, the company is dedicating its efforts to advancing its high grade gold, copper and zinc Bisha Project in Eritrea. A feasibility study for this project was completed in 2006. Nevsun’s mining license covers an area of 16.5 square kilometers (includes the Bisha Main Zone deposit and the Northwest Zone deposit) within a mining agreement area of approximately 39 square kilometers. For further information, visit the Company's web site at www.nevsun.com.
New Guinea Gold Corporation (TSX:NGG CN)
New Guinea Gold Corporation (TSX: NGG CN), the premier junior explorer and miner in Papua New Guinea, has direct and indirect interests in twelve properties. With 75,000 + metres of drilling completed, extensive gold or copper-gold-molybdenum mineralization has been discovered at 11 of the properties while the 12th contains widespread and extensive alluvial gold. The company’s Sinivit mine is anticipated to generate cash flow for on-going exploration of other large scale targets. For further information, visit the Company's web site at www.newguineagold.ca.
NGAS Resources, Inc. (NASDAQ: NGAS)
NGAS Resources, Inc. (NASDAQ: NGAS), an independent exploration and production company, has focused its operations primarily on the Appalachian Basin. The company generates its own geological prospects in this region and has strategically structured its business to achieve capital appreciation through growth in natural gas reserves, production, and cash flow. NGAS has the competitive advantage of acquiring nearby acreage not yet developed. For further information, visit the Company's web site at www.ngas.com.
Nile Therapeutics, Inc. (NASDAQ: NLTX)
Nile Therapeutics, Inc. (NASDAQ: NLTX), a clinical-stage biopharmaceutical company, is focused on developing novel products designed to treat cardiovascular disease. CD-NP, the company’s lead compound, is a chimeric natriuretic peptide that is currently in clinical studies for an initial indication of acute decompensated heart failure. Additionally, the company is also developing CU-NP, a chimeric natriuretic peptide, and 2NTX-99, a small molecule with anti-atherothrombotic and nitric oxide donating properties. For further information, visit the Company's web site at www.nilethera.com.
NMT Medical, Inc. (NASDAQ: NMTI)
NMT Medical, Inc. (NASDAQ: NMTI), a leader in the emerging field of structural heart repair, is focused on designing, developing, manufacturing and marketing proprietary implant technologies that allow interventional cardiologists to treat certain structural heart disease through minimally invasive, catheter-based procedures. By working with qualified physicians, the company has provided minimally invasive treatment for an array of cardiac defects for more than two decades. For further information, visit the Company's web site at www.nmtmedical.com.
Nkwe Platinum Limited (ASX: NKP AU)
Nkwe Platinum Limited (ASX: NKP AU) is an emerging platinum company with a primary focus on mid-level projects and market capitalization. The company has five key project areas with identified mineralization that contain 17M oz of resources spread over 15,000 ha. Nkwe aims to add significant shareholder value through acquiring, exploring, developing and commercializing Platinum Group Elements (PGE) and associated base metal projects in the Bushveld Complex of South Africa. For further information, visit the Company's web site at www.nkweplatinum.com.
North Peace Energy Corp. (TSX: NPE CN)
North Peace Energy Corp. (TSX: NPE CN) has an in situ oil sands project in northern Alberta with 86,400 acres of leases bridging the Peace River and Athabasca oil sands areas. The company’s is currently focused on utilizing a robust and proven in-situ recovery method to advance the development of its resources. With no debt and a clean balance sheet, North Peace is poised for significant growth. For further information, visit the Company's web site at www.northpec.ca.
Northfield Laboratories, Inc. (NASDAQ: NFLD)
Northfield Laboratories, Inc. (NASDAQ: NFLD), a leading developer of oxygen-carrying red blood cell substitute, is focused on addressing the need for the treatment of life-threatening blood loss when oxygen-carrying fluid is required and red blood cells are not available. The company’s PolyHeme product restores lost blood volume and hemoglobin levels and is able to be administered rapidly in massive amounts. For further information, visit the Company's web site at www.northfieldlabs.com.
Northern Star Mining Corporation (TSX: NSM CN)
Northern Star Mining Corporation (TSX: NSM CN), an aggressive exploration company based in Quebec, Canada, has its focus on its primary project, the Midway property, which is well positioned within the heart of the renowned and prolific Abitibi Gold Belt of Northwestern Quebec, Canada. To date, total gold produced in the Abitibi camp is in excess of 60 million ounces. The Midway property has been extensively drilled over the past two years and continues to show evidence of a significant deposit. For further information, visit the Company's web site at www.nsmgold.com.
North Shore Acquisition Corporation (OTC BB: NSAQ)
North Shore Acquisition Corporation (OTC BB: NSAQ) was formed on June 26, 2007 to serve as a vehicle to effect a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or other similar business combination with one or more operating businesses or assets. Their efforts in identifying a prospective target business will not be limited to a particular industry. Barry Gordon serves as North Shore’s President and CEO and brings a wealth of experience and an aggressive business style with him.
NovaBay Pharmaceuticals, Inc. (AMEX: NBY)
NovaBay Pharmaceuticals, Inc. (AMEX: NBY) has focused their efforts on developing innovative product candidates that target the treatment or prevention of a broad array of infections in hospital and community environments. Because of the rapid increase in infectious microbes that are resistant to current drugs, many of these infections have become increasingly difficult to treat. Vitro and in vivo tests have proven that the company’s compounds kill a broad range of bacteria, viruses and other infection causing microbes, even those that are resistant to multiple antibiotics. For further information, visit the Company's web site at www.novabaypharma.com.
NovaDel Pharma, Inc. (AMEX: NVD)
NovaDel Pharma, Inc. (AMEX: NVD), a specialty pharmaceutical company, is focused on developing oral spray formulations of a wide array of marketed therapeutics. NovaMist™, the Company's proprietary technology, allows drugs to be rapidly delivered directly into the bloodstream, which results in faster onset of action and may provide patient benefits in compliance, convenience and safety. Currently, NovaDel's most advanced candidates are designed to treat angina, insomnia, and nausea. For further information, visit the Company's web site at www.novadel.com.
Novavax, Inc. (NASDAQ: NVAX)
Novavax, Inc. (NASDAQ: NVAX), a clinical stage biotechnology company, is focused on creating innovative vaccines that target a wide array of infectious diseases using advanced proprietary virus-like particle (VLP) technology. The company produces these VLP based, potent, recombinant vaccines by leveraging new and efficient manufacturing approaches. Novavax’s long-term goal is to be able to deliver a customized vaccine in the midst of an epidemic. For further information, visit the Company's web site at www.novavax.com.
Novelos Therapeutics, Inc. (OTC BB: NVLT)
Novelos Therapeutics, Inc. (OTC BB: NVLT), a biopharmaceutical company, has its focus on commercializing oxidized glutathione-based compounds for the treatment of Cancer and Hepatitis. The company’s lead compound in Phase 3 development for lung cancer under a Special Protocol Assessment (SPA) and Fast Track, NOV-002, acts together with chemotherapy as a chemoprotectant and chemopotentiator by regulating redox-sensitive cell signaling pathways. For further information, visit the Company's web site at www.novelos.com.
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP)
NPS Pharmaceuticals, Inc. (NASDAQ: NPSP) is focused on the development of specialty therapeutics for gastrointestinal and endocrine disorders. Currently, the company is progressing two late-stage programs: GATTEX™ (teduglutide), which is in Phase 3 clinical development for intestinal failure associated with short bowel syndrome; and NPSP558 (parathyroid hormone 1-84 [rDNA origin] injection), which is in Phase 2 clinical development as a hormone therapy for hypoparathyroidism. For further information, visit the Company's web site at www.npsp.com.
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST)
NUCRYST Pharmaceuticals Corp. (NASDAQ: NCST) is focused on developing, manufacturing, and commercializing medical products designed to fight infection and inflammation based on the company’s patented atomically disordered nanocrystalline silver technology. NUCRYST has found success developing and manufacturing Acticoat™ dressings with SILCRYST™ nanocrystals for Smith & Nephew plc. These products are currently in use by hospitals, clinics, burn centers, doctor’s offices, home healthcare agencies and nursing homes around the globe. For further information, visit the Company's web site at www.nucryst.com.
Nuinsco Resources Limited (TSX: NWI CN)
Nuinsco Resources Limited (TSX: NWI CN), a growth-oriented, multi-commodity mineral exploration and development company, is focused on growing through the exploration and development of world-class mineralized belts in Canada and Turkey. The company also holds equity positions in near-production Victory Nickel Inc. (TSX:Ni), polymetallic producer Gold Hawk Resources Inc. (TSXV:CGK) and copper and gold producer Campbell Resources Inc. (TSX:CCH). For further information, visit the Company's web site at www.nuinsco.ca.
NutraCea (OTC BB: NTRZ)
NutraCea (OTC BB: NTRZ) is focused on processing and distribution stabilized rice bran and other proprietary, rice bran-based ingredients and formulations. Until recently, rice bran and germ were considered as a unnecessary by-product of the commercial rice-milling industry, but NutraCea recognized its unlimited potential as food and nutraceuticals ingredient. The company believes rice bran is positioned to become one of the world’s leading food ingredients for food manufacturers, nutraceuticals, humanitarian aid, as well as petfood and feed manufacturers. For further information, visit the Company's web site at www.nutracea.com.
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS)
Oculus Innovative Sciences, Inc. (NASDAQ: OCLS), a biopharmaceutical company, is focused on developing, manufacturing, and marketing a broad array of products based upon the shelf-stable Microcyn® Technology platform, which has been designed to help prevent and treat infections in wounds, burns and diseases. The Microcyn platform has shown capabilities of safely treating a wide range of pathogens, including antibiotic-resistant strains of bacteria such as MRSA, viruses, fungi and spores. For further information, visit the Company's web site at www.oculusis.com.
OMNI Energy Services Corp. (NASDAQ: OMNI)
OMNI Energy Services Corp. (NASDAQ: OMNI), an integrated oilfield service company, specializes in providing a range of onshore seismic drilling, operational support, permitting, and survey services to geophysical companies operating in logistically difficult and environmentally sensitive terrain. The company also provides dock-side, onshore and offshore non-hazardous, oilfield waste management and environmental cleaning services, including tank and vessel cleaning and safe vessel entry, for oil and gas companies operating in the Gulf of Mexico. For further information, visit the Company's web site at www.omnienergy.com.
Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI)
Omrix Biopharmaceuticals, Inc. (NASDAQ: OMRI) is dedicated to developing innovative technologies that provide safer and more effective options to patients in areas with significant, but unmet medical needs. The company is primarily focused on the areas of biosurgical and passive immunotherapy products. By utilizing their proprietary protein purification technology, novel development capabilities, and manufacturing expertise, the company aims to develop treatments of choice in their respective therapeutic areas. For further information, visit the Company's web site at www.omrix.com.
Oncolytics Biotech, Inc. (NASDAQ: ONCY)
Oncolytics Biotech, Inc. (NASDAQ: ONCY) has focused their efforts on the discovery and development of pharmaceutical products designed to treat of a broad range of human cancers. With headquarters in Calgary, Alberta, Canada, the Company was formed in 1998 to investigate the oncolytic capability of the reovirus, a virus that preferentially replicates in cells with an activated Ras pathway, which happens to be one of the most common families of genetic defects leading to cancer. For further information, visit the Company's web site at www.oncolytics.com.
Oncothyreon, Inc. (NASDAQ: ONTY)
Oncothyreon, Inc. (NASDAQ: ONTY), a biotechnology company, is committed to the development of oncology products designed to improve the lives and outcomes of cancer patients. Currently, the company is in the process of developing multiple therapeutic candidates targeting cancer in specific and effective ways. With headquarters in Seattle, Washington, their pipeline includes both synthetic vaccines and small molecules for a variety of cancer indications. For further information, visit the Company's web site at www.oncothyreon.com.
OncoVista Innovative Therapies, Inc. (OTC BB: OVIT)
OncoVista Innovative Therapies, Inc. (OTC BB: OVIT), a biopharmaceutical company, is focused on developing and commercializing therapies targeted towards cancer that are designed to provide more efficiency while being less toxic. By combining their extensive in-house pre-clinical and clinical know-how with a global drug development network, the company intends to see rapid and cost-effective regulatory approval and commercialization of innovative therapies. For further information, visit the Company's web site at www.oncovista.com.
Opexa Therapeutics, Inc. (NASDAQ: OPXA)
Opexa Therapeutics, Inc. (NASDAQ: OPXA), a biotechnology company, has focused their efforts on the development of patient-specific cellular therapies designed to treat autoimmune diseases such as multiple sclerosis (MS) and diabetes. Tovaxin, the company’s lead product candidate, is an innovative T-cell vaccine used to treat MS. Results from the Phase IIb study have shown a positive trend in reducing annualized relapse rate for patients treated with the drug compared to placebo. For further information, visit the Company's web site at www.opexatherapeutics.com.
Oramed Pharmaceuticals Inc. (OTC BB: ORMP)
Oramed Pharmaceuticals Inc. (OTC BB: ORMP), a commercial drug development company, is applying proprietary expertise in integrative pharmacology to potentially discover new uses for drug candidates. Currently, the company is committing their efforts to developing certain compounds for new uses. Compounds in Ore’s development pipeline include: romazarit (for metabolic disorders), tiapamil (for treatment of diseases of the central nervous system), and GL1001 (for inflammatory bowel disease). For further information, visit the Company's web site at www.oramed.com.
Orko Silver Corp. (TSX: OK CN)
Orko Silver Corp. (TSX: OK CN) is focused on exploring and developing for silver and gold within the borders of Mexico. The Company has a large land position in Durango State, a historically prolific silver mining region located along the Sierra Madre Occidental Mountains and is involved in three main projects, La Preciosa, Santa Monica and San Juan. The company also owns a 100% interest in the La Preciosa Project and the adjacent Santa Monica Project; in addition to a 75% interest in a Joint Venture on the adjacent San Juan property. For further information, visit the Company's web site at www.orkosilver.com.
Orexigen Therapeutics, Inc. (NASDAQ: OREX)
Orexigen Therapeutics, Inc. (NASDAQ: OREX), a biopharmaceutical company, has focused their efforts on the development of pharmaceutical product candidates designed to treat obesity and other central nervous system-related disorders. The company’s lead combination product candidates targeted for obesity include: Contrave®, which is in Phase 3 clinical trials; and Empatic™, which is in the later stages of Phase 2 clinical development. For further information, visit the Company's web site at www.orexigen.com.
Origin Agritech Limited (NASDAQ: SEED)
Origin Agritech Limited (NASDAQ: SEED), a leading agricultural biotechnology company and a top player in seed industry, specializes in researching and developing, producing, selling and distributing agricultural crop seeds. The Company's major seed products are corn, rice, cotton and canola. Located in Beijing, China, the company is focused on crop improvement and utilizes biotechnology to achieve their goals. For further information, visit the company website at: www.originagritech.com.
Orthovita, Inc. (NASDAQ: VITA)
Orthovita, Inc. (NASDAQ: VITA), a novel spine/orthopaedic surgical biomaterials company, is focused on providing progressive bone regeneration and soft tissue healing technologies. The company’s expertise lies in developing and distributing novel, high-tech, synthetic-based biomaterial products. Currently, Orthovita has several key commercial product platforms including: Vitoss Bone Graft Substitute, Vitagel Surgical Hemostat, Cortoss Synthetic Cortical Bone, and Imbibe Delivery and Disposable Systems. For further information, visit the Company's web site at www.orthovita.com.
Oscient Pharmaceuticals Corporation (NASDAQ: OSCI)
Oscient Pharmaceuticals Corporation (NASDAQ: OSCI), a commercial-stage pharmaceutical company, is devoted to marketing two FDA-approved products in the United States: ANTARA® capsules, a cardiovascular product; and FACTIVE® tablets, a fluoroquinolone antibiotic. ANTARA is designed to treat hypercholesterolemia (high blood cholesterol) and hypertriglyceridemia (high triglycerides) in combination with diet. FACTIVE is designed to treat acute bacterial exacerbations of chronic bronchitis and pneumonia. For further information, visit the Company's web site at www.oscient.com.
Osiris Therapeutics, Inc. (NASDAQ: OSIR)
Osiris Therapeutics, Inc. (NASDAQ: OSIR), a leading stem cell therapeutic company, has their focus on developing and marketing products for the treatment of medical conditions in the inflammatory, orthopedic, and cardiovascular areas. The company’s stem cell products have major therapeutic potential because of their ability to promote tissue regeneration, regulate inflammation and prevent pathological scar formation. For further information, visit the Company's web site at www.osiris.com.
Osteologix, Inc. (OTC BB: OLGX)
Osteologix, Inc. (OTC BB: OLGX), a specialty biopharmaceutical company, has dedicated their efforts to improving the health of those afflicted with musculoskeletal diseases through the development of innovative therapies. NB S101, the company’s lead investigational product candidate, is an innovative pharmaceutical agent designed to treat and prevent osteoporosis. Their mission is to partner with the healthcare community to apply new scientific information to the development of beneficial products. For more information please visit www.osteologix.com.
OXiGENE, Inc. (NASDAQ: OXGN)
OXiGENE, Inc. (NASDAQ: OXGN), a biopharmaceutical company, is focused on finding and developing new and improved therapeutics that attend to the substantial, but unmet needs of patients diagnosed with cancer and eye disease. The company’s primary focus is on the development and commercialization of first-in-class and best-in-class vascular disrupting agents (VDAs) designed to treat cancer and eye disease. To date, OXiGENE's VDA product candidates have shown considerable potential in human clinical studies. For further information, visit the Company's web site at www.oxigene.com.
Oxygen Biotherapeutics, Inc. (OTC BB: OXBO)
Oxygen Biotherapeutics, Inc. (OTC BB: OXBO), previously known as Synthetic Blood International, Inc., is focused on transforming patient care through the development of advanced oxygen-based therapies using Oxycyte®, the company’s perfluorocarbon (PFC) therapeutic oxygen carrier, and other solutions. Oxycyte could potentially be used in numerous indications, including traumatic brain injury, sickle-cell pain crisis, decompression sickness, stroke, heart attack, and wound treatment. For further information, visit the Company's web site at www.oxybiomed.com.
Pacific Ridge Exploration Ltd. (TSX: PEX CN)
Pacific Ridge Exploration Ltd. (TSX: PEX CN) is primarily focused on discovering and developing for phosphate in British Columbia. The company recently acquired two phosphate projects in the interior of British Columbia, each offering the opportunity of a multi-deposit discovery. The Baker Basin Project, flagship project of Pacific Ridge, is located in an emerging uranium district in south-western Nunavut. Baker is over 190,000 hectares in size and is known to host at least 20 uranium prospects. For further information, visit the Company's web site at www.pacificridgeexploration.com.
Palatin Technologies, Inc. (AMEX: PTN)
Palatin Technologies, Inc. (AMEX: PTN), a biopharmaceutical company, has dedicated their efforts to developing peptide, peptide mimetic and small molecule agonist compounds. Their primary focus is on melanocortin and natriuretic peptide receptor systems, including acute hospital care products in the cardiovascular field, for treating congestive heart failure, hard-to-control hypertension as well as cardiac surgery organ protection. For further information, visit the Company's web site at www.palatin.com.
Panhandle Oil and Gas, Inc. (NYSE: PHX)
Panhandle Oil and Gas, Inc. (NYSE: PHX) has its operations focused on producing and selling oil and natural gas. The Company’s holdings, including its mineral acreage and its interests in producing wells, are located in Oklahoma. Exploration and development of the Company’s properties are conducted in partnership with operating oil and gas companies. Panhandle is committed to strategically building its reserve base and production volumes in fiscal 2009 and beyond. For further information, visit the Company's web site at www.omnienergy.com.
PanTerra Resource Corp. (TSX: PAN CN)
PanTerra Resource Corp. (TSX: PAN CN), an independent resource company focused on the exploration and development of Shale Gas in the Province of Saskatchewan, Canada, is focused on exploring for and developing shale gas on its land holdings which are located in the Province of Saskatchewan. The company has drilled 36 wells and has a 100% working Interest in the 45 Townships. The company has planned extensive testing and fracture stimulations on the 36 wells to best determine the most efficient and economic method of producing the huge (63 Tcf) in place gas resources. For further information, visit the Company's web site at www.panterraresource.com.
Parallel Petroleum Corporation (NASDAQ: PLLL)
Parallel Petroleum Corporation (NASDAQ: PLLL), an independent energy company headquartered in Midland , Texas, is focused on the acquisition, development, exploration and production of oil and gas using enhanced oil recovery techniques and 3-D seismic technology. The company’s primary areas of operation are the Permian Basin of West Texas, Gulf Coast of South Texas, East Texas, and its three newly announced areas of North Texas, New Mexico and Utah. For further information, visit the Company's web site at www.parallel-petro.com.
Pearl Exploration and Production Ltd. (TSX: PXX CN)
Pearl Exploration and Production Ltd. (TSX: PXX CN), a Canadian oil and gas company, has its focus on North American oil and gas interests, in particular, Alberta, Saskatchewan, Texas and California. The company’s mission is to acquire large heavy oil resources and focus on converting those resources to reserves through implementation of pilot programs including: water flood, steam flood, polymer flood, and Steam-Assisted Gravity Drainage (SAGD). For further information, visit the Company's web site at www.pearleandp.com.
Pelangio Exploration Inc. (TSX: PX CN)PX CN)
Pelangio Exploration Inc. (TSX: PX CN), a Canadian junior gold exploration company, is focused on acquiring and exploring for under-valued or early stage exploration prospects located in world-class gold belts, and is committed to make discoveries that will considerably increase shareholder value. The company’s primary exploration property is a 290 square kilometre early stage exploration property in Ghana, located on strike and adjacent to AngloGold Ashanti's Obuasi gold mine. For further information, visit the Company's web site at www.pelangio.com.
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM)
Peregrine Pharmaceuticals, Inc. (NASDAQ: PPHM), a clinical stage biopharmaceutical company, is committed to developing novel monoclonal antibodies to treat cancer and hepatitis C virus (HCV) infection. The company is currently progressing three distinct clinical programs, bavituximab and Cotara® being its leading product candidates, both of which are in Phase II clinical studies for the treatment of cancer. Additionally, bavituximab is in a Phase I clinical study for the treatment of HCV infection. For further information, visit the Company's web site at www.peregrineinc.com.
Petro Resources Corporation (AMEX: PRC)
Petro Resources Corporation (AMEX: PRC), an independent exploration and production company, is focused on acquiring exploratory leases, producing properties, and secondary enhanced oil recovery projects as well as exploratory drilling and production of oil and natural gas in the United States. The company’s aim is to create and maximize shareholder value by leveraging the expertise of its management team with industry partners to grow a diversified portfolio of oil and natural gas producing projects and prospects. For further information, visit the Company's web site at www.petroresourcescorp.com.
Pharmacopeia, Inc. (NASDAQ: PCOP)
Pharmacopeia, Inc. (NASDAQ: PCOP), a clinical development stage biopharmaceutical company, is focused on discovering and developing innovative small molecule therapeutics to attend to significant medical needs. The company’s broad portfolio of clinical and preclinical candidates are currently under development internally or with partners, including nine clinical compounds in Phase 2 or Phase 1 development. For further information, visit the Company's web site at www.pcop.com.
Pharmasset, Inc. (NASDAQ: VRUS)
Pharmasset, Inc. (NASDAQ: VRUS), a clinical-stage pharmaceutical company, is focused on discovering, developing and commercializing innovative drugs for the treatment of viral infections. The company’s primary focus is on developing of oral therapeutics for the treatment of hepatitis B virus, hepatitis C virus and human immunodeficiency virus (HIV). Their product candidates include: Clevudine (for treating chronic HBV infection), R7128 (for treating HCV), and R7128 (for treating HIV). For further information, visit the Company's web site at www.pharmsset.com.
PharmAthene, Inc. (AMEX: PIP)
PharmAthene, Inc. (AMEX: PIP) is focused on addressing the critical needs of the United States and its allies through the development and commercialization of medical countermeasures against biological and chemical weapons. Currently, the company’s lead product development programs include: SparVax, an anthrax vaccine; a third generation rPA anthrax vaccine; Valortim, an antibody designed to prevent and treat anthrax infection; Protexia, a bioscavenger; and RypVax, a dual antigen vaccine for plague. For further information, visit the Company's web site at www.pharmathene.com.
PhotoMedex, Inc. (NASDAQ: PHMD)
PhotoMedex, Inc. (NASDAQ: PHMD) provides novel solutions designed for application in the areas of dermatology, therapeutic skin care and surgical products & services. The company is currently developing proprietary excimer laser and fiber-optic systems to treat dermatological applications such as psoriasis and vitiligo. PhotoMedex’s XTRAC® was the first FDA market-cleared excimer laser system designed to treat dermatological applications such as psoriasis and vitiligo. For further information, visit the Company's web site at www.photomedex.com.
Adeona Pharmaceuticals, Inc. AEN)
Adeona Pharmaceuticals, Inc. (AEN), a development-stage, specialty pharmaceutical company, has dedicated its efforts to developing proprietary, late-stage drug candidates designed to treat autoimmune and central nervous system (CNS) diseases. The company’s strategy is to exclusively in-license proprietary, clinical-stage drug candidates that have proven clinical efficacy for the treatment medical diseases that are as of yet unattended to. For further information, visit the Company's web site at www.adeonapharma.com.
Platinum Australia Limited (ASX: PLA AU)
Platinum Australia Limited (ASX: PLA AU) is committed to discovering and developing Platinum Group Metal ("PGM") Projects in Australia and around the world. In South Africa, the company is developing the Smokey Hills PGM Project which is scheduled to commence production in the first half of 2008. This project consists of an open pit and underground mining operation with an onsite processing facility capable of producing ~100,000 oz 4E PGM per annum. For further information, visit the Company's web site at www.platinumaus.com.au.
Pluristem Therapeutics, Inc. (NASDAQ: PSTI)
Pluristem Therapeutics, Inc. (NASDAQ: PSTI), a bio-therapeutics company, has their focus on commercializing allogeneic (non-personalized) cell therapy products designed to treat a range of severe degenerative, ischemic and autoimmune disorders. Each of Pluristem’s products begin as mesenchymal stromal cells (MSCs). These cells are derived from the human placenta, an organ that has been considered medical waste after childbirth, but recognized by the company as a source of embryonic, non-controversial source of cells. For further information, visit the Company's web site at www.pluristem.com.
Polaris Minerals Corporation (TSX: PLS CN)
Polaris Minerals Corporation (TSX: PLS CN) is solely focused on supplying construction aggregates to coastal urban markets on the western seaboard of North America. The company has targeted markets where accelerating local supply deficits and increasing road distribution costs allow marine transported aggregates to be competitive in the hub of key coastal urban markets. Polaris is led by CEO Marco Romero who has more than 28 years of experience in the mining industry. For further information, visit the Company's web site at www.polarmin.com.
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD)
Poniard Pharmaceuticals, Inc. (NASDAQ: PARD), a biopharmaceutical company, has their focus on developing and commercializing novel oncology products designed to impact the lives of people with cancer. Currently, the company’s development efforts are focused on picoplatin, a new generation of platinum chemotherapy agent that could potentially become a platform product. Poniard is studying this potential platform product in a number of cancer indications, combinations and formulations. For further information, visit the Company's web site at www.poniard.com.
Prana Biotechnology Ltd. (NASDAQ: PRAN)
Prana Biotechnology Ltd. (NASDAQ: PRAN) has developed a proprietary portfolio of class-leading chemical compounds. The company combines this portfolio of compounds with a drug development program to discover novel therapeutics in multiple disease indications. Prana’s focus is currently on meeting the needs of patients diagnosed with neurological diseases, particularly Alzheimer‘s, Parkinson‘s and Huntington‘s diseases. For further information, visit the Company's web site at www.pranabio.com.
Pro-Pharmaceuticals, Inc. (AMEX: PRW)
Pro-Pharmaceuticals, Inc. (AMEX: PRW), a development-stage company, is focused on the discovery, development, and commercialization of first-in-class, targeted therapeutic compounds designed to treat cancer, liver, microbial and inflammatory diseases. The company’s current focus is on developing a new generation of anti-cancer treatments by utilizing carbohydrate polymers to improve survival rates and improve the quality of life for cancer patients. For further information, visit the Company's web site at www.pro-pharmaceuticals.com.
Prospect Acquisition Corporation (AMEX: PAX)
Prospect Acquisition Corporation (AMEX: PAX) is a newly organized blank check company formed for the purpose of acquiring control of, through a merger, capital stock exchange, asset acquisition, stock purchase, reorganization or similar business combination, one or more businesses or assets in the financial service industry. On November 20, 2007 Prospect completed an initial public offering of 25,000,000 units at an offering price of $10.00 per unit, generating gross proceeds of $250,000,000. For further information, visit the company website at: www.prospectac.com.
Protalex, Inc. (OTC BB: PRTX)
Protalex, Inc. (OTC BB: PRTX), a biotechnology company, is focused on developing a new class of drugs designed to treat a variety of autoimmune disorders. PRTX-100, the company’s lead compound, is currently being developed for a rare blood clotting disorder and rheumatoid arthritis. This compound is a highly-purified form of Staphylococcal Protein A (SpA or Protein A) and has been used in FDA-approved extracorporeal immunoadsorption systems for both idiopathic thrombocytopenic purpura and rheumatoid arthritis. For further information, visit the Company's web site at www.protalex.net.
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT)
Provectus Pharmaceuticals, Inc. (OTC BB: PVCT), a development stage company, is focused on safer, more effective, less invasive and more economical oncology and dermatology therapies. Currently, the company is conducting Phase 2 clinical trials of their proprietary drugs designed to treat psoriasis, metastatic melanoma, and atopic dermatitis. Provectus has developed multiple intellectual properties and technologies in the areas of imaging, medical devices and biotechnology. For further information, visit the Company's web site at www.pvct.com.
pSivida Corp. (NASDAQ: PSDV)
pSivida Corp. (NASDAQ: PSDV) has focused their efforts on developing drug delivery products, with an initial focus on ophthalmology and oncology. The company generates revenues through the marketing of the only two FDA approved sustained release back of the eye treatments for chronic eye disease. Substantial revenues are anticipated shortly from their varied late-stage product portfolio that includes a next generation product designed to treat Diabetic Macular Edema as well as other ophthalmic applications. For further information, visit the Company's web site at www.psivida.com.
Puda Coal, Inc. (OTC BB: PUDC)
Puda Coal, Inc. (OTC BB: PUDC) specializes in providing premium grade cleaned coking coal to the steel manufacturing industry for the use in making coke in China. The company does this through its operating subsidiary, Shanxi Puda Coal Group Co., Ltd. The company has been growing at a very fast-pace and now provides nearly 50% of China’s coke. For further information, visit the company website at: www.pudacoalinc.com.
Qiao Xing Universal Telephone, Inc. (NASDAQ: XING)
Qiao Xing Universal Telephone, Inc. (NASDAQ: XING) is a leading provider of both fixed-line and wireless phones to China's booming telecom market. Experts in the marketplace have called Qiao Xing the most undervalued Chinese ADR and the Chinese Nokia. With a large population in China and the emergence of Cell-Phone technology, this company may be a hidden gem. For further information, visit the company website at: www.qiaoxing.com.
QLT, Inc. (NASDAQ: QLTI)
QLT, Inc. (NASDAQ: QLTI), a global biopharmaceutical company, has dedicated their efforts to discovering, developing and commercializing novel therapies. The company’s research and development efforts are focused on the field of ophthalmology. QLT leverages its three unique technology platforms, photodynamic therapy, Atrigel® and punctal plugs with drugs, to develop products such as Visudyne® and Eligard® and future product opportunities. For further information, visit the Company's web site at www.qltinc.com.
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR)
Questcor Pharmaceuticals, Inc. (NASDAQ: QCOR), a specialty pharmaceutical company, is committed to providing prescription drugs designed to address central nervous system (CNS) disorders. Currently, the company is building a core portfolio of both marketed and development-stage products that attend to substantial, but unmet medical needs. Questcor’s aim is to develop and commercialize their own proprietary products, while staying open to partnering concepts to leverage assets and further build its portfolio. For further information, visit the Company's web site at www.questcor.com.
Rainy River Resources Ltd. (TSX: RR CN)
Rainy River Resources Ltd. (TSX: RR CN), a well financed junior exploration company, is led by an exploration team that has over 200 years of combined gold exploration experience. The company’s project is located 80 kilometers south of Kenora in northwestern Ontario. The project encompasses 26,000 hectares unpatented mining claims, purchased patents (mining and/or surface rights), mining lease. For further information, visit the Company's web site at www.rainyriverresources.com.
RAM Energy Resources, Inc. (NASDAQ: RAME)
RAM Energy Resources, Inc. (NASDAQ: RAME), an independent oil and gas company, is focused on acquiring, exploring, exploiting and developing oil and natural gas properties and producing oil and natural gas. The company’s properties are primarily located in Texas, Oklahoma, West Virginia and Louisiana. RAM has had proven success since 1987 and has accumulated substantial long-lived natural gas and oil reserves at relatively moderate depths. For further information, visit the Company's web site at www.ramenergy.com.
Raptor Pharmaceuticals Corp. (OTC BB: RPTP)
Raptor Pharmaceuticals Corp. (OTC BB: RPTP) has its business strategically divided into two segments: its 100% ownership of Raptor Pharmaceutical Inc., a development stage biotechnology company focused on bioengineeing drug candidates and drug-targeting platforms derived from the human receptor-associated protein and related proteins; and its 100% ownership of Bennu Pharmaceuticals Inc., a development stage company created with the purpose of developing clinical-stage products. For further information, visit the Company's web site at www.raptorpharma.com.
Range Resources Corporation (NYSE: RRC)
Range Resources Corporation (NYSE: RRC), an independent oil and gas company, operates in the Southwestern, Appalachian and Gulf Coast regions of the United States. The company utilizes a growth strategy that targets exploitation of its sizeable inventory of lower risk development drilling opportunities. As of the end of 2007, drilling inventory included more than 11,000 proven drilling projects, and leasehold position of 3.4 (2.7 net) million acres. For further information, visit the Company's web site at www.rangeresources.com.
Redpoint Bio Corporation (OTC BB: RPBC)
Redpoint Bio Corporation (OTC BB: RPBC), a leading biotechnology company, is focused on developing better tasting products for the pharmaceutical, food and beverage industries. The recent progression in taste biology has produced a number of new approaches to the discovery and development of innovative taste blockers and enhancers. The company leverages its modern tools of biotechnology to discover revolutionary ways to make medicines more palatable and enhance the taste of prepared foods and beverages. For further information, visit the Company's web site at www.redpointbio.com.
RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN)
RegeneRx Biopharmaceuticals, Inc. (AMEX: RGN), a publicly-traded biopharmaceutical company, focuses their efforts on discovering and developing innovative molecules that increase the speed of tissue and organ repair. With headquarters in Bethesda, Maryland, the company leverages its outsourcing business model to efficiently control costs while developing drug candidates. RegeneRX believes this business model improves their ability to rapidly allocate resources to various projects without investing in infrastructure. For further information, visit the Company's web site at www.regenerx.com.
Remedent, Inc. (OTC BB: REMI)
Remedent, Inc. (OTC BB: REMI) is a Belgium company that strives to be a world leader in the research and development, manufacturing and marketing of oral care and cosmetic dentistry products. Remedent currently has two divisions: One that serves dental care and the other that caters to over-the-counter consumer market. With a vast array of products that are sold exclusively thru pharmacies and drug stores, Remedent is a company to keep an eye on. For further information, visit the company website at: www.remedent.com.
Repligen Corporation (NASDAQ: RGEN)
Repligen Corporation (NASDAQ: RGEN) has focused their efforts on the development of innovative therapeutics for neurological disorders. The company’s current clinical development programs are being conducted in the areas of pancreatic MRI imaging, bipolar disorder, Friedreich's ataxia and Huntington's disease. Repligen generates profits from its recombinant Protein A and has a secured source of revenue via its licensing of CTLA4-Ig. The company also receives royalties from Bristol-Myers Squibb. For further information, visit the Company's web site at www.repligen.com.
Repros Therapeutics, Inc. (NASDAQ: RPRX)
Repros Therapeutics, Inc. (NASDAQ: RPRX) is focused on developing oral small molecule drugs to treat substantial, but unmet medical needs. The company has a proven track-record of rapidly progressing their therapeutic candidates through clinical development with efficiency. Proellex, the company’s lead drug, selectively blocks the progesterone receptor and may treat uterine fibroids, endometriosis and anemia associated with uterine fibroids. For further information, visit the Company's web site at www.reprosrx.com.
Response Biomedical Corporation (TSX: RBM CN)
Response Biomedical Corporation (TSX: RBM CN) is focused on developing, manufacturing, and marketing rapid on-site diagnostic tests designed to be used with its RAMP(R) Platform for clinical and environmental applications. The company’s novel platform represents a new paradigm in diagnostics that advantageously provides high sensitivity and dependable information in moments. The RAMP system potentially could be applied to over 250 medical and non-medical tests currently performed in laboratories. For further information, visit the Company's web site at www.responsebio.com.
Response Genetics, Inc. (NASDAQ: RGDX)
Response Genetics, Inc. (NASDAQ: RGDX) has focused their efforts on the research and development of pharmacogenomic cancer diagnostic tests based on its patented technologies. These technologies allow the extraction and analysis of genetic information from genes derived from tumor samples stored as formalin-fixed and paraffin-embedded specimens. RGI generates revenues through diagnostic testing services and the sales of its proprietary analytical pharmacogenomic testing services of clinical trial specimens. For further information, visit the Company's web site at www.responsegenetics.com.
Result Energy Inc. (TSX: RTE CN)
Result Energy Inc. (TSX: RTE CN), a junior oil & gas exploration and production company, is focused on expanding operations through a combination of internally developed prospects and strategic acquisitions. The company has interests in producing oil & gas wells in 4 separate areas, primarily in northern Alberta and west-central Saskatchewan. James Reimer, Executive Vice-President, brings more than 25 years of experience to the company and is renowned as a top industry expert regarding Paleozoic hydrothermal play systems. For further information, visit the Company's web site at www.resultenergy.com.
Resverlogix Corp. (TSX: RVX CN)
Resverlogix Corp. (TSX: RVX CN), a leading biotechnology company, is committed to developing innovative therapies designed to address the unmet needs of important global medical markets. The company’s NexVas™ program is mainly focused on developing novel small molecules that enhance ApoA-I. Resverlogix’s second focus is on relieving the dreadful burden of atherosclerosis and other important diseases such as acute coronary syndrome, diabetes, Alzheimer’s disease and other vascular disorders. For further information, visit the Company's web site at www.resverlogix.com.
Rex Energy Corporation (NASDAQ: REXX)
Rex Energy Corporation (NASDAQ: REXX), an independent energy company, is focused on acquiring, producing, exploring and developing oil and gas, with properties concentrated in the Appalachian, Illinois and Permian regions. The company strategically exploits its sizeable inventory of lower risk developmental drilling locations, while pursuing higher potential exploration drilling prospects. The company believes its success is the result of its seasoned and diversified management team. For further information, visit the Company's web site at www.rexenergycorp.com.
Richmont Mines Inc. (AMEX: RIC)
Richmont Mines Inc. (AMEX: RIC) is focused on producing gold in Northeast Canada and has extensive expertise in gold exploration, development and mining. The company’s key strengths lie in its ability to develop exploration projects and operate underground narrow vein gold mines. Richmont’s properties are located in the provinces of Quebec, Ontario and Newfoundland and Labrador. Richmont aims to become a profitable, intermediate North American producer of gold. For further information, visit the Company's web site at www.richmont-mines.com.
RINO International Corporation (OTC BB: RINO)
RINO International Corporation (OTC BB: RINO) is a leading provider of environmental protection equipment for the iron and steel industry in China. Specifically, RINO designs, manufactures, installs and services proprietary and patented wastewater treatment, flue gas desulphurization equipment, and high temperature anti-oxidation systems, which are all designed to reduce either industrial pollution and/or improve energy utilization. With an array of products that stem from waste water treatment to heavy machining services, RINO is a step ahead of the competition. For further information, visit the company website at www.rinogroup.com.
Rockwell Medical Technologies, Inc. (NASDAQ: RMTI)
Rockwell Medical Technologies, Inc. (NASDAQ: RMTI), the recognized leader in delivering high quality hemodialysis solutions, powders and ancillary products to dialysis providers, is devoted to providing the highest quality products with the most dependable in the nation. The company advantageously uses its own fleet of trucks and drivers to deliver drum pump-off service. The team is dedicated to providing timely shipment of dialysate concentrate and associated products vital to patient care. For further information, visit the Company's web site at www.rockwellmed.com.
Rosetta Genomics, Ltd. (NASDAQ: ROSG)
Rosetta Genomics, Ltd. (NASDAQ: ROSG), an innovative molecular diagnostics company, utilizes microRNAs, a collection of recently discovered non-coding control genes, to develop a broad array of tests for cancers and women’s health indications. These non-coding genes have demonstrated to be highly sensitive and tissue specific biomarkers. The company’s early recognition of microRNAs’ vast potential has led to great discovery and has the establishment of a leading intellectual property (IP) portfolio. For further information, visit the Company's web site at www.rosettagenomics.com.
RXi Pharmaceuticals Corp. (NASDAQ: RXII)
RXi Pharmaceuticals Corp. (NASDAQ: RXII), a discovery-stage biopharmaceutical company, is focused on developing and commercializing proprietary therapeutics, based on RNA interference (RNAi), to treat various human diseases. The company aims to leverage RNAi-based technologies across multiple therapeutic areas to initially treat neurological diseases, metabolic diseases and cancer. For further information, visit the Company's web site at www.rxipharma.com.
Rubicon Minerals Corporation (TSX: RMX CN)
Rubicon Minerals Corporation (TSX: RMX CN), a well-funded, top tier gold exploration company, draws strength from its management team’s track record of discovery. The company controls over 65,000 acres of prime exploration ground in the prolific Red Lake gold camp of Ontario, Canada, which hosts Goldcorp's high-grade, world class Red Lake Mine. The Phoenix Gold Project is Rubicon's 100%-controlled flagship property and is located in the heart of this producing camp. For further information, visit the Company's web site at www.rubiconminerals.com.
Sancon Resources Recovery, Inc. (OTC BB: SRRY)
Sancon Resources Recovery, Inc. (OTC BB: SRRY) is an environmental service company that specializes in the collection, processing, and selling of reprocessed material such as plastic, metal, paper, cardboard, glass, etc. The recycled materials are re-used by Sancon's manufacturing clients to make a wide variety of new products that include: outdoor furniture, construction materials, building materials, packaging materials, and various other products. For further information, visit the company website at: www.sanconinc.com.
Santa Fe Gold Corporation (OTC BB: SFEG)
Santa Fe Gold Corporation (OTC BB: SFEG) is working towards becoming a major player in the precious metals mining field. The company aims to produce substantial cash flow from precious metals holdings while creating a portfolio of quality exploration and development projects. All four of Santa Fe Gold’s advanced properties are within the politically stable and mining friendly jurisdictions of the southwest United States. For further information, visit the Company's web site at www.santafegoldcorp.com.
Santarus, Inc. (NASDAQ: SNTS)
Santarus, Inc. (NASDAQ: SNTS), a specialty pharmaceutical company, has focused their efforts acquiring, developing and commercializing proprietary products that meet the needs of patients treated by gastroenterologists or primary care physicians. The company is currently commercializing ZEGERID® Capsules and Powder for Oral Suspension to treat upper gastrointestinal diseases and disorders, including gastroesophageal reflux disease (GERD). For further information, visit the Company's web site at www.santarus.com.
Saratoga Resources Inc. (OTC BB: SROE)
Saratoga Resources Inc. (OTC BB: SROE), an Austin, Texas based energy development company, focuses on the acquisition, development and exploration of energy resources while maintaining efficient operations and high environmental standards. Currently, the company operates production from over a dozen fields in Texas and Louisiana and employs a staff of 24 full-time professionals. Saratoga has an extensive portfolio of low-risk behind pipe and undrilled development opportunities and intends to partner with other companies to exploit higher-risk upside opportunities. For further information, visit the Company's web site at www.saratogaresources.net.
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN)
SciClone Pharmaceuticals, Inc. (NASDAQ: SCLN), a biopharmaceutical company, is focused on developing and commercializing innovative therapeutics designed to treat life-threatening diseases. The company’s strategy is to in-license late-stage clinical products, and then develop them for commercialization throughout the world. SciClone simultaneously strives to increase revenues and important cash flow to fund the expansion of its business as well as the development of a worldwide product portfolio. For further information, visit the Company's web site at www.sciclone.com.
SCOLR Pharma, Inc. (AMEX: DDD)
SCOLR Pharma, Inc. (AMEX: DDD), a specialty pharmaceutical company, focuses on developing and liscensing Controlled Delivery Technology (CDT®). This technology platform contains multiple patented oral drug delivery technologies for prescription, OTC and nutritional compounds. Through alliances with pharmaceutical and natural products industry companies, SCOLR co-develops new products and adds value as well as protection to existing product franchises. For further information, visit the Company's web site at www.scolr.com.
Senesco Technologies, Inc. (AMEX: SNT)
Senesco Technologies, Inc. (AMEX: SNT) is focused on researching and developing genetic technologies that improve commercial agriculture and treat significant medical conditions. The company’s platform technology is based on the identification and characterization of specific genes known to be responsible for plant cell death (senescence) and programmed cell death in humans (apoptosis). Senesco’s patented pending genetic technologies have the advantage of having broad applicability. For further information, visit the Company's web site at www.senesco.com.
Sepracor, Inc. (NASDAQ: SEPR)
Sepracor, Inc. (NASDAQ: SEPR), a research-based pharmaceutical company, has focused their efforts on treating and preventing human disease by discovering, developing and commercializing innovative pharmaceutical products designed to serve large and growing markets. The company’s drug development program has proven its success by yielding a portfolio of pharmaceutical products and candidates. The focus of the program is on treating respiratory and central nervous system (CNS) disorders. For further information, visit the Company's web site at www.sepracor.com.
Sequenom, Inc. (NASDAQ: SQNM)
Sequenom, Inc. (NASDAQ: SQNM) is focused on providing superior genetic analysis products designed to translate genomic science into advanced solutions for biomedical research, agricultural applications, molecular medicine and non-invasive prenatal diagnostics research, and possibly clinical utility. MassARRAY, the company’s high-performance DNA analysis platform, efficiently and precisely measures the amount of genetic target material as well as the variations within. For further information, visit the Company's web site at www.sequenom.com.
Shengkai Company Ltd. (OTC BB: SOSA)
Shengkai Company Ltd. (OTC BB: SOSA) is an enterprise with high and new technology registered in the Economic & Technical Development Area of Tianjin, PRC. The key technology is the development, design and manufacture of the ceramic materials. SK products have been widely applied in various industries such as petroleum and aerospace. The company is led by Wang Chen and has applied for more than 10 patents. For further information, visit the company website at: www.Shenkai.com.
Shengtai Pharmaceutical Inc., (OTC BB: SGTI)
Shengtai Pharmaceutical Inc., (OTC BB: SGTI) is China's leading manufacturer and supplier of pharmaceutical grade glucose for medicinal purposes. In addition to their pharmaceutical glucose series of products, they also produce other medicinal product lines as well such as industrial glucose, syrup, starch, avermectins, dextrin, maltose and maltitol, which are used for food, beverage and industrial production. Based in China, Shengtai has an international client-base. For further information, visit the company website at: www.shengtaipharmaceutical.com.
Sherwood Copper Corp. (TSX: SWC CN)
Sherwood Copper Corp. (TSX: SWC CN) has its primary focus on profitably producing and developing high grade, open pit base and precious metals mines in Canada. The company’s high grade Minto copper-gold mine began commercial production in October of last year and is currently undergoing an expansion and optimization process. Additionally, the Company is advancing its high grade Kutcho copper project towards a production decision. For further information, visit the Company's web site at www.sherwoodcopper.com.
Shine Media Acquisition Corporation (OTC BB: SHND)
Shine Media Acquisition Corporation (OTC BB: SHND) is a young company located in China that was founded in 2005. Shine Media intends to acquire a direct or indirect ownership through a merger, capital stock exchange, asset or stock acquisition, other similar business combination, or control through contractual arrangements of one or more operating businesses in the media and advertising industry in China. Shine Media is led by their CEO, President and Director David Chen who is a renowned name in the advertising industry in China. For further information, visit the company website at: www.shndu.com.
Shiner International, Inc. (NASDAQ: BEST)
Shiner International, Inc. (NASDAQ: BEST) is China's leading manufacturer and marketer of four types of technology driven packaging film products: anti-counterfeit films, coated films, BOPP films and color printed films. With a strong core group of company scientists, the young company holds 13 patents and has an international client base. For further information, visit the company website at: www.shinerinc.com.
Silver Shield Resources Inc. (TSX: SSR CN)
Silver Shield Resources Inc. (TSX: SSR CN) is primarily focused on the acquisition, exploration and development of mineral resource properties in Northern Ontario and Mexico. The company is currently a party to option agreements relating to five properties including the Welsh Mine Property in the historically prolific silver producing Elk Lake-Gowganda area of Ontario and the La Cumbre Property in Guerrero, Mexico. Exploration efforts are led by Raymond Lashbrook who has 38 years experience in mineral exploration, mine engineering and geology. For further information, visit the Company's web site at www.silvershieldresources.com.
Silvercorp Metals Inc. (TSX: SVM CN)
Silvercorp Metals Inc. (TSX: SVM CN) is focused on acquiring, exploration, and developing silver related mineral properties, with a primary focus on the People's Republic of China ("China"). In Henan Province it is operating and developing four Silver-Lead-Zinc mines at the Ying Mining Camp. In Guangdong Province, it is applying for a mining permit for the newly acquired GC/SMT property, owned through a 95% Chinese subsidiary. Additionally, Silvercorp is exploring the Na-Bao Polymetalic Project in Qinghai Province. For further information, visit the Company's web site at www.silvercorp.ca.
Sinovac Biotech, Ltd. (AMEX: SVA)
Sinovac Biotech, Ltd. (AMEX: SVA) is one of the emerging biotech companies in China. Sinovac (also known in China as Beijing Kexing Bioproducts) specializes in the research, development, commercialization, and sales of human vaccines for infectious illnesses such as Hepatitis A and Hepatitis B, influenza and “SARS”. While the young company has gained national recognition for its Hepatitis A vaccine, they are the only company in the world to have been granted permission to begin clinical trials for a vaccine to prevent SARS. For further information, visit the company website at: www.Sinovac.com.
Skygold Ventures Ltd. (TSX: SKV CN)
Skygold Ventures Ltd. (TSX: SKV CN) is a Vancouver-based resource company focused on exploring for gold in the prolific Cariboo Mining District in south central British Columbia. The company has utilized its technical advantage from the knowledge and data being produced from the Spanish Mountain discovery to play a dominant role in the development of an emerging new gold district stretching some 500 miles through the Quesnel Trough of central B.C. For further information, visit the Company's web site at www.skygold.ca.
SkyPeople Fruit Juice (OTC BB: SPFJ)
SkyPeople Fruit Juice (OTC BB: SPFJ) is an up and coming company located in Chino, California. The Company is engaged in the business of research and development, production and sales of concentrated fruit juices, fast-frozen and freeze-dried fruits and vegetables and fruit juice drinks. Many experts in the marketplace view the young company as being undervalued. Skystar Bio-pharmaceutical Company (OTC BB: SKBI) has grown to become one of China's leading manufacturers and distributors of vaccines and medicines for poultry, livestock and domestic pets. The vaccines developed by Skystar have assisted the farming industry in China and have been helpful to veterinarians. With 173 products already in the marketplace, Skystar is growing at a rapid pace. For further information, visit the company website at: www.skystarbio-pharmaceutical.com.
Smartheat, Inc. (OTC BB: SPFJ)
Smartheat, Inc. (OTC BB: SMHT) is a Chinese company that is operating in the pate heat exchange market. In recent years, this marker has become extremely profitable in China. The company’s green" plate heat exchanger (PHE) technology helps reduce fossil fuel related costs and pollution by capturing and recycling waste heat, making Smartheat a friend to the marketplace and the environment. For further information, visit the company website at: www.smartheatinc.com.
Solar Enertech Corporation (OTC BB: SOEN)
Solar Enertech Corporation (OTC BB: SOEN) is a manufacturer of high quality photovoltaic (“PV”) solar energy cells and state-of-the-art solar applications and has established a partnership in a Joint R&D Lab with Shanghai University for the development of research programs designed to increase the overall efficiency of solar cells. The company has gained national recognition for its innovations in solar panel applications. For further information, visit the company website at: www.solarenertech.com.
Solar Power, Inc. (OTC BB: SOPW)
Solar Power, Inc. (OTC BB: SOPW) is a leading manufacturer, supplier and installer of photovoltaic solar power solutions that deliver reliable and efficient alternative means of electricity. SPI provides its own unique brand of turnkey solar power solutions to commercial and public sector customers across the United States. While based in the United States, Solar Power Inc. owns and operates its own manufacturing facility in Shenzhen, China. For further information, visit the company website at: www.solarpowerinc.net.
Somanetics Corporation (NASDAQ: SMTS)
Somanetics Corporation (NASDAQ: SMTS) focuses on developing, manufacturing and marketing the INVOS® Cerebral/Somatic Oximeter. This non-invasive patient monitoring system constantly measures changes in the blood oxygen levels in patients with or at risk for restricted blood flow. The INVOS System also provides the information necessary to identify oxygen imbalances in tissues beneath the sensor, allowing medical professionals to take corrective action. For further information, visit the Company's web site at www.somanetics.com.
Southwestern Energy Company (NYSE: SWN)
Southwestern Energy Company (NYSE: SWN), an integrated energy company headquartered in Houston, Texas, focuses its efforts on the exploration for and production of natural gas. Currently, the company’s operations are focused on Arkansas, Oklahoma, Texas, New Mexico, and Louisiana. Southwestern Energy primarily conducts its exploration and production activities through its wholly-owned subsidiaries, Southwestern Energy Production Company and SEECO, Inc. For further information, visit the Company's web site at www.swn.com.
Soyo Group, Inc. (OTC BB: SOYO)
Soyo Group, Inc. (OTC BB: SOYO), a California based company, is an innovative provider of consumer electronics such as: LCD HDTV’s, Home Theatre Furniture, Bluetooth Headsets, Portable Storage Devices, Computer Monitors, Computer Motherboards and Computer Peripheral Devices. SOYO developed these products to meet the growing needs of technology savvy consumers in all markets. The company is growing at a very fast-pace and is moving to a larger facility in order to handle the demand of their business. For further information, visit the company website at: www.soyo.com.
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI)
Spectrum Pharmaceuticals, Inc. (NASDAQ: SPPI), a specialty pharmaceutical company, is focusing their efforts on addressing cancer and other unmet medical needs. With headquarters in Irvine, California, the company employs approximately 65 employees that meticulously strive to bring new drugs through clinical development and regulatory approval. Spectrum’s staff is devoted to promoting excellence and aims to make a difference every day. For further information, visit the Company's web site at www.spectrumpharm.com.
Storm Cat Energy Corporation (AMEX: SCU)
Storm Cat Energy Corporation (AMEX: SCU), an independent oil and gas company, focuses on the exploration, production and development of large unconventional gas reserves from fractured shales, coal beds, tight sand formations and from conventional formations. The company has producing properties in Wyoming's Powder River Basin, and Arkansas' Arkoma Basin and exploration and development acreage in Canada. For further information, visit the Company's web site at www.stormcatenergy.com.
Sterling Resources Ltd. (TSX: SLG CN)
Sterling Resources Ltd. (TSX: SLG CN), a Calgary based energy company, is focused on exploring, developing and producing crude oil and natural gas in selected areas throughout the world. The company’s initial strategy for growth includes obtaining high initial working interests, leveraging alliances with leading UK services companies for new technology, manage financing and technical risk by obtaining industry partners, and acquiring production if it adds synergy to existing initiatives. For further information, visit the Company's web site at www.sterling-resources.com.
Strathmore Minerals Corp. (TSX: STM CN)
Strathmore Minerals Corp. (TSX: STM CN) is focused on becoming a leading uranium producer in the United States. Their efforts are concentrated on the acquisition and development of advanced uranium projects in the two largest uranium producing regions in the United States: the Gas Hills Uranium District in Wyoming and the Grants Mineral District, New Mexico, but were abandoned by the major uranium mining companies during the 1980s and 1990s. For further information, visit the Company's web site at www.strathmoreminerals.com.
Stroud Resources Ltd. (TSX: SDR CN)
Stroud Resources Ltd. (TSX: SDR CN), an exploration company focused on the discovery and exploration of silver and gold deposits, is completely debt free and has yearly cash flow of approximately $200,000 from its 3.75% interest in six natural gas and gas condensate wells. Currently, the company has two gold properties in Ontario Canada, and two silver projects in Mexico. The Hislop gold project located in Timmins Ontario with indicated resources of 102,750 oz. and the Santo Domingo Silver project based in Mexico are both 100% owned by Stroud Resources. For further information, visit the Company's web site at www.stroudresourcesltd.com.
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS)
Sunesis Pharmaceuticals, Inc. (NASDAQ: SNSS), an emerging biopharmaceutical company, has focused their efforts on creating new medicines designed to improve the lives of patients diagnosed with cancer. The company is currently building a pipeline of drugs that selectively block vital mechanisms necessary for tumor growth and survival. Sunesis recognizes that the fight against cancer is an enormous mission that requires an integrated approach and innovation. For further information, visit the Company's web site at www.sunesis.com.
SuperGen, Inc. (NASDAQ: SUPG)
SuperGen, Inc. (NASDAQ: SUPG) is focused on building a global, sustainable business by developing and commercializing new drug candidates for oncologists, hematologists, and their patients. The company’s staff is made up of talented individuals who recognize the incredible challenges of drug development. Although some work along and other on teams, each employee brings a distinct perspective to his or her job and is focused on the goal of bringing better products to cancer patients in need. For further information, visit the Company's web site at www.sunesis.com.
Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN)
Sunwin International Neutraceuticals, Inc. (OTC BB: SUWN) is a Chinese company that is engaged in the manufacture and sale of a wide range of neutraceutical products. Sunwin’s product lines include zero-calorie all natural Stevia sweeteners, traditional Chinese medicines, as well as veterinary medicines and animal feeds prepared from 100% organic herbal ingredients. Sunwin has built an integrated global organization with the sourcing and production capabilities to satisfy the needs of global consumers. For further information, visit the company website at: www.sunwininternational.com.
Synta Pharmaceuticals Corp. (NASDAQ: SNTA)
Synta Pharmaceuticals Corp. (NASDAQ: SNTA), a biopharmaceutical company, has dedicated their efforts to discovering, developing, and commercializing innovative pharmaceutical products for extending and enhancing the lives of patients with severe medical conditions, including cancer and chronic inflammatory disease. The company has an exceptional chemical compound library, an integrated discovery engine, and a pipeline of small molecule drug candidates with innovative chemical structures and distinct mechanisms of action. For further information, visit the Company's web site at www.syntapharma.com.
Synvista Therapeutics, Inc. (AMEX: SYI)
Synvista Therapeutics, Inc. (AMEX: SYI), a biopharmaceutical company, is focused on the development of drugs to treat and prevent cardiovascular disease and nephropathy in people with diabetes. The Company has identified multiple product candidates innovatively approach some of the largest pharmaceutical markets. The Company's portfolio includes orally bioavailable, organoselenium mimics of glutathione peroxidase. For further information, visit the Company's web site at www.alteon.com.
Targanta Therapeutics Corporation (NASDAQ: TARG)
Targanta Therapeutics Corporation (NASDAQ: TARG), a biopharmaceutical company, is dedicated to developing and commercializing innovative antibiotics that treat serious infections in the hospital and other institutional settings. The company’s lead antibiotic, oritavancin, is designed to treat serious gram-positive bacterial infections, including complicated skin and skin structure infections, or cSSSI, and bacteremia, a blood stream infection. Additionally, Targanta is developing multiple antibacterial agents, including an oral version of oritavancin targeting Clostridium difficile-related conditions. For further information, visit the Company's web site at www.targanta.com.
Targeted Genetics Corporation (NASDAQ: TGEN)
Targeted Genetics Corporation (NASDAQ: TGEN) is focused on developing and commercializing molecular therapeutics that target the underlying cause of an array of serious diseases that have substantial, but unmet medical needs. The company’s lead product candidate is being designed to treat inflammatory arthritis, and additional programs target HIV/AIDS, congestive heart failure and Huntington's disease. Targeted Genetics’ varied pipeline has been developed through the leveraging of the company’s intellectual property related to gene delivery, and core capabilities in critical functions. For further information, visit the Company's web site at www.targetedgenetics.com.
TechPrecision Corporation (OTC BB: TPCS)
TechPrecision Corporation (OTC BB: TPCS) is focused on excelling in the precision manufacturing industry while offering comprehensive program management and integration services. The company’s customer base resides within a broad range of industries, including Aerospace, Alternative Energy, Medical and Nuclear industry segments. Chairman and CEO James Reindl leads the company with more than 15 years experience in the management of multi-company operations. For further information, visit the Company's web site www.techprecision.com.
Ternium S.A. (NYSE: TX)
Ternium S.A. (NYSE: TX), a manufacturer of flat and long steel products, is focused on consolidating the operations of steel companies located in Argentina, Mexico, Guatemala and United States. Ternium is one of Latin America’s leading steel companies with an annual crude steel production capacity of 10.8 million tons. Under the direction of Chairman Paolo Rocca, and CEO Daniel Novegil, Ternium brings the professionalism and dedication of more than 18,000 employees. For further information, visit the Company's web site at http://www.ternium.com/en.
The Female Health Company (AMEX: FHC)
The Female Health Company (AMEX: FHC), the sole manufacturer and marketer of the FC1 and FC2 female condoms, provides an innovative option to women that protects against both sexually transmitted diseases and unintended pregnancy. The Company holds exclusive product and technology patents for FC1 in the United States, Australia, Brazil, Canada, France, Germany, Italy, Spain, the United Kingdom, the People’s Republic of China, South Korea and Japan, while patents are pending for FC2. For further information, visit the Company's web site at www.femalehealth.com.
The Management Network Group, Inc. (NASDAQ: TMNG)
The Management Network Group, Inc. (NASDAQ: TMNG) is a leading provider of professional services to the converging communications media and entertainment industries and the capital formation firms that support it. From strategy consulting to management consulting, The Management Network Group is a leader in all communication fields. For further information, visit the company website at: www.tmng.com.
ThermoEnergy Corporation (OTC BB: TMEN)
ThermoEnergy Corporation (OTC BB: TMEN) is focused on becoming a significant force within the global municipal and industrial wastewater and power generation industries. The company helps clients succeed with efficient, cost effective wastewater treatment and power generation technologies. ThermoEnergy’s clean combustion fuel technologies enable industrial clients and other consumers who rely on oil and natural gas to take advantage of cheaper energy sources while meeting air emission standards and achieving full CO2 capture. For further information, visit the Company's web site at www.thermoenergy.com.
ThermoGenesis Corp. (NASDAQ: KOOL)
ThermoGenesis Corp. (NASDAQ: KOOL) has their focus on the regenerative medicine market. This focus inspired the company to create a wholly-owned subsidiary named Vantus Inc. This subsidiary is a veterinary stem cell laboratory service that has collaborations with the UC Davis School of Veterinary Medicine’s Center for Equine Health and its Stem Cell Regenerative Medicine group to conduct research and development to enhance the collecting, processing, and storing of stem cells. For further information, visit the Company's web site at www.thermogenesis.com.
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD)
Threshold Pharmaceuticals, Inc. (NASDAQ: THLD), a biotechnology company, focuses on discovering and developing therapeutics based on Tumor Hypoxia, a powerful scientific platform that offers broad potential to treat most solid tumors. The company is currently building a pipeline of drugs that may be more effective and less toxic to healthy tissues than conventional drugs. Their staff consists of research scientists and business professionals with successful track records in the biotech industry. For further information, visit the Company's web site at www.thresholdpharm.com.
Tianyin Pharmaceutical Co., Inc. (OTC BB: TYNP)
Tianyin Pharmaceutical Co., Inc. (OTC BB: TYNP) is a leading manufacturer and supplier engaged in the development, manufacturing, marketing and sale of modernized traditional Chinese medicines and other pharmaceuticals in China. The company currently offers 34 comprehensive products with 50 more in their corporate pipeline. For further information, visit the company website at: www.tianyinpharma.com.
Titan Pharmaceuticals, Inc. (AMEX: TTP)
Titan Pharmaceuticals, Inc. (AMEX: TTP) has their focus on the late-stage development and commercialization of innovative treatments for central nervous system disorders. In addition to their first product in clinical testing, Probuphine, the Company has plans to develop its ProNeura sustained drug delivery technology for other potential treatment applications where conventional treatment is limited by inconsistency in blood drug levels and poor patient compliance. For further information, visit the Company's web site at www.titanpharm.com.
Tongxin International, Ltd. (NASDAQ: TXIC)
Tongxin International, Ltd. (NASDAQ: TXIC) is one of China’s leading automobile manufacturers and offers an array of autos that keep the company a step ahead of the competition. With a unique shape and style, Tongxin International has developed a look and feel that is unlike other Chinese auto manufacturers and has far more products in their pipeline than their competitors. For further information, visit the company website at: www.hntx.com.
Toreador Resources Corporation (NASDAQ: TRGL)
Toreador Resources Corporation (NASDAQ: TRGL), a well-rounded independent oil and gas company, has a promising inventory of producing properties and exploratory prospects in Turkey, France, Romania and Hungary. The company aims to grow oil and natural gas reserves, production volumes and cash flows through the drilling of internally generated prospects. Toreador Resources’ also seeks complementary acquisitions of new interests in its core geographic areas of operation. For further information, visit the Company's web site at www.toreador.net.
Tournigan Energy Ltd. (TSX: TVC CN)
Tournigan Energy Ltd. (TSX: TVC CN), a uranium and gold exploration and development company, holds a portfolio of highly prospective properties in Europe. The company's flagship property, Kuriskova, is a high-grade uranium deposit in Eastern Slovakia that holds substantial exploration upside potential. President and CEO Dorian Nicol leads the company with more than three decades of international mining experience. He has a B.Sc. in geology from M.I.T. and a Master's Degree in Geology from Indiana University. For further information, visit the Company's web site at www.tournigan.com.
Trans Energy, Inc. (OTC BB: TENG)
Trans Energy, Inc. (OTC BB: TENG), an independent exploration and production company, is focused on exploring, developing and producing oil and natural gas in the Appalachian Basin. The company, operating since 1994, restructured itself during 2006 with a new management team, a focus on oil and gas development, and a business plan for rapid growth. Chief Operating Officer and Director of the Company William F. Woodburn has more than three decades of experience in the oil and gas industry. For further information, visit the Company's web site at www.transenergyinc.com.
Trans-Orient Petroleum Ltd. (OTC BB: TOPLF)
Trans-Orient Petroleum Ltd. (OTC BB: TOPLF) is focused on leveraging advanced drilling and multi-fracturing technology to unlock the potentially vast oil and gas resource contained in world-class source rocks. The company has multi-million acre permits in New Zealand's East Coast Basin. This basin is an exploration frontier renowned for fractured reservoir potential, and Trans-Orient is at the forefront of this opportunity. For further information, visit the Company's web site at www.transorient.com.
Transdel Pharmaceuticals, Inc. (OTC BB: TDLP)
Transdel Pharmaceuticals, Inc. (OTC BB: TDLP), a specialty pharmaceutical company, is dedicated to developing and commercializing non-invasive topically delivered medications. Ketotransdel, Transdel’s lead topical drug, leverages the company’s proprietary Transdel™ cream formulation to facilitate the passage of ketoprofen through the skin to reach underlying tissue where the drug exerts its prolonged localized anti-inflammatory and analgesic effect. For further information, visit the Company's web site at www.transdelpharma.com.
Transgenomic, Inc. (OTC BB: TBIO)
Transgenomic, Inc. (OTC BB: TBIO), a global biotechnology company, is focused on providing novel products and services for automated high sensitivity genetic variation and mutation analysis. The company’s offerings currently include systems, products, discovery and laboratory testing services that find application in the academic and medical research, clinical laboratory and pharmaceutical markets in the fields of pharmacogenomics and personalized medicine. For further information, visit the Company's web site at www.transgenomic.com.
Trubion Pharmaceuticals, Inc. (NASDAQ: TRBN)
Trubion Pharmaceuticals, Inc. (NASDAQ: TRBN), a biopharmaceutical company, focuses its efforts on creating a pipeline of innovative protein therapeutic product candidates designed to treat autoimmune and inflammatory diseases and cancer. The company aims to develop an assortment of first-in-class and best-in-class products, customized for optimal safety, efficacy, and convenience. Trubion’s product development efforts are focused on three technology pillars that encompass the expanded foundation for Trubion product development. For further information, visit the Company's web site at www.trubion.com.
TUSK Energy Corporation (TSX: TSK CN)
TUSK Energy Corporation (TSX: TSK CN) is focused on the acquisition, exploration, development and production of oil and natural gas reserves in three focus areas in the northwestern part of the Western Canadian Sedimentary Basin. The company is currently developing natural gas in the Conroy area of northeastern British Columbia and light oil and natural gas in the Peace River Arch and Mega/Gutah areas of northern Alberta. For further information, visit the Company's web site at www.tusk-energy.com.
TXCO Resources, Inc. (NASDAQ: TXCO)
TXCO Resources, Inc. (NASDAQ: TXCO), a full-cycle oil and gas exploration and production company, has a diversified exploitation, development and exploration project inventory. The company has more than 800,000 net acres under lease (1.3 million gross acres) and utilizes its geological and geophysical expertise to increase shareholder value. TXCO Resources applies new technology to overlooked opportunities in high-potential areas that offer multiple resource plays and thousands of drilling prospects. For further information, visit the Company's web site at www.txco.com.
Unbridled Energy Corporation (TSX: UNE CN)
Unbridled Energy Corporation (TSX: UNE CN), an independent natural gas evaluation and production company, specializes in shale gas and tight gas sands opportunities in two main basins within North America. The company strategically applies a lower risk production enhancement strategy on existing wells, and the latest horizontal drilling and fracing technologies on new wells in well known shale gas and tight gas sands formations in the Appalachian Basin. For further information, visit the Company's web site at www.unbridledenergy.com.
Unigene Laboratories, Inc. (OTC BB: UGNE)
Unigene Laboratories, Inc. (OTC BB: UGNE), a biopharmaceutical company, engages in the research, production and delivery of small proteins that have shown or may potentially demonstrate medical benefits. In addition to the company’s patented manufacturing technology designed to produce many peptides cost-effectively, Unigene has patented oral and nasal delivery technologies that have demonstrated the ability to deliver medically useful amounts of various peptides into the bloodstream. For further information, visit the Company's web site at www.unigene.com.
Union Drilling, Inc. (NASDAQ: UDRL)
Union Drilling, Inc. (NASDAQ: UDRL) is focused on providing contract land drilling services and equipment to oil and gas companies in the United States. The company primarily serves natural gas producers who operate in the most active exploration and productions areas in the country. Currently, Vero Energy owns and operates a fleet of 71 marketed rigs, with most of its rigs operating in unconventional natural gas producing areas, where specialized drilling techniques are required. For further information, visit the Company's web site at www.uniond.com.
Unit Corporation (NYSE: UNT)
Unit Corporation (NYSE: UNT), a diversified energy company, is focused on the exploration for and production of oil and natural gas, the acquisition of producing oil and natural gas properties, the contract drilling of onshore oil and natural gas wells, and the gathering and processing of natural gas. The company’s operations are mainly located in the Mid-Continent region, including the Anadarko, Arkoma, Permian, Rocky Mountains and Gulf Coast Basins. For further information, visit the Company's web site at www.unitcorp.com.
Uranerz Energy Corporation (AMEX: URZ)
Uranerz Energy Corporation (AMEX: URZ), a pure-play uranium company, has its focus on acquiring, exploring and developing properties within the uranium sector. The company is led by an experienced team of mining personnel, many of whom are former officers, senior management and employees of the original Uranerz Exploration and Mining Limited and related companies. Currently, Uranerz Energy Corporation has uranium properties in Saskatchewan (Canada) and Wyoming (U.S.A.). For further information, visit the Company's web site at www.uranerz.com.
Uranium Energy Corp. (AMEX: UEC)
Uranium Energy Corp. (AMEX: UEC), a US-based junior resource Uranium Mining company, is focused on becoming a near-term ISR uranium producer in the United States. The company controls one of the largest historical uranium mining exploration and development databases in the US. Through the leveraging of these databases, the Company has acquired advanced uranium properties throughout the southwestern US. For further information, visit the Company's web site at www.uraniumenergy.com.
Uroplasty, Inc. (AMEX: UPI)
Uroplasty, Inc. (AMEX: UPI), a global medical device company, is focused on developing, manufacturing, and marketing products for the minimally invasive treatment of voiding dysfunctions and pelvic disorders. The company offers a wide range of products that meet the demands of healthcare professionals and patients. Their devices help healthcare professionals increase the efficiency of their treatment options while reducing patient risk. For further information, visit the Company's web site at www.uroplasty.com.
Vero Energy Inc. (TSX: VRO CN)
Vero Energy Inc. (TSX: VRO CN), a Calgary based, growth oriented company, is focused on the exploration, development and production of natural gas, natural gas liquids and oil in Western Canada. To date, the company has achieved significant growth in: production and production per share; cash flow and cash flow per share; reserves and reserves per share. Vero’s aim is to grow through the drill bit, but also explores prudent acquisition opportunities. For further information, visit the Company's web site at www.veroenergy.ca.
VIA Pharmaceuticals, Inc. (NASDAQ: VIAP)
VIA Pharmaceuticals, Inc. (NASDAQ: VIAP) is focused on developing a pipeline of small-molecule drugs designed to target a substantial, but unmet medical need – reducing inflammation in the blood vessel wall. This is known as an underlying cause of atherosclerosis and its complications, including heart attack and stroke. VIA-2291, the company’s lead drug candidate, is currently in a number of Phase 2 clinical trials in patients with cardiovascular disease. For further information, visit the Company's web site at www.viapharmaceuticals.com.
Vical Incorporated (NASDAQ: VICL)
Vical Incorporated (NASDAQ: VICL) is focused on researching and developing biopharmaceutical products designed to prevent and treat serious or life-threatening diseases. Possible applications of the company's DNA delivery technology include DNA vaccines for infectious diseases or cancer, cancer immunotherapeutics, and cardiovascular therapies. By strategically partnering with other pharmaceutical companies and biotechnology companies, the company hopes to expand its product pipeline. For further information, visit the Company's web site at www.vical.com.
Victory Nickel Inc. (TSX: NI CN)
Victory Nickel Inc. (TSX: NI CN), growth-oriented Canadian nickel company, holds more than 660 million pounds of in-situ nickel in National Instrument 43-101-compliant measured and indicated resources at its Minago, Mel and Lac Rocher sulphide nickel deposits. The company has one of Canada’s largest undeveloped sulphide nickel inventories, and is anticipating production this year from its Lac Rocher project in northwestern Quebec. For further information, visit the Company's web site at www.victorynickel.ca.
VioQuest Pharmaceuticals, Inc. (OTC BB: VOQP)
VioQuest Pharmaceuticals, Inc. (OTC BB: VOQP) , a New Jersey-based biotechnology company, is focused on becoming a leader in the successful development of novel drug therapies designed to target both the molecular basis of cancer and side effects of treatment. The company’s oncology portfolio currently includes: Xyfid™, for the treatment of dry skin conditions and to manage the burning and itching associated with various dermatoses; VQD-002, a targeted inhibitor of Akt activation; and Lenocta™, an inhibitor of certain protein tyrosine phosphatases. For further information, visit the Company's web site at www.vioquestpharm.com.
ViroPharma Incorporated (NASDAQ: VPHM)
ViroPharma Incorporated (NASDAQ: VPHM), a multinational biotechnology company, is focused on developing and commercializing innovative products that target unmet medical needs. The company is currently dedicating their efforts to developing these products for physician specialists that support patients with serious diseases caused by CMV, C. difficile, and hereditary angioedema. Maribavir, VioPharma’s lead clinical compound, is an orally-administered antiviral Phase 3 drug designed to prevent cytomegalovirus (CMV) disease in transplant patients. For further information, visit the Company's web site at www.viropharma.com.
VirtualScopics, Inc. (NASDAQ: VSCP)
VirtualScopics, Inc. (NASDAQ: VSCP) provides superior precision and reproducibility through their computer-assisted analysis techniques. The company’s technologies enable faster and more reliable detection of disease progression or therapeutic benefit, accelerating the clinical trial process, and providing a foundation for future diagnostic applications. VirtualScopics’ originates from research initially undertaken at the University of Rochester Medical Center and School of Engineering. For further information, visit the Company's web site at www.virtualscopics.com.
VIVUS, Inc. (NASDAQ: VVUS)
VIVUS, Inc. (NASDAQ: VVUS), a pharmaceutical company, is focused on developing and commercializing next-generation therapeutic products designed to target obesity and sexual health. The potential market for obesity ranges from $5 billion to $10 billion annually according to speculating analysts, while the potential market for an effective diabetes therapy that causes weight loss is in excess of $2 billion. The indications targeted by VIVUS' sexual health products each represent a potential market of more than $1 billion per annum. For further information, visit the Company's web site at www.vivus.com.
Vyteris, Inc. (OTC BB: VYTR)
Vyteris, Inc. (OTC BB: VYTR), the maker of the first active drug delivery patch to receive market approval from the (FDA), was founded with the purpose of developing, manufacturing and commercializing pharmaceutical products based upon novel, advanced drug delivery technology. This technology delivers drugs through the skin using low-level electrical energy, causing little to no disturbance. By utilizing Vyteris’ technology, many of the shortcomings of existing drug delivery methods can be eliminated or minimized. For further information, visit the Company's web site at www.vyteris.com.
WaferGen Biosystems, Inc. (OTC BB: WGBS)
WaferGen Biosystems, Inc. (OTC BB: WGBS) is focused on developing, manufacturing and commercializing next-generation systems for gene expression, genotyping, stem cell research and cell biology for the life science and pharmaceutical industries. The company is developing what could become the platform of choice for genetic analysis as well as cell monitoring enabling genomics and cell biology from research to clinic. WaferGen’s innovative systems are the first of their kind, providing researchers with critical performance advantages that are not available with existing technologies. For further information, visit the Company's web site at www.wafergen.com.
Warren Resources, Inc. (NASDAQ: WRES)
Warren Resources, Inc. (NASDAQ: WRES), an independent energy company, is focused on the exploration and development of domestic onshore natural gas and oil reserves. The company is one of the leading developers of coalbed methane natural gas in the Rocky Mountain region. As of the end of 2007, Warren owned natural gas and oil interests in approximately 230,738 gross (129,555 net) acres. The company has plans to develop its California properties through directional and horizontal drilling. For further information, visit the Company's web site at www.warrenresources.com.
Western Copper Corporation (TSX: WRN CN)
Western Copper Corporation (TSX: WRN CN), an exploration and development company, is focused on advancing its mineral properties to production. The company owns significant gold, copper and molybdenum resources and reserves in four Canadian properties: the Carmacks Copper Project and the Casino Project in the Yukon, the Hushamu property in British Columbia and the Redstone property in the Northwest Territories. Additionally, Western Copper owns the Sierra Almoloya property in Mexico. For further information, visit the Company's web site at www.westerncoppercorp.com.
WorldWater & Solar Technologies Corp. (OTC BB: WWAT)
WorldWater & Solar Technologies Corp. (OTC BB: WWAT), an international solar engineering and water management company, is focused on providing solutions to water supply and energy problems. The Company’s patented AquaMax™ solar electric systems are capable of operating pumps and motors up to 1,000 horsepower (hp) for irrigation, refrigeration and cooling, and water utilities, making it the first company in the world to deliver mainstream solar electric pumping capacity. For further information, visit the Company's web site at www.worldwater.com.
Worldwide Energy & Manufacturing USA, Inc. (OTC BB: WEMU)
Worldwide Energy & Manufacturing USA, Inc. (OTC BB: WEMU) is a fast growing engineering and quality control firm. Worldwide Energy specializes in international contract manufacturing. A California Corporation founded in 1993, Worldwide is also a China manufacturer that has a competitive advantage in its ability to timely deliver high quality components at manufacturing costs that are at least fifty percent (50%) less than what Worldwide’s customers pay for similar products in the United States. For further information, visit the company website at: www.wwmusa.com.
Wuhan General Group, Inc. (NASDAQ: WUHN)
Wuhan General Group, Inc. (NASDAQ: WUHN) is a holding company that designs, manufactures, and distributes industrial blowers and turbines. Wuhan’s primary business operations are conducted through its operating subsidiaries Wuhan Blower Co., Ltd. (Wuhan Blower) and Wuhan Generating Equipment Co., Ltd. (Wuhan Generating Equipment). Wuhan was formerly known as the United Nations Film Corporation and has been a major player in the power generation field since its inception. For further information, visit the company website at: www.wuhangeneral.com.
XenoPort, Inc. (NASDAQ: XNPT)
XenoPort, Inc. (NASDAQ: XNPT), a biopharmaceutical company, focuses their efforts on developing a portfolio of internally discovered product candidates that leverage the body's natural nutrient transporter mechanisms to improve the therapeutic benefits of drugs. The company has directed their focus on developing and commercializing on potential treatments of central nervous system, or CNS, disorders. Their most advanced product candidate, XP13512 (also known as Solzira™), is in the process of being evaluated for the treatment of restless legs syndrome, or RLS, in a Phase 3 clinical program. For further information, visit the Company's web site at www.xenoport.com.
XOMA, Ltd. (NASDAQ: XOMA)
XOMA, Ltd. (NASDAQ: XOMA) is focused on the discovery and development of antibodies, one of the most powerful and transformative fields of drug innovation today. By building on its pioneering proprietary pipeline, antibody discovery and development platform, and multiple revenue streams, the company is creating novel human antibody therapeutics that could revolutionize medicine and reshape people’s lives. For further information, visit the Company's web site at www.xoma.com.
Xsunx, Inc. (OTC BB: XSNX)
Xsunx, Inc. (OTC BB: XSNX), a thin-film photovoltaic (“TFPV”) company, is focused on executing a phased plan to build and install 100 mega-watts (MW) of amorphous silicon (“a-Si”) thin film solar module manufacturing capacity. XsunX has designed its TFPV product to service a wide range of installation environments and deliver performance characteristics that address the needs of solar farm and utility grade applications. For further information, visit the Company's web site at www.xsunx.com.
YM BioSciences, Inc. (AMEX: YMI)
YM BioSciences, Inc. (AMEX: YMI), an oncology company, is focused on identifying, developing and commercializing a variety of products for patients on a global basis. The Company is advancing two late-stage products: Nimotuzumab, a humanized monoclonal antibody designed to target the epidermal growth factor receptor (EGFR); and AeroLEF®, a proprietary, inhaled-delivery composition of free and liposome-encapsulated fentanyl. Nimotuzumab has received approval in multiple countries for treating types of head and neck cancer, while AeroLEF is in development for the treatment of moderate to severe pain. For further information, visit the Company's web site at www.ymbiosciences.com.
ZBB Energy Corporation (AMEX: ZBB)
ZBB Energy Corporation (AMEX: ZBB), a leading innovator of energy storage systems, is focused on providing energy storage systems to utility companies, industrial and commercial organizations and renewable energy generators. The company’s aim is to develop and produce products that increase energy efficiency, minimize the impact on the environment and maximize the use of renewable energy. Founded in 1981, ZBB is headquartered in Wisconsin with offices located in Perth, Australia. For further information, visit the Company's web site at www.zbbenergy.com.
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP)
ZIOPHARM Oncology, Inc. (NASDAQ: ZIOP), a biopharmaceutical company, focuses on developing and commercializing a varied, risk-sensitive portfolio of in-licensed cancer drugs that address unmet medical needs. The company’s business strategy is to utilize new insights from molecular and cancer biology to understand the effectiveness and safety limitations of approved and developmental cancer therapies and identify proprietary and related molecules for better patient treatment. For further information, visit the Company's web site at www.ziopharm.com.
|
|
